ID,Cohort,ReferenceCoded,Reference,YearPublished,YearDataCollection,StudyType,Country,AgeMean,AgeRangeLower,AgeRangeUpper,OutcomeDefinitionLabel,Severity,Predictor,Predictor_clean,ReverseD,PredictorCoded,PredictorBroad,Test_dependency,Rcode,metaP_code,effectType,ratesControl,IncludeStudy,IncludeD,
1,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,NewZealand,27,18,35,Can.PLE,psych_like,Gender (male vs. female),Gender (male),yes,Gender,Demographic,independent,extract_thomas_gender,pEstimate_thomas_gender,cohen,,Yes,Yes,
2,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,NewZealand,27,18,35,Can.PLE,psych_like,Frequency (heavy vs. light),Frequency (heavy),no,CannabisSeverity,CannabisHistory,independent,extract_thomas_frequency,pEstimate_thomas_frequency,cohen,,Yes,Yes,
3,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,NewZealand,27,18,35,Can.PLE,psych_like,current vs. former user,Cannabis use (current),yes,CannabisSeverity,CannabisHistory,independent,extract_thomas_currentCan,pEstimate_thomas_currentCan,cohen,,Yes,Yes,
4,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,NewZealand,27,18,35,Can.PLE,psych_like,Cannabis dependency (present vs. absent),Cannabis dependency,no,CannabisSeverity,CannabisHistory,independent,extract_thomas_dependeny,pEstimate_thomas_dependeny,cohen,,Yes,Yes,
5,Thomas,Thomas_survey,"Thomas, Huw. ""A community survey of adverse effects of cannabis use."" Drug and alcohol dependence 42, no. 3 (1996): 201-207.",1996,1994-1994,Observational,NewZealand,27,18,35,Can.PLE,psych_like,rates,rates,no,rates,rates,NA,thomas1996_canPLEDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
7,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,US,34.96,18,80,Can.PAR,psych_like,Recreational use (vs. medical),Recreational use (vs. medical),no,Reason (medicinal vs. recreational),CannabisHistory,independent,extract_SextonParanoia_reasonUse,pEstimate_SextonParanoia_reasonUse,cohen,,Yes,Yes,
8,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,US,34.96,18,80,Can.HAL,psych_like,Recreational use (vs. medical),Recreational use (vs. medical),no,Reason (medicinal vs. recreational),CannabisHistory,independent,extract_SextonHallucinations_reasonUse,pEstimate_SextonHallucinations_reasonUse,cohen,,Yes,Yes,
9,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,US,34.96,18,80,Can.PAR,psych_like,Age,Age,yes,Age,Demographic,independent,extract_SextonParanoiaAge,pEstimate_SextonParanoiaAge,cohen,,Yes,Yes,
10,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,US,34.96,18,80,Can.HAL,psych_like,Age,Age,yes,Age,Demographic,independent,extract_SextonHallucinationAge,pEstimate_SextonHallucinationAge,cohen,,Yes,Yes,
11,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,US,34.96,18,80,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,sexton2019_canParDF,NA,rates,,Yes,Yes,
12,Sexton,Sexton_survey,"Sexton, Michelle, Carrie Cuttler, and Laurie K. Mischley. ""A survey of cannabis acute effects and withdrawal symptoms: Differential responses across user types and age."" The Journal of Alternative and Complementary Medicine 25, no. 3 (2019): 326-335.",2019,2013-2018,Observational,US,34.96,18,80,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,sexton2019_canHalDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
14,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.PAR,psych_like,Depression (present vs. absent),Depression,no,Depression,MentalHealthPersonality,independent,arendt_depression_paranoiaEstimate,pEstimate_arendt_depression_paranoia,cohen,,Yes,Yes,
15,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.DEL,psych_like,Depression (present vs. absent),Depression,no,Depression,MentalHealthPersonality,independent,"pes(p=pValueNS_allStudies, n.1=arendt_depressed_n, n.2=arendt_nonDepressed_n)",pEstimate_arendt_depression_delusions,cohen,,Yes,Yes,
16,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.DEP,psych_like,Depression (present vs. absent),Depression,no,Depression,MentalHealthPersonality,independent,"pes(p=pValueNS_allStudies, n.1=arendt_depressed_n, n.2=arendt_nonDepressed_n)",pEstimate_arendt_depression_depersionalisation,cohen,,No,No,
17,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.HAL,psych_like,Depression (present vs. absent),Depression,no,Depression,MentalHealthPersonality,independent,"pes(p=pValueNS_allStudies, n.1=arendt_depressed_n, n.2=arendt_nonDepressed_n)",pEstimate_arendt_depression_hallucinations,cohen,,Yes,Yes,
18,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.PAR,psych_like,Violence (present vs. absent),Violence,no,Agression,MentalHealthPersonality,independent,"pes(p=pValueNS_allStudies, n.1=arendt_violent_n, n.2=arendt_nonViolent_n)",pEstimate_arendt_violence_paranoia,cohen,,Yes,Yes,
19,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.DEL,psych_like,Violence (present vs. absent),Violence,no,Agression,MentalHealthPersonality,independent,"pes(p=pValueNS_allStudies, n.1=arendt_violent_n, n.2=arendt_nonViolent_n)",pEstimate_arendt_violence_delusions,cohen,,Yes,Yes,
21,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.HAL,psych_like,Violence (present vs. absent),Violence,no,Agression,MentalHealthPersonality,independent,"pes(p=pValueNS_allStudies, n.1=arendt_violent_n, n.2=arendt_nonViolent_n)",pEstimate_arendt_violence_hallucinations,cohen,,Yes,Yes,
22,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.DEL,psych_like,rates,rates,no,rates,rates,NA,arendt2007_canDelDF,NA,rates,,Yes,Yes,
23,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,arendt2007_canParDF,NA,rates,,Yes,Yes,
24,Arendt,Arendt_CUDsample,"Arendt, Mikkel, Raben Rosenberg, Lone Fjordback, Jack Brandholdt, Leslie Foldager, Leo Sher, and Povl Munk-Jørgensen. ""Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects."" Psychological medicine 37, no. 7 (2007): 935-945.",2007,2002-2004,Observational,Denmark,22.3,16,30,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,arendt2007_canHalDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
26,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,Age (younger),Age (young),no,Age,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_age,cohen,,Yes,Yes,
27,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,Gender (male vs. female),Gender (male),no,Gender,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_gender,cohen,,Yes,Yes,
28,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,Ethnicity,Ethnicity,no,Ethnicity,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_ethnicity,cohen,,Yes,Yes,
29,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,GeneralHealth,General health,no,Health,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_health,cohen,,Yes,Yes,
30,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,SocioeconomicStatus,SES,no,SES,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_hallucination_ses,cohen,,Yes,Yes,
31,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,Cannabis dependency (present vs. absent),Cannabis dependency,no,CannabisSeverity,CannabisHistory,independent,extract_levyHallucinations_CUD,pEstimate_levyHallucinations_CUD,cohen,,Yes,Yes,
32,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,Frequency (high vs. low),Frequency (heavy),no,CannabisSeverity,CannabisHistory,independent,extract_levyHallucinations_frequency,pEstimate_levyHallucinations_frequency,cohen,,Yes,Yes,
33,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,Anxiety (present vs. absent),Anxiety,no,Anxiety,MentalHealthPersonality,independent,extract_levyHallucinations_anxiety,pEstimate_levyHallucinations_anxiety,cohen,,Yes,Yes,
34,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,Depression (present vs. absent),Depression,no,Depression,MentalHealthPersonality,independent,extract_levyHallucinations_depression,pEstimate_levyHallucinations_depression,cohen,,Yes,Yes,
35,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,Age,Age,no,Age,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_age,cohen,,Yes,Yes,
36,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,Gender (male vs. female),Gender (male),no,Gender,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_gender,cohen,,Yes,Yes,
37,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,Ethnicity,Ethnicity,no,Ethnicity,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_ethnicity,cohen,,Yes,Yes,
38,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,GeneralHealth,General health,no,Health,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_health,cohen,,Yes,Yes,
39,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,SocioeconomicStatus,SES,no,SES,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=40, n.2=106)",pEstimate_levy_paranoia_ses,cohen,,Yes,Yes,
40,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,Cannabis dependency (present vs. absent),Cannabis dependency,no,CannabisSeverity,CannabisHistory,independent,extract_levyParanoia_CUD,pEstimate_levyParanoia_CUD,cohen,,Yes,Yes,
41,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,Frequency (heavy vs. light),Frequency (heavy),no,CannabisSeverity,CannabisHistory,independent,extract_levyParanoia_frequency,pEstimate_levyParanoia_frequency,cohen,,Yes,Yes,
42,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,Anxiety (present vs. absent),Anxiety,no,Anxiety,CannabisHistory,independent,extract_levyParanoia_anxiety,pEstimate_levyParanoia_anxiety,cohen,,Yes,Yes,
43,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,Depression (present vs. absent),Depression,no,Depression,CannabisHistory,independent,extract_levyParanoia_depression,pEstimate_levyParanoia_depression,cohen,,Yes,Yes,
44,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,levy2019_canHalDF,NA,rates,,Yes,Yes,
45,Levy,Levy_survey,"Levy, Sharon, and Elissa R. Weitzman. ""Acute Mental Health Symptoms in Adolescent Marijuana Users."" JAMA pediatrics 173, no. 2 (2019): 185-186.",2018,NA,Observational,US,16.6,14,18,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,levy2019_canParDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
47,Barkus,Barkus_sample,"Barkus, Emma, and Shon Lewis. ""Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample."" Psychological Medicine 38, no. 9 (2008): 1267-1276.",2008,NA,Observational,UK,22,NA,NA,Can.PLE,psych_like,Schizotype (high vs. low),Schizotype (high),no,PsychosisLiability,MentalHealthPersonality,independent,"fes(barkus_schizotype_psych_f, barkus_n/2, barkus_n/2,  dig=20)",pEstimate_barkus_schizotype_psych,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
49,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PAR,psych_like,Pre-existing psychosis (present vs. absent),Pre-existing psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extracted_bianconi_PsychosisLiability_paranoia,pEstimate_bianconi_patients_paranoia,cohen,,Yes,Yes,
50,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.HAL,psych_like,Pre-existing psychosis (present vs. absent),Pre-existing psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extracted_bianconi_PsychosisLiability_hallucinations,pEstimate_bianconi_patients_hallucination,cohen,,Yes,Yes,
51,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,Pre-existing psychosis (present vs. absent),Pre-existing psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extracted_bianconi_Caseness_PsychosisLike_regression,pEstimate_bianconi_caseness,cohen,,Yes,Yes,
52,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,CannabisType (high vs. low potency),Cannabis potency (high),no,THCcontent,CannabisStrain,independent,extracted_bianconi_TypeCan_PsychosisLike_regression,pEstimate_bianconi_typeCan,cohen,,Yes,Yes,
53,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,CannabisBeliefs,Cannabis beliefs,no,Other,Other,independent,extracted_bianconi_belief_PsychosisLike_regression,pEstimate_bianconi_belief,cohen,,Yes,Yes,
54,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,AlcoholUse,Alcohol use,no,Alcohol,OtherDrugs,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes,
55,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,OtherDrugUse,Other drug use,no,OtherDrugs,OtherDrugs,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,No,No,
56,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,CigaretteUse,Cigarette use,no,Nicotine,OtherDrugs,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes,
57,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,Money spent on cannabis,Cannabis amount (high),no,CannabisSeverity,CannabisHistory,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes,
58,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,DurationCannabisUse,Long-term cannabis use,no,CannabisDuration,CannabisHistory,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes,
59,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PLE,psych_like,FrequencyCannabisUse,Frequency (heavy),no,CannabisSeverity,CannabisHistory,independent,"pes(p=pValueNS_allStudies, n.1=bianconi_regression_n/2, n.2=bianconi_regression_n/2)",pEstimate_bianconi_ns,cohen,,Yes,Yes,
60,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,bianconi2016_canParDF,NA,rates,,Yes,Yes,
61,Bianconi,GAP_EUGEI,"Bianconi, F., M. Bonomo, A. Marconi, A. Kolliakou, S. A. Stilo, C. Iyegbe, P. Gurillo Muñoz et al. ""Differences in cannabis-related experiences between patients with a first episode of psychosis and controls."" Psychological medicine 46, no. 5 (2016): 995-1003.",2016,2005-2011,Observational,Uk,28.5,NA,NA,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,bianconi2016_canHalDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
63,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,UK,20.6,16,23,High.PLE,psych_like,"AKT1 (rs2494732, risk allele: C)","AKT1 (rs2494732, risk allele: C)",no,AKT1,excluded,independent,"compute.es::tes(2.443 , n_morgan/2, n_morgan/2, dig=20)",pEstimate_morgan_akt,cohen,,Yes,Yes,
64,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,UK,20.6,16,23,High.PLE,psych_like,Gender (male vs. female),Gender (male),yes,Gender,excluded,independent,"compute.es::tes(1.042 , n_morgan/2, n_morgan/2, dig=20)",pEstimate_morgan_gender,cohen,,Yes,Yes,
65,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,UK,20.6,16,23,High.PLE,psych_like,Schizotype,Schizotype (high),no,PsychosisLiability,excluded,independent,"compute.es::tes(8.410 , n_morgan/2, n_morgan/2, dig=20) ",pEstimate_morgan_schizotype,cohen,,Yes,Yes,
66,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,UK,20.6,16,23,High.PLE,psych_like,Cannabis dependency (present vs. absent),Cannabis in system (high),no,Tolerance,excluded,independent,"compute.es::tes(0.688 , n_morgan/2, n_morgan/2, dig=20) ",pEstimate_morgan_canDep,no,,no,exluded as not placebo-controlled experiment,
67,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,UK,20.6,16,23,High.PLE,psych_like,Ethnicity ,Ethnicity ,no,Ethnicity,excluded,independent,"compute.es::tes(1.614 , n_morgan/2, n_morgan/2, dig=20)",pEstimate_morgan_ethnicity,cohen,,Yes,Yes,
68,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,UK,20.6,16,23,High.PLE,psych_like,YearsCannabisUse,Long-term cannabis use,yes,CannabisDuration,excluded,independent,"compute.es::tes(2.019 , n_morgan/2, n_morgan/2, dig=20)",pEstimate_morgan_yearsCan,cohen,,Yes,Yes,
69,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,UK,20.6,16,23,High.PLE,psych_like,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",no,CandidateGene,excluded,independent,"compute.es::tes(0.691 , n_morgan/2, n_morgan/2, dig=20) ",pEstimate_morgan_comt,cohen,,Yes,Yes,
70,Morgan,Morgan_Curran_MRC,"Morgan, C. J. A., T. P. Freeman, J. C. H. V. Powell, and H. V. Curran. ""AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers."" Translational psychiatry 6, no. 2 (2016): e738.",2016,NA,QuasiExperimental,UK,20.6,16,23,High.PLE,psych_like,THC/CBD ratio,CBD content (low),no,CBD,excluded,independent,"compute.es::tes(0.799 , n_morgan_sub/2, n_morgan_sub/2, dig=20) ",pEstimate_morgan_strain,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
72,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Single dose smoked  (quasiexperimental),Single dose smoked ,no,Other,excluded,dependent,extract_curran2019_dose_PSI,pEstimate_curran2019_dose_PSI,cohen,,no,no,
73,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Single dose smoked  (quasiexperimental),Single dose smoked ,no,Other,excluded,dependent,extract_curran2019_dose_BPRS,pEstimate_curran2019_dose_BPRS,cohen,,no,no,
74,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Cannabis dependency (present vs. absent),Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_PSI_cannabis_dependence_r, n=curran2019_cannabis_dependence_n, dig=20)",pEstimate_curran2019_PSI_cannabis_dependence,cohen,,no,no,
75,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Cannabis dependency (present vs. absent),Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_BPRS_cannabis_dependence_r, n=curran2019_cannabis_dependence_n, dig=20)",pEstimate_curran2019_BPRS_cannabis_dependence,cohen,,no,no,
76,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Cannabis use disorder (present vs. absent),Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_PSI_dsm_CUD_r, n=curran2019_dsm_CUD_n, dig=20)",pEstimate_curran2019_PSI_dsm_CUD,cohen,,no,no,
77,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Cannabis use disorder (present vs. absent),Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_BPRS_dsm_CUD_r, n=curran2019_dsm_CUD_n, dig=20)",pEstimate_curran2019_BPRS_dsm_CUD,cohen,,no,no,
78,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Age,Age,no,Age,Demographic,independent,"res(curran2019_PSI_age_r, n=curran2019_age_n, dig=20)",pEstimate_curran2019_PSI_age,cohen,,Yes,Yes,
79,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Age,Age,no,Age,Demographic,independent,"res(curran2019_BPRS_age_r, n=curran2019_age_n, dig=20)",pEstimate_curran2019_BPRS_age,cohen,,Yes,Yes,
80,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Gender (male vs. female),Gender (male),no,Gender,Demographic,independent,"res(curran2019_PSI_gender_r, n=curran2019_gender_n, dig=20)",pEstimate_curran2019_PSI_gender,cohen,,Yes,Yes,
81,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Gender (male vs. female),Gender (male),no,Gender,Demographic,independent,"res(curran2019_BPRS_gender_r, n=curran2019_gender_n, dig=20)",pEstimate_curran2019_BPRS_gender,cohen,,Yes,Yes,
82,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC content (increasing %),Potency (high),no,THCcontent,CannabisStrain,independent,"res(curran2019_PSI_perTHCcontent_r, n=curran2019_perTHCcontent_n, dig=20)",pEstimate_curran2019_PSI_perTHCcontent,cohen,,Yes,Yes,
83,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC content (increasing %),Potency (high),no,THCcontent,CannabisStrain,independent,"res(curran2019_BPRS_perTHCcontent_r, n=curran2019_perTHCcontent_n, dig=20)",pEstimate_curran2019_BPRS_perTHCcontent,cohen,,Yes,Yes,
84,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,CBD content in smoked cannabis,CBD content (low),no,CBDcontent,CannabisStrain,independent,"res(curran2019_PSI_perCBDcontent_r, n=curran2019_perCBDcontent_n, dig=20)",pEstimate_curran2019_PSI_perCBDcontent,cohen,,Yes,Yes,
85,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,CBD content in smoked cannabis,CBD content (low),no,CBDcontent,CannabisStrain,independent,"res(curran2019_BPRS_perCBDcontent_r, n=curran2019_perCBDcontent_n, dig=20)",pEstimate_curran2019_BPRS_perCBDcontent,cohen,,Yes,Yes,
86,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC in urine (increasing THC-COOH/creatinine),Cannabis in system (high),no,THC-COOH levels,CannabisDynamics,independent,"res(curran2019_PSI_THCconcentration_urine_r, n=curran2019_THCconcentration_urine_n, dig=20)",pEstimate_curran2019_PSI_THCconcentration_urine,cohen,,Yes,Yes,
87,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC in urine (increasing THC-COOH/creatinine),Cannabis in system (high),no,THC-COOH levels,CannabisDynamics,independent,"res(curran2019_BPRS_THCconcentration_urine_r, n=curran2019_THCconcentration_urine_n, dig=20)",pEstimate_curran2019_BPRS_THCconcentration_urine,cohen,,Yes,Yes,
88,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC in hair (analyte present vs. absent),Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_PSI_THCconcentration_hair_r, n=curran2019_THCconcentration_hair_n, dig=20)",pEstimate_curran2019_PSI_THCconcentration_hair,cohen,,no,no,
89,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC in hair (analyte present vs. absent),Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_BPRS_THCconcentration_hair_r, n=curran2019_THCconcentration_hair_n, dig=20)",pEstimate_curran2019_BPRS_THCconcentration_hair,cohen,,no,no,
90,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,CBD in hair (analyte absent vs. present),CBD in hair,no,CBDcontent,CannabisStrain,independent,"res(curran2019_PSI_CBDconcentration_hair_r, n=curran2019_CBDconcentration_hair_n, dig=20)",pEstimate_curran2019_PSI_CBDconcentration_hair,cohen,,Yes,Yes,
91,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,CBD in hair (analyte absent vs. present),CBD in hair,no,CBDcontent,CannabisStrain,independent,"res(curran2019_BPRS_CBDconcentration_hair_r, n=curran2019_CBDconcentration_hair_n, dig=20)",pEstimate_curran2019_BPRS_CBDconcentration_hair,cohen,,Yes,Yes,
92,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,CBN in hair (analyte present vs. absent),CBN in body (high),no,Other,Other,independent,"res(curran2019_PSI_CBNconcentration_hair_r, n=curran2019_CBNconcentration_hair_n, dig=20)",pEstimate_curran2019_PSI_CBNconcentration_hair,cohen,,Yes,Yes,
93,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,CBN in hair (analyte present vs. absent),CBN in body (high),no,Other,Other,independent,"res(curran2019_BPRS_CBNconcentration_hair_r, n=curran2019_CBNconcentration_hair_n, dig=20)",pEstimate_curran2019_BPRS_CBNconcentration_hair,cohen,,Yes,Yes,
94,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC-COOH in hair (analyte present vs. absent),Cannabis in system (high),no,THC-COOH levels,CannabisDynamics,independent,"res(curran2019_PSI_THC_COOHhair_r, n=curran2019_THC_COOHhair_n, dig=20)",pEstimate_curran2019_PSI_THC_COOHhair,cohen,,Yes,Yes,
95,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC-COOH in hair (analyte present vs. absent),Cannabis in system (high),no,THC-COOH levels,CannabisDynamics,independent,"res(curran2019_BPRS_THC_COOHhair_r, n=curran2019_THC_COOHhair_n, dig=20)",pEstimate_curran2019_BPRS_THC_COOHhair,cohen,,Yes,Yes,
96,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC-OH in hair (analyte present vs. absent),Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_PSI_THC_OHhair_r, n=curran2019_THC_OHhair_n, dig=20)",pEstimate_curran2019_PSI_THC_OHhair,cohen,,no,no,
97,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,THC-OH in hair (analyte present vs. absent),Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_BPRS_THC_OHhair_r, n=curran2019_THC_OHhair_n, dig=20)",pEstimate_curran2019_BPRS_THC_OHhair,cohen,,no,no,
98,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Age when first used (younger),Age onset cannabis use (young),no,Age onset,CannabisHistory,independent,"res(curran2019_PSI_age_firstUse_r, n=curran2019_age_firstUse_n, dig=20)",pEstimate_curran2019_PSI_age_firstUse,cohen,,Yes,Yes,
99,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Age when first used (younger),Age onset cannabis use (young),no,Age onset,CannabisHistory,independent,"res(curran2019_BPRS_age_firstUse_r, n=curran2019_age_firstUse_n, dig=20)",pEstimate_curran2019_BPRS_age_firstUse,cohen,,Yes,Yes,
100,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Recency of use (longer abstinence),Cannabis in system (high),yes,Tolerance,CannabisDynamics,independent,"res(curran2019_PSI_recency_days_r, n=curran2019_recency_days_n, dig=20)",pEstimate_curran2019_PSI_recency_days,cohen,,no,no,
101,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Recency of use (longer abstinence),Cannabis in system (high),yes,Tolerance,CannabisDynamics,independent,"res(curran2019_BPRS_recency_days_r, n=curran2019_recency_days_n, dig=20)",pEstimate_curran2019_BPRS_recency_days,cohen,,no,no,
102,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Days per months used cannabis (more days),Frequency (heavy),no,Tolerance,CannabisDynamics,independent,"res(curran2019_PSI_frequecny_month_r, n=curran2019_frequecny_month_n, dig=20)",pEstimate_curran2019_PSI_frequecny_month,cohen,,no,no,
103,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Days per months used cannabis (more days),Frequency (heavy),no,Tolerance,CannabisDynamics,independent,"res(curran2019_BPRS_frequecny_month_r, n=curran2019_frequecny_month_n, dig=20)",pEstimate_curran2019_BPRS_frequecny_month,cohen,,no,no,
104,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Time to smoke 3.5g cannabis,Frequency (heavy),yes,Tolerance,CannabisDynamics,independent,"res(curran2019_PSI_time_smoked3.5g_r, n=curran2019_time_smoked3.5g_n, dig=20)",pEstimate_curran2019_PSI_time_smoked3.5g,cohen,,no,no,
105,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Time to smoke 3.5g cannabis,Frequency (heavy),no,Tolerance,CannabisDynamics,independent,"res(curran2019_BPRS_time_smoked3.5g_r, n=curran2019_time_smoked3.5g_n, dig=20)",pEstimate_curran2019_BPRS_time_smoked3.5g,cohen,,no,no,
106,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Prefered potency (high potency),Potency (high),no,THCcontent,CannabisStrain,independent,"res(curran2019_PSI_highPotency_preference_r, n=curran2019_highPotency_preference_n, dig=20)",pEstimate_curran2019_PSI_highPotency_preference,cohen,,Yes,Yes,
107,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Prefered potency (high potency),Potency (high),no,THCcontent,CannabisStrain,independent,"res(curran2019_BPRS_highPotency_preference_r, n=curran2019_highPotency_preference_n, dig=20)",pEstimate_curran2019_BPRS_highPotency_preference,cohen,,Yes,Yes,
108,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Money spent on cannabis,Cannabis amount (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_PSI_money_spent_week_r, n=curran2019_money_spent_week_n, dig=20)",pEstimate_curran2019_PSI_money_spent_week,cohen,,no,no,
109,Curran,Morgan_Curran_MRC,"Curran, H. Valerie, Chandni Hindocha, Celia JA Morgan, Natacha Shaban, Ravi K. Das, and Tom P. Freeman. ""Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?."" Psychological medicine 49, no. 9 (2019): 1574-1580.",2019,NA,QuasiExperimental,UK,20.6,16,23,THC.PLE,psych_like,Money spent on cannabis,Cannabis amount (high),no,Tolerance,CannabisDynamics,independent,"res(curran2019_BPRS_money_spent_week_r, n=curran2019_money_spent_week_n, dig=20)",pEstimate_curran2019_BPRS_money_spent_week,cohen,,no,no,
,,,,,,,,,,,,,,,,,,,,,,,,,
111,Henquet,HenquetExperiment,"Henquet, Cécile, Araceli Rosa, Lydia Krabbendam, Sergi Papiol, Lourdes Fa_anás, Marjan Drukker, Johannes G. Ramaekers, and Jim van Os. ""An experimental study of catechol-o-methyltransferase Val 158 Met moderation of _-9-tetrahydrocannabinol-induced effects on psychosis and cognition."" Neuropsychopharmacology 31, no. 12 (2006): 2748.",2016,NA,Experiment,Netherlands,27.4,18,56,THC.PLE,psych_like,Single dose smoked  (0% vs 13% THC) [in cases with pre-existing psychosis],Single dose smoked (13% THC) [in cases with psychosis],no,Other,Other,dependent,"beta_to_d_independent(beta=beta_henquet_THC, se=se_henquet_THC, n=n_effective_henquet)",pEstimate_henquet_THCdose,cohen,,No,No,
112,Henquet,HenquetExperiment,"Henquet, Cécile, Araceli Rosa, Lydia Krabbendam, Sergi Papiol, Lourdes Fa_anás, Marjan Drukker, Johannes G. Ramaekers, and Jim van Os. ""An experimental study of catechol-o-methyltransferase Val 158 Met moderation of _-9-tetrahydrocannabinol-induced effects on psychosis and cognition."" Neuropsychopharmacology 31, no. 12 (2006): 2748.",2016,NA,Experiment,Netherlands,27.4,18,56,THC.PLE,psych_like,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",no,COMT,CandidateGene,independent,"chies(1.19, n_effective_henquet, dig=50)",pEstimate_henquet_gen_can_interaction,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
114,Cuttler,Sexton_survey,"Cuttler, Carrie, Laurie K. Mischley, and Michelle Sexton. ""Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users."" Cannabis and cannabinoid research 1, no. 1 (2016): 166-175.",2016,NA,Observational,US,33.72,18,80,Can.PAR,psych_like,Gender (male vs. female),Gender (male),yes,Gender,Demographic,independent,extract_cuttler_paranoia,pEstimate_cuttler_paranoia,cohen,,Yes,Yes,
115,Cuttler,Sexton_survey,"Cuttler, Carrie, Laurie K. Mischley, and Michelle Sexton. ""Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users."" Cannabis and cannabinoid research 1, no. 1 (2016): 166-175.",2016,NA,Observational,US,33.72,18,80,Can.HAL,psych_like,Gender (male vs. female),Gender (male),no,Gender,Demographic,independent,extract_cuttler_hallucinations,pEstimate_cuttler_hallucinations,cohen,,Yes,Yes,
116,Cuttler,Sexton_survey,"Cuttler, Carrie, Laurie K. Mischley, and Michelle Sexton. ""Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users."" Cannabis and cannabinoid research 1, no. 1 (2016): 166-175.",2016,NA,Observational,US,33.72,18,80,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,cuttler2016_canParDF,NA,rates,,Yes,Yes,
117,Cuttler,Sexton_survey,"Cuttler, Carrie, Laurie K. Mischley, and Michelle Sexton. ""Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users."" Cannabis and cannabinoid research 1, no. 1 (2016): 166-175.",2016,NA,Observational,US,33.72,18,80,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,cuttler2016_canHalDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
119,Vadhan,Vadhan,"Vadhan, Nehal P., Cheryl M. Corcoran, Gill Bedi, John G. Keilp, and Margaret Haney. ""Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study."" Psychiatry research 257 (2017): 372-374.",2017,NA,Experiment,US,NA,NA,NA,THC.PAR,psych_like,Clinical high-risk for psychosis  vs. control,High risk psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,"mes(vadhan_cases_5percTHC_t1_m, vadhan_healthy_5percTHC_t1_m, vadhan_cases_5percTHC_t1_sd, vadhan_healthy_5percTHC_t1_sd, vadhan_cases_n, vadhan_healthy_n, dig=20)",pEstimate_vadhan_caseness_paranoia_smoked_0perc_5.5percTHC,cohen,,Yes,Yes,
120,Vadhan,Vadhan,"Vadhan, Nehal P., Cheryl M. Corcoran, Gill Bedi, John G. Keilp, and Margaret Haney. ""Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study."" Psychiatry research 257 (2017): 372-374.",2017,NA,Experiment,US,NA,NA,NA,THC.PAR,psych_like,Single dose smoked (50% of joint) (0% vs 5% THC) [in UHR subjects],Single dose smoked (5% THC) [in UHR subjects],no,Other,excluded,dependent,extract_vadhan_cases_paranoia_smoked_0perc_5.5percTHC,pEstimate_vadhan_cases_paranoia_smoked_0perc_5.5percTHC,cohen,,No,No,
121,Vadhan,Vadhan,"Vadhan, Nehal P., Cheryl M. Corcoran, Gill Bedi, John G. Keilp, and Margaret Haney. ""Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study."" Psychiatry research 257 (2017): 372-374.",2017,NA,Experiment,US,NA,NA,NA,THC.PAR,psych_like,Single dose smoked (50% of joint) (0% vs 5% THC),Single dose smoked (5% THC),no,SingleDose,excluded,dependent,extract_vadhan_healthy_paranoia_smoked_0perc_5.5percTHC,pEstimate_vadhan_healthy_paranoia_smoked_0perc_5.5percTHC,cohen,,No,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
123,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,UK,29.5,18,NA,Can.PLE,psych_like,Cessation of use (current vs. former),Cannabis use (current),no,CannabisSeverity,CannabisHistory,independent,extracted_Sami_PsychLike_ceased_continued,pEstimate_Sami_psychlike_ceased_vs_continued,cohen,,Yes,Yes,
124,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,UK,29.5,18,NA,Can.PLE,psych_like,Gender (male vs. female) in ceased cannabis users,Gender (male),no,Gender,Demographic,independent,extracted_Sami_PsychLike_ceased_sex,pEstimate_Sami_psychlike_gender_ceased,cohen,,Yes,Yes,
125,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,UK,29.5,18,NA,Can.PLE,psych_like,Gender (male vs. female) in continued cannabis users,Gender (male),no,Gender,Demographic,independent,extracted_Sami_PsychLike_continued_sex,pEstimate_Sami_psychlike_gender_continued,cohen,,Yes,Yes,
126,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,UK,29.5,18,NA,Can.PLE,psych_like,Intention to quit cannabis in the future (yes vs. no),Intention to quit,no,Other,Other,independent,extracted_Sami_PsychLike_quit,pEstimate_Sami_continued_quit_yes_vs_no,cohen,,Yes,Yes,
127,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,UK,29.5,18,NA,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,sami2019survey_canParDF,NA,rates,,Yes,Yes,
128,Sami,SamiSurvey,"Sami, Musa, Caitlin Notley, Christos Kouimtsidis, Michael Lynskey, and Sagnik Bhattacharyya. ""Psychotic-like experiences with cannabis use predict cannabis cessation and desire to quit: a cannabis discontinuation hypothesis."" Psychological medicine 49, no. 1 (2019): 103-112.",2018,2015-2016,Observational,UK,29.5,18,NA,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,sami2019survey_canHalDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
130,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,US,27.3,NA,NA,THC.PAR,psych_like,Route (25mg THC: vaporizer vs. smoke),Route (vaporized),no,Route (vaporized),CannabisDynamics,dependent,extract_spindle_paranoia_25mgTHC_smoked_vs_vaped,pEstimate_Spindle_paranoia_vaporizer_smoke_25mgTHC,cohen,,No,No,
131,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,US,27.3,NA,NA,THC.PAR,psych_like,Single dose smoked (0mg vs 10mg THC),Single dose smoked (10mg THC),no,SingleDose,CannabisDynamics,dependent,extract_spindle_paranoia_smoked_0mg_10mgTHC,pEstimate_spindle_paranoia_smoked_0mg_10mgTHC,cohen,,Yes,Yes,
132,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,US,27.3,NA,NA,THC.PAR,psych_like,Single dose smoked (0mg vs 25mg THC),Single dose smoked (25mg THC),no,SingleDose,CannabisDynamics,dependent,extract_spindle_paranoia_smoked_0mg_25mgTHC,pEstimate_spindle_paranoia_smoked_0mg_25mgTHC,cohen,,Yes,Yes,
133,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,US,27.3,NA,NA,THC.PAR,psych_like,Single dose vaped (0mg vs 10mg THC),Single dose vaped (10mg THC),no,SingleDose,CannabisDynamics,dependent,extract_spindle_paranoia_vaped_0mg_10mgTHC,pEstimate_spindle_paranoia_vaped_0mg_10mgTHC,cohen,,Yes,Yes,
134,Spindle1,Spindle2018,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial."" JAMA network open 1, no. 7 (2018): e184841-e184841.",2018,2016-2017,Experiment,US,27.3,NA,NA,THC.PAR,psych_like,Single dose vaped (0mg vs 25mg THC),Single dose vaped (25mg THC),no,SingleDose,CannabisDynamics,dependent,extract_spindle_paranoia_vaped_0mg_25mgTHC,pEstimate_spindle_paranoia_vaped_0mg_25mgTHC,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
136,Spindle2,Spindle2019,"Spindle, Tory R., Edward J. Cone, Nicolas J. Schlienz, John M. Mitchell, George E. Bigelow, Ronald Flegel, Eugene Hayes, and Ryan Vandrey. ""Acute pharmacokinetic profile of smoked and vaporized cannabis in human blood and oral fluid."" Journal of analytical toxicology 43, no. 4 (2019): 233-258.",2019,2016-2017,Experiment,US,27.3,NA,NA,THC.HAL,psych_like,rates,rates,no,rates,rates,NA,spindle2019vapeTHC_halDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
138,Spindle3,MEGA_Vandrey_Schlienz_Spindle,"Spindle, Tory R., Edward J. Cone, Elia Goffi, Elise M. Weerts, John M. Mitchell, Ruth E. Winecker, George E. Bigelow, Ronald R. Flegel, and Ryan Vandrey. ""Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users."" Drug and Alcohol Dependence (2020): 107937.",2020,NA,Experiment,US,31,18,45,THC.PAR,psych_like,Single dose vaped (0mg vs 3.7mg THC of CBD dominant cannabis),Single dose vaped (3.7mg THC),no,SingleDose,CannabisDynamics,dependent,extract_spindle2020_paranoia_canCBD,pEstimate_spindle2020_paranoia_canCBD,cohen,,Yes,Yes,
139,Spindle3,MEGA_Vandrey_Schlienz_Spindle,"Spindle, Tory R., Edward J. Cone, Elia Goffi, Elise M. Weerts, John M. Mitchell, Ruth E. Winecker, George E. Bigelow, Ronald R. Flegel, and Ryan Vandrey. ""Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users."" Drug and Alcohol Dependence (2020): 107937.",2020,NA,Experiment,US,31,18,45,THC.PAR,psych_like,Gender (male vs. female),Gender (male),yes,Gender,Demographic,independent,"fes(spindle2020_paranoia_sex_f, spindle2020_male_n, spindle2020_female_n,  dig=20)",pEstimate_spindle2020_paranoia_sex,cohen,,No,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
141,Schlienz,Vandrey_T32DA07209,"Schlienz, Nicolas J., Tory R. Spindle, Edward J. Cone, Evan S. Herrmann, George E. Bigelow, John M. Mitchell, Ronald Flegel, Charles LoDico, and Ryan Vandrey. ""Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis."" Drug and alcohol dependence (2020): 107969.",2020,NA,Experiment,US,25.2,18,45,THC.PAR,psych_like,Single dose oral (0mg vs 10mg THC),Single dose oral (10mg THC),no,SingleDose,CannabisDynamics,dependent,extract_schlienz2020_edibleTHC_0mg_10mgTHC,pEstimate_schlienz2020_edibleTHC_0mg_10mgTHC,cohen,,Yes,Yes,
142,Schlienz,Vandrey_T32DA07209,"Schlienz, Nicolas J., Tory R. Spindle, Edward J. Cone, Evan S. Herrmann, George E. Bigelow, John M. Mitchell, Ronald Flegel, Charles LoDico, and Ryan Vandrey. ""Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis."" Drug and alcohol dependence (2020): 107969.",2020,NA,Experiment,US,25.2,18,45,THC.PAR,psych_like,Single dose vaped (0mg vs 25mg THC),Single dose vaped (25mg THC),no,SingleDose,CannabisDynamics,dependent,extract_schlienz2020_edibleTHC_0mg_25mgTHC,pEstimate_schlienz2020_edibleTHC_0mg_25mgTHC,cohen,,Yes,Yes,
143,Schlienz,Vandrey_T32DA07209,"Schlienz, Nicolas J., Tory R. Spindle, Edward J. Cone, Evan S. Herrmann, George E. Bigelow, John M. Mitchell, Ronald Flegel, Charles LoDico, and Ryan Vandrey. ""Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis."" Drug and alcohol dependence (2020): 107969.",2020,NA,Experiment,US,25.2,18,45,THC.PAR,psych_like,Single dose vaped (0mg vs 50mg THC),Single dose vaped (50mg THC),no,SingleDose,CannabisDynamics,dependent,extract_schlienz2020_edibleTHC_0mg_50mgTHC,pEstimate_schlienz2020_edibleTHC_0mg_50mgTHC,cohen,,Yes,Yes,
144,Schlienz,Vandrey_T32DA07209,"Schlienz, Nicolas J., Tory R. Spindle, Edward J. Cone, Evan S. Herrmann, George E. Bigelow, John M. Mitchell, Ronald Flegel, Charles LoDico, and Ryan Vandrey. ""Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis."" Drug and alcohol dependence (2020): 107969.",2020,NA,Experiment,US,25.2,18,45,THC.PAR,psych_like,Dose response oral (0mg/10mg/25mf/ 50mg THC),Dose response oral (0mg/10mg/25mf/ 50mg THC),no,DoseResponseTHC,CannabisDynamics,dependent,"pes(0.00009, n_effective_schlienz2020_edibleTHC/2, n_effective_schlienz2020_edibleTHC/2, dig=50)",pEstimate_schlienz2020_edibleTHC_doseTHC,cohen,,No,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
146,Fuente,Fuente,"de la Fuente, Alethia, Federico Zamberlan, Andrés Sánchez Ferrán, Facundo Carrillo, Enzo Tagliazucchi, and Carla Pallavicini. ""Over eight hundred cannabis strains characterized by the relationship between their psychoactive effects, perceptual profiles, and chemical compositions."" bioRxiv (2019): 759696.",2019,2010-2018,Observational,Worldwide,NA,NA,NA,Can.PAR,psych_like,Type of cannabis (indica vs. sativa),Indica (vs. sativa),no,Other,Other,independent,"mes(M_Indica, M_Sativa, SD_Indica, SD_Sativa, N_Indica, N_Sativa, dig=20)",pEstimate_fuente2019_paranoia_indica_sativa,cohen,,Yes,Yes,
147,Fuente,Fuente,"de la Fuente, Alethia, Federico Zamberlan, Andrés Sánchez Ferrán, Facundo Carrillo, Enzo Tagliazucchi, and Carla Pallavicini. ""Over eight hundred cannabis strains characterized by the relationship between their psychoactive effects, perceptual profiles, and chemical compositions."" bioRxiv (2019): 759696.",2019,2010-2018,Observational,Worldwide,NA,NA,NA,Can.PAR,psych_like,Type of cannabis (indica vs. hybrid),Indica (vs. hybrid),no,Other,Other,independent,"mes(M_Indica, M_Hybrid, SD_Indica, SD_Hybrid, N_Indica, N_Hybrid, dig=20)",pEstimate_fuente2019_paranoia_indica_hybrid,cohen,,Yes,Yes,
148,Fuente,Fuente,"de la Fuente, Alethia, Federico Zamberlan, Andrés Sánchez Ferrán, Facundo Carrillo, Enzo Tagliazucchi, and Carla Pallavicini. ""Over eight hundred cannabis strains characterized by the relationship between their psychoactive effects, perceptual profiles, and chemical compositions."" bioRxiv (2019): 759696.",2019,2010-2018,Observational,Worldwide,NA,NA,NA,Can.PAR,psych_like,Type of cannabis (hybrid vs. sativa),Hybrid (vs. sativa),no,Other,Other,independent,"mes(M_Hybrid, M_Sativa, SD_Hybrid, SD_Sativa, N_Hybrid, N_Sativa, dig=20)",pEstimate_fuente2019_paranoia_sativa_hybrid,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
150,Mason,Morgan_Curran_MRC,"Mason, O., C. J. A. Morgan, S. K. Dhiman, A. Patel, N. Parti, and H. V. Curran. ""Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis."" Psychological medicine 39, no. 6 (2009): 951-956.",2009,NA,QuasiExperimental,UK,24.2,NA,NA,High.PLE,psych_like,Frequency of cannabis use,Cannabis in system (high),yes,Tolerance,exlcuded,independent,"res(mason_can_r, n=mason_can_frequency_n, dig=20)",pEstimate_mason_canFrequency_psychlike,cohen,,no,no,
151,Mason,Morgan_Curran_MRC,"Mason, O., C. J. A. Morgan, S. K. Dhiman, A. Patel, N. Parti, and H. V. Curran. ""Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis."" Psychological medicine 39, no. 6 (2009): 951-956.",2009,NA,QuasiExperimental,UK,24.2,NA,NA,High.PLE,psych_like,Cannabis group (current user vs. control with at least 6 months of use),Cessation of use (current user),no,Cessation,exlcuded,independent,"fes(mason_can_vs_control_PSI_f, mason_can_n, mason_control_n,  dig=20)",pEstimate_mason_can_vs_control_PSI,cohen,,no,no,
152,Mason,Morgan_Curran_MRC,"Mason, O., C. J. A. Morgan, S. K. Dhiman, A. Patel, N. Parti, and H. V. Curran. ""Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis."" Psychological medicine 39, no. 6 (2009): 951-956.",2009,NA,QuasiExperimental,UK,24.2,NA,NA,High.PAR,psych_like,Cannabis group (current user vs. control with at least 6 months of use),Cessation of use (current user),no,Cessation,exlcuded,independent,"fes(mason_can_vs_control_paranoia_f, mason_can_n, mason_control_n,  dig=20)",pEstimate_mason_can_vs_control_paranoia,cohen,,no,no,
153,Mason,Morgan_Curran_MRC,"Mason, O., C. J. A. Morgan, S. K. Dhiman, A. Patel, N. Parti, and H. V. Curran. ""Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis."" Psychological medicine 39, no. 6 (2009): 951-956.",2009,NA,QuasiExperimental,UK,24.2,NA,NA,High.PLE,psych_like,Schizotype (high vs. low),Schizotype (high),no,PsychosisLiability,exlcuded,independent,"fes(mason_highSchizotype_vs_lowSchizotype_PSI_f, mason_can_n, mason_control_n,  dig=20)",pEstimate_mason_highSchizotype_vs_lowSchizotype_PSI,cohen,,no,no,
,,,,,,,,,,,,,,,,,,,,,,,,,
155,D'Souza,DSouza,"D'Souza, Deepak Cyril, Edward Perry, Lisa MacDougall, Yola Ammerman, Thomas Cooper, Gabriel Braley, Ralitza Gueorguieva, and John Harrison Krystal. ""The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis."" Neuropsychopharmacology 29, no. 8 (2004): 1558-1572.",2004,NA,Experiment,US,29,NA,NA,THC.PLE,psych_like,Caseness (psychosis patient vs health control),Psychosis,no,PsychosisLiability,MentalHealthPersonality,dependent,"chies(chiSquEstimate_souza_dose_case_interaction, n_effective_healthy_souza+n_effective_cases_souza, dig=50)",pEstimate_Dsouza_PANSS_pos_dose_case_interaction,cohen,,Yes,No,
156,D'Souza,DSouza,"D’Souza, Deepak Cyril, Walid Michel Abi-Saab, Steven Madonick, Kimberlee Forselius-Bielen, Anne Doersch, Gabriel Braley, Ralitza Gueorguieva, Thomas B. Cooper, and John Harrison Krystal. ""Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction."" Biological psychiatry 57, no. 6 (2005): 594-608.",2005,NA,Experiment,US,44,NA,NA,THC.PLE,psych_like,Single dose IV (0mg vs 2.5mg),Single dose IV (2.5mg),no,SingleDose,CannabisDynamics,dependent,extract_souza_2.5mg_THC_panss,pEstimate_Dsouza_PANSS_pos_dose,cohen,,Yes,No,
157,D'Souza,DSouza,"D’Souza, Deepak Cyril, Walid Michel Abi-Saab, Steven Madonick, Kimberlee Forselius-Bielen, Anne Doersch, Gabriel Braley, Ralitza Gueorguieva, Thomas B. Cooper, and John Harrison Krystal. ""Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction."" Biological psychiatry 57, no. 6 (2005): 594-608.",2005,NA,Experiment,US,44,NA,NA,THC.PLE,psych_like,Single dose IV (0mg vs 5mg),Single dose IV (5mg),no,SingleDose,CannabisDynamics,dependent,extract_souza_5mg_THC_panss,pEstimate_Dsouza_PANSS_pos_dose,cohen,,Yes,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
159,Solowij,Solowij,"Solowij, Nadia, Samantha Broyd, Lisa-marie Greenwood, Hendrika van Hell, Dave Martelozzo, Kuna Rueb, Juanita Todd et al. ""A randomised controlled trial of vaporised _ 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects."" European archives of psychiatry and clinical neuroscience 269, no. 1 (2019): 17-35.",2019,NA,Experiment,Australia,NA,21,44,High.DEL,psych_like,Intoxication experiences (8mg THC),Intoxication experiences (8mg THC),no,SubjectiveHigh,exlcuded,independent,"res(rValueNS_allStudies, n=nSolowij, dig=20) ",pEstimate_solowij_delusions,cohen,,no,no,
160,Solowij,Solowij,"Solowij, Nadia, Samantha Broyd, Lisa-marie Greenwood, Hendrika van Hell, Dave Martelozzo, Kuna Rueb, Juanita Todd et al. ""A randomised controlled trial of vaporised _ 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects."" European archives of psychiatry and clinical neuroscience 269, no. 1 (2019): 17-35.",2019,NA,Experiment,Australia,NA,21,44,High.PAR,psych_like,Intoxication experiences (8mg THC),Intoxication experiences (8mg THC),no,SubjectiveHigh,exlcuded,independent,"res(rValueNS_allStudies, n=nSolowij, dig=20) ",pEstimate_solowij_paranoia,cohen,,no,no,
,,,,,,,,,,,,,,,,,,,,,,,,,
162,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,Gender (male vs. female),Gender (male),no,Gender,Demographic,independent,extract_krebs_gender,pEstimate_krebs_gender,cohen,,Yes,Yes,
163,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,Family history (mood disorder),Mood disorder (fam hx),no,Depression,MentalHealthPersonality,independent,extract_krebs_mood,pEstimate_krebs_mood,cohen,,Yes,Yes,
164,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,Family history (psychosis),Psychosis (fam hx),yes,PsychosisLiability,MentalHealthPersonality,independent,extract_krebs_psychosishx,pEstimate_krebs_psychosishx,cohen,,Yes,Yes,
165,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,Age (young vs. old),Age (young),yes,Age,Demographic,independent,extract_krebs_age,pEstimate_krebs_age,cohen,,Yes,Yes,
166,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"CNR1 (rs806379, risk allele: T)","CNR1 (rs806379, risk allele: T)",yes,CNR1,CandidateGene,independent,"chies(KrebsCNR1_rs806379,59+485, dig=50)",pEstimate_krebs_rs806379,cohen,,Yes,Yes,
167,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"CNR1 (rs1535255, risk allele: C)","CNR1 (rs1535255, risk allele: C)",no,CNR1,CandidateGene,independent,"chies(KrebsCNR1_rs1535255,58+485, dig=50)",pEstimate_krebs_rs1535255,cohen,,Yes,Yes,
168,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"CNR1 (rs2023239, risk allele: A)","CNR1 (rs2023239, risk allele: A)",yes,CNR1,CandidateGene,independent,"chies(KrebsCNR1_rs2023239, 59+481, dig=50)",pEstimate_krebs_rs2023239,cohen,,Yes,Yes,
169,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"CNR1 (rs1049353, A)","CNR1 (rs1049353, A)",no,CNR1,CandidateGene,independent,"chies(KrebsCNR1_rs1049353, 59+476, dig=50)",pEstimate_krebs_rs1049353,cohen,,Yes,Yes,
170,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"CNR1 (rs12720071, risk allele: G)","CNR1 (rs12720071, risk allele: G)",yes,CNR1,CandidateGene,independent,"chies(KrebsCNR1_rs12720071, 59+485, dig=50)",pEstimate_krebs_rs12720071,cohen,,Yes,Yes,
171,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",no,COMT,CandidateGene,independent,"chies(KrebsCOMT_rs4680, 59+479, dig=50)",pEstimate_krebs_rs4680,cohen,,Yes,Yes,
172,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"BDNF (rs6265, risk allele: G)","BDNF (rs6265, risk allele: G)",no,BDNF,CandidateGene,independent,"chies(KrebsBDNF_rs6265, 59+479, dig=50)",pEstimate_krebs_rs6265,cohen,,Yes,Yes,
173,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"AKT1 (rs1130233, risk allele: A)","AKT1 (rs1130233, risk allele: A)",no,AKT1,CandidateGene,independent,"chies(KrebsAKT_rs1130233, 59+479, dig=50)",pEstimate_krebs_rs1130233,cohen,,Yes,Yes,
174,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,"AKT1 (rs2494732, risk allele: C)","AKT1 (rs2494732, risk allele: C)",yes,AKT1,CandidateGene,independent,"chies(KrebsAKT_rs2494732, 59+479, dig=50)",pEstimate_krebs_rs2494732,cohen,,Yes,Yes,
175,Krebs,Krebs,"Krebs, M. O., Y. Morvan, T. Jay, R. Gaillard, and O. Kebir. ""Psychotomimetic effects at initiation of cannabis use are associated with cannabinoid receptor 1 (CNR1) variants in healthy students."" Molecular psychiatry 19, no. 4 (2014): 402-403.",2014,NA,Observational,France,19.8,NA,NA,Can.PLE,psych_like,rates,rates,no,rates,rates,NA,krebs2014_PLE_DF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
177,Barkus,Barkus_sample2,"Barkus, Emma J., John Stirling, Richard S. Hopkins, and Shon Lewis. ""Cannabis-induced psychosis-like experiences are associated with high schizotypy."" Psychopathology 39, no. 4 (2006): 175-178.",2006,NA,Observational,UK,22.1,NA,NA,Can.PLE,psych_like,Schizotype (disorganised),Schizotype (disorganized),no,PsychosisLiability,MentalHealthPersonality,independent,"res(spqb_d_cor, n=N_Barkus_2006, dig=20)",pEstimate_barkus_spqb_d_cor,cohen,,Yes,Yes,
178,Barkus,Barkus_sample2,"Barkus, Emma J., John Stirling, Richard S. Hopkins, and Shon Lewis. ""Cannabis-induced psychosis-like experiences are associated with high schizotypy."" Psychopathology 39, no. 4 (2006): 175-178.",2006,NA,Observational,UK,22.1,NA,NA,Can.PLE,psych_like,Schizotype (cognitive-perceptual),Schizotype (cognitive-perceptual),no,PsychosisLiability,MentalHealthPersonality,independent,"res(spqb_cp_cor, n=N_Barkus_2006, dig=20)",pEstimate_barkus_spqb_cp_cor,cohen,,Yes,Yes,
179,Barkus,Barkus_sample2,"Barkus, Emma J., John Stirling, Richard S. Hopkins, and Shon Lewis. ""Cannabis-induced psychosis-like experiences are associated with high schizotypy."" Psychopathology 39, no. 4 (2006): 175-178.",2006,NA,Observational,UK,22.1,NA,NA,Can.PLE,psych_like,Schizotype,Schizotype,no,PsychosisLiability,MentalHealthPersonality,independent,"res(spqb_tot_cor, n=N_Barkus_2006, dig=20)",pEstimate_barkus_spqb_tot_cor,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
181,Winstock,Winstock,"Winstock, Adam R., and Monica J. Barratt. ""Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample."" Drug and alcohol dependence 131, no. 1-2 (2013): 106-111.",2013,2012,Observational,Worldwide,NA,NA,NA,Can.PAR,psych_like,Type of cannabis (spice vs. normal),Synthetic cannabis,no,THCcontent,CannabisStrain,dependent,extract_winstock_delusional,pEstimate_winstock_delusional,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
183,Englund,Englund,"Englund, Amir, Zerrin Atakan, Aleksandra Kralj, Nigel Tunstall, Robin Murray, and Paul Morrison. ""The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial."" Journal of Psychopharmacology 30, no. 2 (2016): 140-151.",2016,NA,Experiment,UK,23.8,21,35,THC.PLE,psych_like,Single dose IV (0mg vs 1mg THC),Single dose IV (1mg THC),no,SingleDose,CannabisDynamics,dependent,extract_englund_cape_IV_1mg_THC,pEstimate_englund_cape_IV_1mg_THC,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
185,Stone,Stone,"Stone, J.M., Morrison, P.D., Brugger, S., Nottage, J., Bhattacharyya, S., Sumich, A., Wilson, D., Tunstall, N., Feilding, A., Brenneisen, R. and McGuire, P., 2012. Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence. Molecular psychiatry, 17(6), pp.568-569.",2012,NA,Experiment,UK,26,21,31,THC.PAR,psych_like,Single dose IV (0mg vs 1.25mg THC),Single dose IV (1.25mg THC),no,SingleDose,CannabisDynamics,dependent,extract_stone_paranoia_0perc_1.25mgTHC,pEstimate_stone_paranoia_0perc_1.25mgTHC,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
187,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,UK,22,NA,NA,THC.PLE,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,"pes(p_PSI_8mgTHC, n_effective_morgan_experiment/2, n_effective_morgan_experiment/2, dig=20) ",pEstimate_morgan_PSI_8mgTHC,cohen,,No,No,
188,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,UK,22,NA,NA,THC.DEL,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,extract_morgan_psi_delusions_8mgTHC,pEstimate_morgan_psi_delusions_8mgTHC,cohen,,Yes,Yes,
189,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,UK,22,NA,NA,THC.PAR,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,extract_morgan_psi_paranoia_8mgTHC,pEstimate_morgan_psi_paranoia_8mgTHC,cohen,,Yes,Yes,
190,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,UK,22,NA,NA,THC.PLE,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,extract_morgan_bprs_8mgTHC,pEstimate_morgan_bprs_8mgTHC,cohen,,Yes,Yes,
191,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,UK,22,NA,NA,THC.PLE,psych_like,CBD (16mg),CBD (16mg),no,CBD (administration),CannabisDynamics,dependent,extract_morgan_bprs_8mgTHC_16mgCBD,pEstimate_morgan_bprs_8mgTHC_16mgCBD,cohen,,Yes,Yes,
192,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,UK,22,NA,NA,THC.DEL,psych_like,CBD (16mg),CBD (16mg),no,CBD (administration),CannabisDynamics,dependent,extract_morgan_psi_delusions_16mgCBD,pEstimate_morgan_delusions_8mgTHC_16mgCBD,cohen,,Yes,Yes,
193,Morgan,Morgan_Curran_Experiment,"Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV (2018) Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry 8:181",2018,NA,Experiment,UK,22,NA,NA,THC.PAR,psych_like,CBD (16mg),CBD (16mg),no,CBD (administration),CannabisDynamics,dependent,extract_morgan_psi_paranoia_16mgCBD,pEstimate_morgan_paranoia_8mgTHC_16mgCBD,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
195,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, Philip McGuire, David Lythgoe, Steve Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis."" Molecular psychiatry (2019): 1-10.",2019,,Experiment,UK,24.44,NA,NA,THC.PLE,psych_like,Single dose IV 1.19 mg/2 ml THC,Single dose IV 1.19 mg/2 ml THC,no,SingleDose,CannabisDynamics,dependent,"pes(colizzi_panss_pos_THC_p, n_effective_colizzi_experiment/2, n_effective_colizzi_experiment/2, dig=20) ",pEstimate_colizzi_panss_pos_THC,cohen,,Yes,Yes,
196,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, Philip McGuire, David Lythgoe, Steve Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis."" Molecular psychiatry (2019): 1-10.",2019,,Experiment,UK,24.44,NA,NA,THC.PLE,psych_like,Glutamate levels (baseline),Glutamate levels (baseline),no,Glutamate,Neurotransmission,independent,colizzi_can_sensitive_glutamate_baseline,pEstimate_colizzi_can_sensitive_glutamate_baseline,cohen,,Yes,Yes,
197,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, Philip McGuire, David Lythgoe, Steve Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis."" Molecular psychiatry (2019): 1-10.",2019,,Experiment,UK,24.44,NA,NA,THC.PLE,psych_like,Change in glutamate levels (following THC administration),Glutamate levels (change following THC),no,Other,Other,independent,"mes(colizzi_can_sensitive_glutamate_change_mean, colizzi_can_non_sensitive_glutamate_change_mean, colizzi_can_sensitive_glutamate_change_sd, colizzi_can_non_sensitive_glutamate_change_sd, colizzi_sensitive_n, colizzi_non_sensitive_n, dig=20)",pEstimate_colizzi_can_sensitive_glutamate_change,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
199,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Pre−existing psychosis (present vs. absent),Psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,eugei_sami_PLEs_casenessExtracted,pEstimate_eugei_sami_PLEs_caseness,cohen,,Yes,Yes,
200,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Frequency of cannabis use,Frequency (heavy),no,CannabisSeverity,CannabisHistory,independent,eugei_sami_PLEs_frequencyExtracted,pEstimate_eugei_sami_PLEs_frequency,cohen,,Yes,Yes,
201,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,CannabisType (high vs. low potency),Cannabis type (high potency),no,THCcontent,CannabisStrain,independent,eugei_sami_PLEs_potencyExtracted,pEstimate_eugei_sami_PLEs_potency,cohen,,Yes,Yes,
202,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Money spent on cannabis,Cannabis amount (high),no,CannabisSeverity,CannabisHistory,independent,eugei_sami_PLEs_moneyExtracted,pEstimate_eugei_sami_PLEs_money,cohen,,Yes,Yes,
203,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Frequency of cannabis use x caseness interaction,Frequency (heavy),no,Other,Other,independent,eugei_sami_PLEs_frequencyxcasenessExtracted,pEstimate_eugei_sami_PLEs_frequencyxcaseness,cohen,,Yes,Yes,
204,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Potency (high vs. low potency)  x caseness interaction,Potency (high)  x caseness interaction,no,Other,Other,independent,eugei_sami_PLEs_potencyxcasenessExtracted,pEstimate_eugei_sami_PLEs_potencyxcaseness,cohen,,Yes,Yes,
205,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Money spent on cannabis  x caseness interaction,Cannabis amount  x caseness interaction,no,Other,Other,independent,eugei_sami_PLEs_moneyxcasenessExtracted,pEstimate_eugei_sami_PLEs_moneyxcaseness,cohen,,Yes,Yes,
206,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Inhalant use (lifetime),Inhalant use (lifetime),no,Inhalants,OtherDrugs,independent,eugei_sami_PLEs_inhalantsLifetimeExtracted,pEstimate_eugei_sami_PLEs_inhalantsLifetime,cohen,,Yes,Yes,
207,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Inhalant misuse (lifetime),Inhalant misuse (lifetime),no,Inhalants,OtherDrugs,independent,eugei_sami_PLEs_inhalantsmisuseExtracted,pEstimate_eugei_sami_PLEs_inhalantsmisuse,cohen,,Yes,Yes,
208,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Crack use (lifetime),Crack use (lifetime),no,Crack,OtherDrugs,independent,eugei_sami_PLEs_crackLifetimeExtracted,pEstimate_eugei_sami_PLEs_crackLifetime,cohen,,Yes,Yes,
209,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Crack misuse (lifetime),Crack misuse (lifetime),no,Crack,OtherDrugs,independent,eugei_sami_PLEs_crackmisuseExtracted,pEstimate_eugei_sami_PLEs_crackmisuse,cohen,,Yes,Yes,
210,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Cocaine use (lifetime),Cocaine use (lifetime),no,Cocaine,OtherDrugs,independent,eugei_sami_PLEs_cocaineLifetimeExtracted,pEstimate_eugei_sami_PLEs_cocaineLifetime,cohen,,Yes,Yes,
211,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Cocaine misuse (lifetime),Cocaine misuse (lifetime),no,Cocaine,OtherDrugs,independent,eugei_sami_PLEs_cocainemisuseExtracted,pEstimate_eugei_sami_PLEs_cocainemisuse,cohen,,Yes,Yes,
212,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Stimulant use (lifetime),Stimulant use (lifetime),no,Stimulants,OtherDrugs,independent,eugei_sami_PLEs_stimulantsLifetimeExtracted,pEstimate_eugei_sami_PLEs_stimulantsLifetime,cohen,,Yes,Yes,
213,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Stimulant misuse (lifetime),Stimulant misuse (lifetime),no,Stimulants,OtherDrugs,independent,eugei_sami_PLEs_stimulantsmisuseExtracted,pEstimate_eugei_sami_PLEs_stimulantsmisuse,cohen,,Yes,Yes,
214,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Sedative use (lifetime),Sedative use (lifetime),no,Sedatives,OtherDrugs,independent,eugei_sami_PLEs_sedativesLifetimextracted,pEstimate_eugei_sami_PLEs_sedativesLifetime,cohen,,Yes,Yes,
215,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Sedative misuse (lifetime),Sedative misuse (lifetime),no,Sedatives,OtherDrugs,independent,eugei_sami_PLEs_sedativesmisuseExtracted,pEstimate_eugei_sami_PLEs_sedativesmisuse,cohen,,Yes,Yes,
216,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Opioid use (lifetime),Opioid use (lifetime),no,Opioids,OtherDrugs,independent,eugei_sami_PLEs_opioidsLifetimeExtracted,pEstimate_eugei_sami_PLEs_opioidsLifetime,cohen,,Yes,Yes,
217,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Opioid misuse (lifetime),Opioid misuse (lifetime),no,Opioids,OtherDrugs,independent,eugei_sami_PLEs_opioidsmisuseExtracted,pEstimate_eugei_sami_PLEs_opioidsmisuse,cohen,,Yes,Yes,
218,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Hallucinogen use (lifetime),Hallucinogen use (lifetime),no,Hallucinogens,OtherDrugs,independent,eugei_sami_PLEs_hallucinogensLifetimeExtracted,pEstimate_eugei_sami_PLEs_hallucinogensLifetime,cohen,,Yes,Yes,
219,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Hallucinogen misuse (lifetime),Hallucinogen misuse (lifetime),no,Hallucinogens,OtherDrugs,independent,eugei_sami_PLEs_hallucinogensmisuseExtracted,pEstimate_eugei_sami_PLEs_hallucinogensmisuse,cohen,,Yes,Yes,
220,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Ketamine use (lifetime),Ketamine use (lifetime),no,Ketamine,OtherDrugs,independent,eugei_sami_PLEs_ketamineLifetimeExtracted,pEstimate_eugei_sami_PLEs_ketamineLifetime,cohen,,Yes,Yes,
221,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Ketamine misuse (lifetime),Ketamine misuse (lifetime),no,Ketamine,OtherDrugs,independent,eugei_sami_PLEs_ketaminemisuseExtracted,pEstimate_eugei_sami_PLEs_ketaminemisuse,cohen,,Yes,Yes,
222,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Novel psychoactive substance use (lifetime),Novel psychoactive substance use (lifetime),no,NPC,OtherDrugs,independent,eugei_sami_PLEs_novelPsychoactLifetimeExtracted,pEstimate_eugei_sami_PLEs_novelPsychoactLifetime,cohen,,Yes,Yes,
223,Sami,GAP_EUGEI,"Sami, M., Quattrone, D., Ferraro, L., Tripoli, G., Cascia, E., Gayer-Anderson, C., . . . Forti, M. (2020). Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. Psychological Medicine, 1-9. doi:10.1017/S0033291720000847",2020,2010-2015,Observational,"UK, Holland, Spain, France, Italy, Brazil",31.4,NA,NA,Can.PLE,psych_like,Novel psychoactive substance misuse (lifetime),Novel psychoactive substance misuse (lifetime),no,NPC,OtherDrugs,independent,eugei_sami_PLEs_novelPsychoactmisuseExtracted,pEstimate_eugei_sami_PLEs_novelPsychoactmisuse,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
225,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, S., Atakan, Z., Martin-Santos, R., Crippa, J.A., Kambeitz, J., Prata, D., Williams, S., Brammer, M., Collier, D.A. and McGuire, P.K., 2012. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Molecular psychiatry, 17(12), pp.1152-1155.",2012,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,"AKT1 (rs1130233, risk allele: A)","AKT (rs1130233, risk allele: A)",yes,AKT1,CandidateGene,independent,"fes(bhattacharyya_AKT1_psych_change_THC_f, bhattacharyya_AKT1_psych_change_THC_carrierA_n, bhattacharyya_AKT1_psych_change_THC_homozygousG_n,  dig=20)",pEstimate_bhattacharyya_AKT1_psych_change_THC,cohen,,Yes,Yes,
226,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, S., Atakan, Z., Martin-Santos, R., Crippa, J.A., Kambeitz, J., Prata, D., Williams, S., Brammer, M., Collier, D.A. and McGuire, P.K., 2012. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function. Molecular psychiatry, 17(12), pp.1152-1155.",2012,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,"DAT1 (3’UTR VNTR, risk allele: 9-repeat variant)","DAT1 (3’UTR VNTR, risk allele: 9-repeat variant)",no,DAT1,CandidateGene,independent,"fes(bhattacharyya_DAT1_psych_change_THC_f, bhattacharyya_AKT1_psych_change_THC_carrier9repeat_n, bhattacharyya_AKT1_psych_change_THC_homozygous10repeat_n,  dig=20)",pEstimate_bhattacharyya_DAT1_psych_change_THC,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
228,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, José Alexandre Crippa, Paul Allen, Rocio Martin-Santos, Stefan Borgwardt, Paolo Fusar-Poli, Katya Rubia et al. ""Induction of psychosis byδ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing."" Archives of general psychiatry 69, no. 1 (2012): 27-36.",2012,2012,Experiment,UK,26.67,NA,NA,THC.PLE,psych_like,Single dose oral (0mg vs 10mg THC),Single dose oral (10mg THC),no,SingleDose,CannabisDynamics,dependent,extract_bhattacharyya_10mgTHC_PANSS_pos,pEstimate_bhattacharyya_10mgTHC_PANSS_pos,cohen,,No,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
230,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Age (mean age differences between cannabis sensitive and non-sensitive individuals),Age (younger),no,Age,Demographic,independent,"mes(atakan2013_TP_age_mean, atakan2013_NP_age_mean, atakan2013_TP_age_SD, atakan2013_NP_age_SD, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_age,cohen,,No,No,
231,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Years of education (more years),Education (more),no,Education,Demographic,independent,atakan2013_TP_educationExtracted,pEstimate_atakan2013_TP_education,cohen,,No,No,
232,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Frequency of cannabis use,Cannabis in system (high),no,Tolerance,CannabisDynamics,independent,"pes(atakan2013_TP_cannabisSeverity_p, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_cannabis,cohen,,No,No,
233,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Cigarette smoker,Cigarette use (yes),no,Nicotine,OtherDrugs,independent,"pes(atakan2013_TP_cigarette_p, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_cigarette,cohen,,No,No,
234,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,AlcoholUse,Alcohol use,no,Alcohol,OtherDrugs,independent,"pes(atakan2013_TP_alcoholSeverity_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_alcohol,cohen,,No,No,
235,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Other drug use (used verus not used),Other drugs (used),no,OtherDrugs,OtherDrugs,independent,"pes(atakan2013_TP_otherDrugs_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_otherDrugs,cohen,,No,No,
236,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Employment status (unemployed verus employed),Employment status (unemployed),yes,EmploymentStatus,Demographic,independent,extract_atakan2013_TP_employment,pEstimate_atakan2013_TP_employment,cohen,,Yes,Yes,
237,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Anxiety (baseline STAI),Prior anxiety (high),yes,Anxiety,MentalHealthPersonality,independent,"pes(atakan2013_TP_baselinePLC_STAI_p, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_baselinePLC_STAI,cohen,,Yes,Yes,
238,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Subjective drug effects rating,Subjective drug effects rating (ARCI),no,SubjectiveHigh,CannabisDynamics,independent,"pes(atakan2013_TP_baselinePLC_ARCI_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_ARCI,cohen,,Yes,Yes,
239,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Intoxication level following THC administration,Intoxication level,no,SubjectiveHigh,CannabisDynamics,independent,"pes(atakan2013_TP_THC_AIS_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_ARCI,cohen,,Yes,Yes,
240,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,VAMS tranquillization subscale,VAMS tranquillization subscale,yes,Other,Other,independent,"pes(atakan2013_TP_baselinePLC_VAMS_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_VAMS,cohen,,Yes,Yes,
241,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Psychosis symptoms prior to THC administration (PANSS positive),Psychosis symptoms prior THC administration,yes,PsychosisLiability,MentalHealthPersonality,independent,"pes(atakan2013_TP_baselinePLC_PANSS_pos_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_PANSS_pos,cohen,,Yes,Yes,
242,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,PANSS negative score prior THC administration,PANSS negative score prior THC administration,yes,Other,Other,independent,"pes(atakan2013_TP_baselinePLC_PANSS_neg_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_PANSS_neg,cohen,,Yes,Yes,
243,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,PANSS general symptom score prior THC administration,PANSS general symptom score prior THC administration,yes,Other,Other,independent,"pes(atakan2013_TP_baselinePLC_PANSS_gen_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_PANSS_gen,cohen,,Yes,Yes,
244,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,PANSS total score prior THC administration,PANSS total score prior THC administration,yes,Other,Other,independent,"pes(atakan2013_TP_baselinePLC_PANSS_tot_p, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_PANSS_tot,cohen,,Yes,Yes,
245,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Reaction time to Go signals (Go/No-Go task),Reaction time to Go signals (Go/No-Go task),no,Other,Other,independent,"mes(atakan2013_TP_recT_mean, atakan2013_NP_recT_mean, atakan2013_TP_recT_SD, atakan2013_NP_recT_SD, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_recT,cohen,,Yes,Yes,
246,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Reaction time to Oddball signals (Go/No-Go task),Reaction time to Oddball signals (Go/No-Go task),no,Other,Other,independent,"mes(atakan2013_TP_recT_Odd_mean, atakan2013_NP_recT_Odd_mean, atakan2013_TP_recT_Odd_SD, atakan2013_NP_recT_Odd_SD, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_recT_Odd,cohen,,Yes,Yes,
247,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Inhibition error  (Go/No-Go task),Inhibition error  (Go/No-Go task),no,Other,Other,independent,"mes(atakan2013_TP_impulse_mean, atakan2013_NP_impulse_mean, atakan2013_TP_impulse_SD, atakan2013_NP_impulse_SD, atakan2013_TP_n, atakan2013_NP_n, dig=20)",pEstimate_atakan2013_TP_impulse,cohen,,Yes,Yes,
248,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Heart rate prior THC administration,Heart rate prior THC administration,no,Other,Other,independent,"pes(pValueNS_allStudies, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_baselinePLC_heartRate,cohen,,Yes,Yes,
249,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Attenuated activation in right middle temporal gyrus,Attenuated activation in right middle temporal gyrus,no,Other,Other,independent,"pes(0.00069, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_MTG_activation,cohen,,Yes,Yes,
250,Atakan,Bhattacharyya_CBD,"Atakan, Z., S. Bhattacharyya, P. Allen, R. Martin-Santos, J. A. Crippa, 2SJ Borgwardt, P. Fusar-Poli et al. ""Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers."" Psychological medicine 43, no. 6 (2013): 1255-1267.",2013,NA,Experiment,UK,26.2,20,40,THC.PLE,psych_like,Attenuated activation in the cerebellum,Attenuated activation in the cerebellum,no,Other,Other,independent,"pes(0.0049, atakan2013_TP_n, atakan2013_NP_n, dig=20) ",pEstimate_atakan2013_TP_cerebellum_activation,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
252,Bloomfield,Morgan_Curran_MRC,"Bloomfield, Michael AP, Celia JA Morgan, Alice Egerton, Shitij Kapur, H. Valerie Curran, and Oliver D. Howes. ""Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms."" Biological psychiatry 75, no. 6 (2014): 470-478.",2014,NA,QuasiExperimental,UK,21.55,18,NA,THC.PLE,psych_like,Dopaminergic function (dopamine synthesis capacity),Dopaminergic function,no,Dopaminergic function,Neurotransmission,independent,"res(bloomberg_dop_synthesis_psych_r, n=bloomberg_dop_synthesis_can_user, dig=20)",pEstimate_bloomberg_dop_synthesis_psych,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
254,Radhakrishnan,DSouza_2,"Radhakrishnan, Rajiv, Patrick D. Skosnik, Jose Cortes-Briones, R. Andrew Sewell, Michelle Carbuto, Ashley Schnakenberg, John Cahill et al. ""GABA deficits enhance the psychotomimetic effects of Δ 9-THC."" Neuropsychopharmacology 40, no. 8 (2015): 2047-2056.",2015,NA,Experiment,US,25.44,NA,NA,THC.PLE,psych_like,Single dose IV (0mg vs 0.015 mg/kg THC),Single dose IV (0.015 mg/kg THC),no,SingleDose,CannabisDynamics,dependent,extract_radhakrishnan_singledose_THC,pEstimate_radhakrishnan_singledose_THC,cohen,,No,No,
255,Radhakrishnan,DSouza_2,"Radhakrishnan, Rajiv, Patrick D. Skosnik, Jose Cortes-Briones, R. Andrew Sewell, Michelle Carbuto, Ashley Schnakenberg, John Cahill et al. ""GABA deficits enhance the psychotomimetic effects of Δ 9-THC."" Neuropsychopharmacology 40, no. 8 (2015): 2047-2056.",2015,NA,Experiment,US,25.44,NA,NA,THC.PLE,psych_like,GABAergic function,GABAergic function,yes,GABAergic function,Neurotransmission,dependent,extract_radhakrishnan_THC_IOM,pEstimate_radhakrishnan_THC_IOM,cohen,,Yes,Yes,
256,Radhakrishnan,DSouza_2,"Radhakrishnan, Rajiv, Patrick D. Skosnik, Jose Cortes-Briones, R. Andrew Sewell, Michelle Carbuto, Ashley Schnakenberg, John Cahill et al. ""GABA deficits enhance the psychotomimetic effects of Δ 9-THC."" Neuropsychopharmacology 40, no. 8 (2015): 2047-2056.",2015,NA,Experiment,US,25.44,NA,NA,THC.PLE,psych_like,Event-related potentials (P300a amplitude) while under the influence of THC,ERP,no,Other,Other,independent,"res(radhakrishnan_PANSS_pos_THC_P300a_r, n=radhakrishnan_PANSS_pos_THC_P300a_n, dig=20)",pEstimate_radhakrishnan_PANSS_pos_THC_P300a,cohen,,Yes,Yes,
257,Radhakrishnan,DSouza_2,"Radhakrishnan, Rajiv, Patrick D. Skosnik, Jose Cortes-Briones, R. Andrew Sewell, Michelle Carbuto, Ashley Schnakenberg, John Cahill et al. ""GABA deficits enhance the psychotomimetic effects of Δ 9-THC."" Neuropsychopharmacology 40, no. 8 (2015): 2047-2056.",2015,NA,Experiment,US,25.44,NA,NA,THC.PLE,psych_like,Event-related potentials (P300b amplitude) while under the influence of THC,ERP,no,Other,Other,independent,"res(radhakrishnan_PANSS_pos_THC_P300b_r, n=radhakrishnan_PANSS_pos_THC_P300b_n, dig=20)",pEstimate_radhakrishnan_PANSS_pos_THC_P300b,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
259,Morrison,Morrison_2.25mg,"Morrison, P. D., V. Zois, D. A. McKeown, T. D. Lee, D. W. Holt, J. F. Powell, S. Kapur, and R. M. Murray. ""The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning."" Psychological medicine 39, no. 10 (2009): 1607-1616.",2009,NA,Experiment,UK,28,21,50,THC.PLE,psych_like,Single dose IV (0mg vs. 2.5 mg THC),Single dose IV (2.5 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_morrison_placebo_PANSS_pos,pEstimate_morrison_placebo_PANSS_pos,cohen,,Yes,Yes,
260,Morrison,Morrison_2.25mg,"Morrison, P. D., V. Zois, D. A. McKeown, T. D. Lee, D. W. Holt, J. F. Powell, S. Kapur, and R. M. Murray. ""The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning."" Psychological medicine 39, no. 10 (2009): 1607-1616.",2009,NA,Experiment,UK,28,21,50,THC.PLE,psych_like,Single dose IV (0mg vs. 2.5 mg THC),Single dose IV (2.5 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_morrison_placebo_CAPE_pos,pEstimate_morrison_placebo_CAPE_pos,cohen,,Yes,Yes,
261,Morrison,Morrison_2.25mg,"Morrison, P. D., V. Zois, D. A. McKeown, T. D. Lee, D. W. Holt, J. F. Powell, S. Kapur, and R. M. Murray. ""The acute effects of synthetic intravenous Δ 9-tetrahydrocannabinol on psychosis, mood and cognitive functioning."" Psychological medicine 39, no. 10 (2009): 1607-1616.",2009,NA,Experiment,UK,28,21,50,High.PLE,psych_like,FrequencyCannabisUse,Cannabis in system (high),no,Tolerance,Excluded,independent,"res(morrison_placebo_PANSS_pos_THC_frequency_r, n=n_morrison_2.5mgTHC_PANSS_pos, dig=20) ",pEstimate_morrison_placebo_PANSS_pos_THC_frequency,cohen,,no,no,
,,,,,,,,,,,,,,,,,,,,,,,,,
263,Liem-Moolenaar,Liem-Moolenaar,"Liem-Moolenaar, Marieke, Erik T. te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn, Ron Hijman, Daan Touw, and J. MA van Gerven. ""Central nervous system effects of haloperidol on THC in healthy male volunteers."" Journal of psychopharmacology 24, no. 11 (2010): 1697-1708.",2010,2007-2008,Experiment,Netherlands,NA,18,38,THC.PLE,psych_like,Single dose intrapulmonary (0mg vs. 2 mg THC),Single dose IP (2 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_liem_2mgTHC_PANSS_pos,pEstimate_liem_2mgTHC_PANSS_pos,cohen,,Yes,Yes,
264,Liem-Moolenaar,Liem-Moolenaar,"Liem-Moolenaar, Marieke, Erik T. te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn, Ron Hijman, Daan Touw, and J. MA van Gerven. ""Central nervous system effects of haloperidol on THC in healthy male volunteers."" Journal of psychopharmacology 24, no. 11 (2010): 1697-1708.",2010,2007-2008,Experiment,Netherlands,NA,18,38,THC.PLE,psych_like,Single dose intrapulmonary (0mg vs. 4 mg THC),Single dose IP (4 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_liem_4mgTHC_PANSS_pos,pEstimate_liem_4mgTHC_PANSS_pos,cohen,,Yes,Yes,
265,Liem-Moolenaar,Liem-Moolenaar,"Liem-Moolenaar, Marieke, Erik T. te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn, Ron Hijman, Daan Touw, and J. MA van Gerven. ""Central nervous system effects of haloperidol on THC in healthy male volunteers."" Journal of psychopharmacology 24, no. 11 (2010): 1697-1708.",2010,2007-2008,Experiment,Netherlands,NA,18,38,THC.PLE,psych_like,Single dose intrapulmonary (0mg vs. 6 mg THC),Single dose IP (6 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_liem_6mgTHC_PANSS_pos,pEstimate_liem_6mgTHC_PANSS_pos,cohen,,Yes,Yes,
266,Liem-Moolenaar,Liem-Moolenaar,"Liem-Moolenaar, Marieke, Erik T. te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn, Ron Hijman, Daan Touw, and J. MA van Gerven. ""Central nervous system effects of haloperidol on THC in healthy male volunteers."" Journal of psychopharmacology 24, no. 11 (2010): 1697-1708.",2010,2007-2008,Experiment,Netherlands,NA,18,38,THC.PLE,psych_like,"D2 blocker (pretreatment with dopaminergic antagonist, haloperidol)",Dopaminergic function,no,Dopaminergic function,Neurotransmission,dependent,"pes(p=liem_PANSS_pos_THC_vs_haloperidol_p, n.1=n_effective_liem_PANSS_pos/2, n.2=n_effective_liem_PANSS_pos/2, dig=20)",pEstimate_liem_PANSS_pos_THC_vs_haloperidol,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
268,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,UK,33,NA,NA,THC.PLE,psych_like,Single dose oral (0mg vs. 10 mg THC),Single dose oral (10 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_stoke_10mgTHC_PSI_tot,pEstimate_stoke_10mgTHC_PSI_tot,cohen,,Yes,Yes,
269,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,UK,33,NA,NA,THC.DEL,psych_like,Single dose oral (0mg vs. 10 mg THC),Single dose oral (10 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_stoke_10mgTHC_PSI_delusion,pEstimate_stoke_10mgTHC_PSI_delusion,cohen,,Yes,Yes,
270,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,UK,33,NA,NA,THC.PAR,psych_like,Single dose oral (0mg vs. 10 mg THC),Single dose oral (10 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_stoke_10mgTHC_PSI_paranoia,pEstimate_stoke_10mgTHC_PSI_paranoia,cohen,,Yes,Yes,
271,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,UK,33,NA,NA,THC.PLE,psych_like,THC plasma levels (10 mg oral THC),THC plasma levels (10 mg oral THC),no,THCplasmaLevel,CannabisDynamics,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_stoke_10mgTHC/2, n.2=n_effective_stoke_10mgTHC/2, dig=20)",pEstimate_stoke_10mgTHC_plasma,cohen,,Yes,Yes,
272,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,UK,33,NA,NA,THC.DEL,psych_like,THC plasma levels (10 mg oral THC),THC plasma levels (10 mg oral THC),no,THCplasmaLevel,CannabisDynamics,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_stoke_10mgTHC/2, n.2=n_effective_stoke_10mgTHC/2, dig=20)",pEstimate_stoke_10mgTHC_plasma,cohen,,Yes,Yes,
273,Stokes,Stokes,"Stokes, Paul RA, Mitul A. Mehta, H. Valerie Curran, Gerome Breen, and Paul M. Grasby. ""Can recreational doses of THC produce significant dopamine release in the human striatum?."" Neuroimage 48, no. 1 (2009): 186-190.",2009,NA,Experiment,UK,33,NA,NA,THC.PAR,psych_like,THC plasma levels (10 mg oral THC),THC plasma levels (10 mg oral THC),no,THCplasmaLevel,CannabisDynamics,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_stoke_10mgTHC/2, n.2=n_effective_stoke_10mgTHC/2, dig=20)",pEstimate_stoke_10mgTHC_plasma,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
275,D'Souza,DSouza,"D’Souza, Deepak Cyril, Gabriel Braley, Rebecca Blaise, Michael Vendetti, Stephen Oliver, Brian Pittman, Mohini Ranganathan et al. ""Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans."" Psychopharmacology 198, no. 4 (2008): 587-603.",2008,NA,Experiment,US,24.89,18,55,THC.PLE,psych_like,Single dose IV THC (2mg) [in individuals with and without CUD],Single dose IV THC (2mg) [in individuals with and without CUD],no,SingleDose,CannabisDynamics,dependent,extract_dsouza2008_IV_THC_PANSS_pos,pEstimate_dsouza2008_IV_THC_PANSS_pos,cohen,,Yes,Yes,
276,D'Souza,DSouza,"D’Souza, Deepak Cyril, Gabriel Braley, Rebecca Blaise, Michael Vendetti, Stephen Oliver, Brian Pittman, Mohini Ranganathan et al. ""Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans."" Psychopharmacology 198, no. 4 (2008): 587-603.",2008,NA,Experiment,US,24.89,18,55,THC.PLE,psych_like,D2 blocker (haloperidol pretreatment),Dopaminergic function,yes,Dopaminergic function,Neurotransmission,dependent,extract_dsouza2008_haloperidol_PANSS_pos,pEstimate_dsouza2008_haloperidol_PANSS_pos,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
278,Freeman,Freeman,"Freeman, D., Dunn, G., Murray, R.M., Evans, N., Lister, R., Antley, A., Slater, M., Godlewska, B., Cornish, R., Williams, J. and Di Simplicio, M., 2015. How cannabis causes paranoia: using the intravenous administration of∆ 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophrenia bulletin, 41(2), pp.391-399.",2015,,Experiment,UK,30,21,50,THC.PAR,psych_like,Single dose IV (0mg vs. 1.5mg THC),Single dose IV (1.5mg THC),no,SingleDose,CannabisDynamics,independent,freeman_paranoia_1.5mgTHCExtracted,pEstimate_freeman_paranoia_1.5mgTHC,cohen,,Yes,Yes,
279,Freeman,Freeman,"Freeman, D., Dunn, G., Murray, R.M., Evans, N., Lister, R., Antley, A., Slater, M., Godlewska, B., Cornish, R., Williams, J. and Di Simplicio, M., 2015. How cannabis causes paranoia: using the intravenous administration of∆ 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophrenia bulletin, 41(2), pp.391-399.",2015,,Experiment,UK,30,21,50,THC.PAR,psych_like,Awareness training before THC administration,Awareness training,no,Other,Other,independent,freeman_paranoia_cogawareness_1.5mgTHCExtracted,pEstimate_freeman_paranoia_cogawareness_1.5mgTHC,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
281,Tunbridge,Freeman,"Tunbridge, Elizabeth M., Graham Dunn, Robin M. Murray, Nicole Evans, Rachel Lister, Katharina Stumpenhorst, Paul J. Harrison, Paul D. Morrison, and Daniel Freeman. ""Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences."" Journal of psychopharmacology 29, no. 11 (2015): 1146-1151.",2015,,Experiment,UK,32,21,50,THC.PLE,psych_like,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",no,COMT,CandidateGene,independent,extracted_tunbridge2015_COMT_CAPEpos,pEstimate_tunbridge2015_COMT_CAPEpos,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
283,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.HAL,psych_like,Caseness (FEP vs healthy),Psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extract_peters_FEPvsHealthy_visualH,pEstimate_peters_FEPvsHealthy_visualH,cohen,,Yes,Yes,
284,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.HAL,psych_like,Caseness (UHR vs healthy),UHR,no,PsychosisLiability,MentalHealthPersonality,independent,extract_peters_UHRvsHealthy_visualH,pEstimate_peters_UHRvsHealthy_visualH,cohen,,Yes,Yes,
285,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.HAL,psych_like,Caseness (FEP vs healthy),Psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extract_peters_FEPvsHealthy_tactileH,pEstimate_peters_FEPvsHealthy_tactileH,cohen,,Yes,Yes,
286,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.HAL,psych_like,Caseness (UHR vs healthy),UHR,no,PsychosisLiability,MentalHealthPersonality,independent,extract_peters_UHRvsHealthy_tactileH,pEstimate_peters_UHRvsHealthy_tactileH,cohen,,Yes,Yes,
287,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.HAL,psych_like,Caseness (FEP vs healthy),Psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extract_peters_FEPvsHealthy_auditoryH,pEstimate_peters_FEPvsHealthy_auditoryH,cohen,,Yes,Yes,
288,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.HAL,psych_like,Caseness (UHR vs healthy),UHR,no,PsychosisLiability,MentalHealthPersonality,independent,extract_peters_UHRvsHealthy_auditoryH,pEstimate_peters_UHRvsHealthy_auditoryH,cohen,,Yes,Yes,
289,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.PAR,psych_like,Caseness (FEP vs healthy),Psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extract_peters_FEPvsHealthy_paranoia,pEstimate_peters_FEPvsHealthy_paranoia,cohen,,Yes,Yes,
290,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.PAR,psych_like,Caseness (UHR vs healthy),UHR,no,PsychosisLiability,MentalHealthPersonality,independent,extract_peters_UHRvsHealthy_paranoia,pEstimate_peters_UHRvsHealthy_paranoia,cohen,,Yes,Yes,
291,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,peters2009_canHalDF,NA,rates,,Yes,Yes,
292,Peters,Peters,"Peters, Bart D., Pelle de Koning, Peter Dingemans, Hiske Becker, Don H. Linszen, and Lieuwe de Haan. ""Subjective effects of cannabis before the first psychotic episode."" Australian and New Zealand Journal of Psychiatry 43, no. 12 (2009): 1155-1162.",2009,,Observational,Netherlands,22.8,18,28,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,peters2009_canParDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
294,D'Souza,DSouza,"D'souza, Deepak Cyril, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, and John Krystal. ""Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis."" Neuropsychopharmacology 33, no. 10 (2008): 2505-2516.",2008,,Experiment,US,24.8,18,55,THC.PLE,psych_like,Single dose IV (0mg vs. 2.5mg THC) [in individuals with CUD],Single dose IV (2.5mg THC) [in individuals with CUD],no,Other,Other,dependent,extract_dsouza_IV_2.5mgTHC_frequ_user_PANSS_tot,pEstimate_dsouza_IV_2.5mgTHC_frequ_user_PANSS_tot,cohen,,Yes,Yes,
295,D'Souza,DSouza,"D'souza, Deepak Cyril, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, and John Krystal. ""Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis."" Neuropsychopharmacology 33, no. 10 (2008): 2505-2516.",2008,,Experiment,US,29,18,55,THC.PLE,psych_like,Single dose IV (0mg vs. 2.5mg THC) [in individuals without CUD],Single dose IV (2.5mg THC),no,SingleDose,CannabisDynamics,dependent,extract_dsouza_IV_2.5mgTHC_control_PANSS_tot,pEstimate_dsouza_IV_2.5mgTHC_control_PANSS_tot,cohen,,Yes,Yes,
296,D'Souza,DSouza,"D'souza, Deepak Cyril, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, and John Krystal. ""Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis."" Neuropsychopharmacology 33, no. 10 (2008): 2505-2516.",2008,,Experiment,US,24.8,18,55,THC.PLE,psych_like,Single dose IV (0mg vs. 5mg THC) [in individuals with CUD],Single dose IV (5mg THC) [in individuals with CUD],no,Other,Other,dependent,extract_dsouza_IV_5mgTHC_frequ_user_PANSS_tot,pEstimate_dsouza_IV_5mgTHC_frequ_user_PANSS_tot,cohen,,Yes,Yes,
297,D'Souza,DSouza,"D'souza, Deepak Cyril, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, and John Krystal. ""Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis."" Neuropsychopharmacology 33, no. 10 (2008): 2505-2516.",2008,,Experiment,US,29,18,55,THC.PLE,psych_like,Single dose IV (0mg vs. 5mg THC) [in individuals without CUD],Single dose IV (5mg THC),no,SingleDose,CannabisDynamics,dependent,extract_dsouza_IV_5mgTHC_control_PANSS_tot,pEstimate_dsouza_IV_5mgTHC_control_PANSS_tot,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
299,Green,Green,"Green, Bob, David Kavanagh, and Ross MCD Young. ""Reasons for cannabis use in men with and without psychosis."" Drug and alcohol review 23, no. 4 (2004): 445-453.",2004,NA,Observational,Australia,30,18,55,Can.PLE,psych_like,Caseness (Psychosis vs.healthy),Psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extract_greenNegativePsych_baseline,pEstimate_green_cases_vs_healthy_symptoms_baseline,cohen,,Yes,Yes,
300,Green,Green,"Green, Bob, David Kavanagh, and Ross MCD Young. ""Reasons for cannabis use in men with and without psychosis."" Drug and alcohol review 23, no. 4 (2004): 445-453.",2004,NA,Observational,Australia,30,18,55,Can.PAR,psych_like,Caseness (Psychosis vs.healthy),Psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extract_green_cases_vs_healthy_paranoia_baseline,pEstimate_green_cases_vs_healthy_paranoia_baseline,cohen,,Yes,Yes,
301,Green,Green,"Green, Bob, David Kavanagh, and Ross MCD Young. ""Reasons for cannabis use in men with and without psychosis."" Drug and alcohol review 23, no. 4 (2004): 445-453.",2004,NA,Observational,Australia,30,18,55,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,green2004_canParDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
303,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,UK,26,21,50,THC.PLE,psych_like,Single dose IV (0mg vs. 1.5mg THC),Single dose IV (1.5mg THC),no,SingleDose,CannabisDynamics,dependent,extract_englund2013_1.5THC_placebo_panss_pos,pEstimate_englund2013_1.5THC_placebo_panss_pos,cohen,,Yes,Yes,send WIUS
304,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,UK,26,21,50,THC.PLE,psych_like,CBD pre-treatment,CBD pre-treatment,no,CBD (administration),CannabisDynamics,independent,extract_englund2013_THC_CBD_panss_pos,pEstimate_englund2013_THC_CBD_panss_pos_increase,cohen,,Yes,Yes,
305,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,UK,26,21,50,THC.PLE,psych_like,CBD pre-treatment,CBD pre-treatment,yes,CBD (administration),CannabisDynamics,independent,extract_chiSqu_englund2013_THC_CBD_panss_pos,pEstimate_englund2013_THC_CBD_actue_psychotic,cohen,,Yes,Yes,
306,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,UK,26,21,50,THC.PAR,psych_like,CBD pre-treatment,CBD pre-treatment,yes,CBD (administration),CannabisDynamics,independent,englund2013_THC_CBD_actue_paranoiaExtract,pEstimate_englund2013_THC_CBD_paranoia,cohen,,Yes,Yes,
307,Englund,Englund2,"Englund, Amir, Paul D. Morrison, Judith Nottage, Dominic Hague, Fergus Kane, Stefania Bonaccorso, James M. Stone et al. ""Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment."" Journal of psychopharmacology 27, no. 1 (2013): 19-27.",2013,NA,Experiment,UK,26,21,50,THC.PLE,psych_like,rates,rates,no,rates,rates,NA,englund2013_THC_panssposDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
309,Morgan,Morgan_Curran_MRC,"Morgan, Celia JA, Grainne Schafer, Tom P. Freeman, and H. Valerie Curran. ""Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study."" The British Journal of Psychiatry 197, no. 4 (2010): 285-290.",2010,NA,QuasiExperimental,UK,21.47,16,23,THC.PLE,psych_like,"Intoxication vs non-intoxication (within-subjcet comparison, low CBD group)",Intoxication vs non-intoxication (within-subject),no,Other,Other,dependent,extract_morgan2010_lowCBD_PSI,pEstimate_morgan2010_lowCBD_PSI,cohen,,No,No,
310,Morgan,Morgan_Curran_MRC,"Morgan, Celia JA, Grainne Schafer, Tom P. Freeman, and H. Valerie Curran. ""Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study."" The British Journal of Psychiatry 197, no. 4 (2010): 285-290.",2010,NA,QuasiExperimental,UK,21.47,16,23,THC.PLE,psych_like,"Intoxication vs non-intoxication (within-subjcet comparison, high CBD group)",Intoxication vs non-intoxication (within-subject),no,Other,Other,dependent,extract_morgan2010_highCBD_PSI,pEstimate_morgan2010_highCBD_PSI,cohen,,No,No,
311,Morgan,Morgan_Curran_MRC,"Morgan, Celia JA, Grainne Schafer, Tom P. Freeman, and H. Valerie Curran. ""Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study."" The British Journal of Psychiatry 197, no. 4 (2010): 285-290.",2010,NA,QuasiExperimental,UK,21.47,16,23,THC.PLE,psych_like,CBD content,CBD content,no,CBDcontent,CannabisStrain,independent,extract_morgan2010_highCBD_vs_lowCBD_PSI,pEstimate_morgan2010_highCBD_vs_lowCBD_PSI,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
313,Kleinloog,Kleinloog,"Kleinloog, Daniël, Marieke Liem-Moolenaar, Gabriël Jacobs, Erica Klaassen, Marieke de Kam, Ron Hijman, and Joop van Gerven. ""Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol?."" Journal of Psychopharmacology 26, no. 10 (2012): 1307-1316.",2012,NA,Experiment,Netherlands,NA,18,45,THC.PLE,psych_like,"Increased dopamine (pretreatment with dopaminergic antagonist, olanzapine)",Dopaminergic function,no,Dopaminergic function,Neurotransmission,dependent,"pes(p=kleinloog2010_PANSS_pos_4mgTHC_olanzapine_p, n.1=kleinloog2010_n_effective/2, n.2=kleinloog2010_n_effective/2, dig=20)",pEstimate_kleinloog2010_PANSS_pos_4mgTHC_olanzapine,cohen,,Yes,Yes,
314,Kleinloog,Kleinloog,"Kleinloog, Daniël, Marieke Liem-Moolenaar, Gabriël Jacobs, Erica Klaassen, Marieke de Kam, Ron Hijman, and Joop van Gerven. ""Does olanzapine inhibit the psychomimetic effects of Δ9-tetrahydrocannabinol?."" Journal of Psychopharmacology 26, no. 10 (2012): 1307-1316.",2012,NA,Experiment,Netherlands,NA,18,45,THC.PLE,psych_like,Single dose intrapulmonary (0mg vs. 4 mg THC),Single dose IP (4 mg THC),no,SingleDose,CannabisDynamics,dependent,"pes(p=kleinloog2010_PANSS_pos_4mgTHC_p, n.1=kleinloog2010_n_effective/2, n.2=kleinloog2010_n_effective/2, dig=20)",pEstimate_kleinloog2010_PANSS_pos_4mgTHC,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
316,Nottage,Morrison_1.25mg,"Nottage, Judith F., James Stone, Robin M. Murray, Alex Sumich, Elvira Bramon-Bosch, and Paul D. Morrison. ""Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis."" Psychopharmacology 232, no. 3 (2015): 519-528.",2014,NA,Experiment,UK,26,NA,NA,High.PLE,psych_like,Ratio of overall 27–45-Hz magnitude to 20–27-Hz magnitude in the resting state on PANSS positive symptoms during intoxication,EEG frequency,no,Excluded,Excluded,independent,"res(nottage2015_neur_oscill_ratio1_panss_pos_r, n=nottage2015_n, dig=20)",pEstimate_nottage2015_neur_oscill_ratio1_panss_pos,cohen,,no,no,
317,Nottage,Morrison_1.25mg,"Nottage, Judith F., James Stone, Robin M. Murray, Alex Sumich, Elvira Bramon-Bosch, and Paul D. Morrison. ""Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis."" Psychopharmacology 232, no. 3 (2015): 519-528.",2014,NA,Experiment,UK,26,NA,NA,High.PLE,psych_like,Ratio of posterior 27–45-Hz magnitude to anterior 20–27-Hz magnitude in the resting state on PANSS positive symptoms during intoxication,EEG frequency,no,Excluded,Excluded,independent,"res(nottage2015_neur_oscill_ratio2_panss_pos_r, n=nottage2015_n, dig=20)",pEstimate_nottage2015_neur_oscill_ratio2_panss_pos,cohen,,no,no,
318,Nottage,Morrison_1.25mg,"Nottage, Judith F., James Stone, Robin M. Murray, Alex Sumich, Elvira Bramon-Bosch, and Paul D. Morrison. ""Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis."" Psychopharmacology 232, no. 3 (2015): 519-528.",2014,NA,Experiment,UK,26,NA,NA,High.PAR,psych_like,Ratio of posterior 27–45-Hz magnitude to anterior 20–27-Hz magnitude in the resting state on PANSS positive symptoms during intoxication,EEG frequency,no,Excluded,Excluded,independent,"res(nottage2015_neur_oscill_ratio2_panss_paranoia_r, n=nottage2015_n, dig=20)",pEstimate_nottage2015_neur_oscill_ratio2_panss_paranoia,cohen,,no,no,
,,,,,,,,,,,,,,,,,,,,,,,,,
320,Collin,Collin,"Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt et al. ""A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis."" Neurological research 32, no. 5 (2010): 451-459.",2010,NA,MedicalTrial,UK,48,NA,NA,Med.HAL,AE,"Medical cannabis (Sativex spray, individual dosage)",MS sample,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_collin2010_sativex_hallucinations,pEstimate_collin2010_sativex_hallucinations,cohen,,Yes,Yes,
321,Collin,Collin,"Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt et al. ""A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis."" Neurological research 32, no. 5 (2010): 451-459.",2010,NA,MedicalTrial,UK,48,NA,NA,Med.PAR,AE,"Medical cannabis (Sativex spray, individual dosage)",MS sample,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_collin2010_sativex_paranoia,pEstimate_collin2010_sativex_paranoia,cohen,,Yes,Yes,
322,Collin,Collin,"Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt et al. ""A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis."" Neurological research 32, no. 5 (2010): 451-459.",2010,NA,MedicalTrial,UK,48,NA,NA,Med.HAL,AE,"Medical cannabis (Sativex spray, individual dosage)",MS sample,no,rates,rates,NA,collin2010_sativex_HallucinationsDF,NA,rates,collin2010_sativex_HallucinationsControl,Yes,Yes,
323,Collin,Collin,"Collin, C., E. Ehler, G. Waberzinek, Z. Alsindi, P. Davies, K. Powell, W. Notcutt et al. ""A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis."" Neurological research 32, no. 5 (2010): 451-459.",2010,NA,MedicalTrial,UK,48,NA,NA,Med.PAR,AE,"Medical cannabis (Sativex spray, individual dosage)",MS sample,no,rates,rates,NA,collin2010_sativex_ParanoiaDF,NA,rates,collin2010_sativex_ParanoiaControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
325,Aragona,Aragona,"Aragona, Massimiliano, Emanuela Onesti, Valentina Tomassini, Antonella Conte, Shiva Gupta, Francesca Gilio, Patrizia Pantano, Carlo Pozzilli, and Maurizio Inghilleri. ""Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study."" Clinical neuropharmacology 32, no. 1 (2009): 41-47.",2009,NA,MedicalTrial,Italy,49.8,18,60,Med.PAR,AE,"Medical cannabis (Sativex spray, individual dosage)",MS sample,no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extract_aragona2009_sativex_paranoia,pEstimate_aragona2009_sativex_paranoia,cohen,,Yes,Yes,
326,Aragona,Aragona,"Aragona, Massimiliano, Emanuela Onesti, Valentina Tomassini, Antonella Conte, Shiva Gupta, Francesca Gilio, Patrizia Pantano, Carlo Pozzilli, and Maurizio Inghilleri. ""Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study."" Clinical neuropharmacology 32, no. 1 (2009): 41-47.",2009,NA,MedicalTrial,Italy,49.8,18,60,Med.PLE,AE,"Medical cannabis (Sativex spray, individual dosage)",MS sample,no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extract_aragona2009_sativex_psychosis,pEstimate_aragona2009_sativex_psychosis,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
328,Duran,Duran,"Duran, Marta, Eulàlia Pérez, Sergio Abanades, Xavier Vidal, Cristina Saura, Margarita Majem, Edurne Arriola et al. ""Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy‐induced nausea and vomiting."" British journal of clinical pharmacology 70, no. 5 (2010): 656-663.",2010,2006-2007,MedicalTrial,Spain,50,34,76,Med.HAL,AE,"Medical cannabis (Sativex spray, individual dosage)",CINV sample,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_duran2010_sativex_psychosis,pEstimate_duran2010_sativex_psychosis,cohen,,Yes,Yes,
329,Duran,Duran,"Duran, Marta, Eulàlia Pérez, Sergio Abanades, Xavier Vidal, Cristina Saura, Margarita Majem, Edurne Arriola et al. ""Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy‐induced nausea and vomiting."" British journal of clinical pharmacology 70, no. 5 (2010): 656-663.",2010,2006-2007,MedicalTrial,Spain,50,34,76,Med.HAL,AE,"Medical cannabis (Sativex spray, individual dosage)",CINV sample,no,Medical cannabis (placebo controlled),rates,NA,duran2010_sativex_PsychosisDF,NA,rates,duran2010_placebo_PsychosisDF,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
331,Ranganathan,DSouza_3,"Ranganathan, Mohini, Joao P. De Aquino, Jose A. Cortes-Briones, Rajiv Radhakrishnan, Brian Pittman, Savita Bhakta, and Deepak C. D’Souza. ""Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans."" Psychopharmacology 236, no. 11 (2019): 3209-3219.",2019,NA,Experiment,US,25,18,55,THC.PLE,psych_like,Single dose IV THC  (0mg vs. 0.05 mg/kg THC),Single dose IV (0.05 mg/kg THC),no,SingleDose,CannabisDynamics,dependent,"pes(p=ranganathan2019_PANSS_pos_p, n.1=n_effective_ranganathan2019/2, n.2=n_effective_ranganathan2019/2, dig=20)",pEstimate_ranganathan2019_PANSS_pos,cohen,,Yes,Yes,
332,Ranganathan,DSouza_3,"Ranganathan, Mohini, Joao P. De Aquino, Jose A. Cortes-Briones, Rajiv Radhakrishnan, Brian Pittman, Savita Bhakta, and Deepak C. D’Souza. ""Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans."" Psychopharmacology 236, no. 11 (2019): 3209-3219.",2019,NA,Experiment,US,25,18,55,THC.PLE,psych_like,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",no,COMT,CandidateGene,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_ranganathan2019/2, n.2=n_effective_ranganathan2019/2, dig=20)",pEstimate_ranganathan2019_PANSS_pos_comt,cohen,,Yes,Yes,
333,Ranganathan,DSouza_3,"Ranganathan, Mohini, Joao P. De Aquino, Jose A. Cortes-Briones, Rajiv Radhakrishnan, Brian Pittman, Savita Bhakta, and Deepak C. D’Souza. ""Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans."" Psychopharmacology 236, no. 11 (2019): 3209-3219.",2019,NA,Experiment,US,25,18,55,THC.PLE,psych_like,Inhibition of COMT (pretreatment with tolcapone),Inhibition of COMT,no,Other,Other,dependent,"pes(p=pValueNS_allStudies, n.1=n_effective_ranganathan2019_tolcapone/2, n.2=n_effective_ranganathan2019_tolcapone/2, dig=20)",pEstimate_ranganathan2019_PANSS_pos_tolcapone,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
335,Thaler,Thaler,"Thaler, Avner, Shira Arad, Lihi Bar-Lev Schleider, Judith Knaani, Tali Taichman, Nir Giladi, and Tanya Gurevich. ""Single center experience with medical cannabis in Gilles de la Tourette syndrome."" Parkinsonism & related disorders 61 (2019): 211-213.",2019,2018-2018,MedicalTrial,Israel,34.5,NA,NA,Med.HAL,AE,"Medical cannabis (THC/CBD mix, individual dosage)",Tourette sample,no,Medical cannabis (uncontrolled),rates,NA,thaler2019_MedCan_hallucinationsDF,NA,rates,,Yes,Yes,
336,Thaler,Thaler,"Thaler, Avner, Shira Arad, Lihi Bar-Lev Schleider, Judith Knaani, Tali Taichman, Nir Giladi, and Tanya Gurevich. ""Single center experience with medical cannabis in Gilles de la Tourette syndrome."" Parkinsonism & related disorders 61 (2019): 211-213.",2019,2018-2018,MedicalTrial,Israel,34.5,NA,NA,Med.PLE,full_episode,"Medical cannabis (THC/CBD mix, individual dosage)",Tourette sample,no,Medical cannabis (uncontrolled),rates,NA,thaler2019_MedCan_psychosisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
338,Balash,Balash,"Balash, Yacov, Lihi Bar-Lev Schleider, Amos D. Korczyn, Herzel Shabtai, Judith Knaani, Alina Rosenberg, Yehuda Baruch, Ruth Djaldetti, Nir Giladi, and Tanya Gurevich. ""Medical cannabis in Parkinson disease: Real-life patients' experience."" Clinical neuropharmacology 40, no. 6 (2017): 268-272.",2017,2013-2015,MedicalTrial,Israel,64.2,NA,NA,Med.HAL,AE,"Medical cannabis (THC/CBD mix, individual dosage)",Parkinson sample,no,Medical cannabis (uncontrolled),rates,NA,balash2019_MedCan_hallucinationsDF,NA,rates,,Yes,Yes,
339,Balash,Balash,"Balash, Yacov, Lihi Bar-Lev Schleider, Amos D. Korczyn, Herzel Shabtai, Judith Knaani, Alina Rosenberg, Yehuda Baruch, Ruth Djaldetti, Nir Giladi, and Tanya Gurevich. ""Medical cannabis in Parkinson disease: Real-life patients' experience."" Clinical neuropharmacology 40, no. 6 (2017): 268-272.",2017,2013-2015,MedicalTrial,Israel,64.2,NA,NA,Med.PLE,full_episode,"Medical cannabis (THC/CBD mix, individual dosage)",Parkinson sample,no,Medical cannabis (uncontrolled),rates,NA,balash2019_MedCan_psychosisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
341,Serpell,Serpell,"Serpell, Michael G., William Notcutt, and Christine Collin. ""Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis."" Journal of neurology 260, no. 1 (2013): 285-295.",2013,NA,MedicalTrial,UK,50,18,NA,Med.HAL,AE,Medical cannabis (Sativex),MS sample,no,Medical cannabis (uncontrolled),rates,NA,serpell2013_Sativex_hallucinationsDF,NA,rates,,Yes,Yes,
342,Serpell,Serpell,"Serpell, Michael G., William Notcutt, and Christine Collin. ""Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis."" Journal of neurology 260, no. 1 (2013): 285-295.",2013,NA,MedicalTrial,UK,50,18,NA,Med.PAR,AE,Medical cannabis (Sativex),MS sample,no,Medical cannabis (uncontrolled),rates,NA,serpell2013_Sativex_paranoiaDF,NA,rates,,Yes,Yes,
343,Serpell,Serpell,"Serpell, Michael G., William Notcutt, and Christine Collin. ""Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis."" Journal of neurology 260, no. 1 (2013): 285-295.",2013,NA,MedicalTrial,UK,50,18,NA,Med.DEL,AE,Medical cannabis (Sativex),MS sample,no,Medical cannabis (uncontrolled),rates,NA,serpell2013_Sativex_delusionsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
345,Lichtman,Lichtman,"Lichtman, Aron H., Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, and Marie T. Fallon. ""Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain."" Journal of pain and symptom management 55, no. 2 (2018): 179-188.",2018,NA,MedicalTrial,Worldwide,60,NA,NA,Med.HAL,AE,Medical cannabis (Sativex),Cancer sample,no,Medical cannabis (placebo controlled),rates,independent,extract_lichtman2018_sativex_hallucinations,pEstimate_lichtman2018_sativex_hallucinations,cohen,,Yes,Yes,
346,Lichtman,Lichtman,"Lichtman, Aron H., Eberhard Albert Lux, Robert McQuade, Sandro Rossetti, Raymond Sanchez, Wei Sun, Stephen Wright, Elena Kornyeyeva, and Marie T. Fallon. ""Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain."" Journal of pain and symptom management 55, no. 2 (2018): 179-188.",2018,NA,MedicalTrial,Worldwide,60,NA,NA,Med.HAL,AE,Medical cannabis (Sativex),Cancer sample,no,Medical cannabis (placebo controlled),rates,NA,lichtman2018_sativex_HallucinationsDF,NA,rates,lichtman2018_sativex_HallucinationsControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
348,Abuhasira,Abuhasira,"Abuhasira, R., Schleider, L. B.-L., Mechoulam, R. and Novack, V. (2018), ‘Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly’, European Journal of Internal Medicine 49, pp. 44-50.",2018,NA,MedicalTrial,Israel,74.5,NA,NA,Med.HAL,AE,Medical cannabis (mixed),Pain-Cancer,no,Medical cannabis (uncontrolled),rates,NA,abuhasira2018_cannabisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
350,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,US,22.9,NA,NA,Can.HAL,psych_like,Family history schizophrenia,Schizophrenia (fam. Hx),no,PsychosisLiability,MentalHealthPersonality,independent,extract_camera2012_hallucinations_famhxSchz,pEstimate_camera2012_hallucinations_famhxSchz,cohen,,Yes,Yes,
351,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,US,22.9,NA,NA,Can.PLE,psych_like,Age of onset of cannabis sue,Age onset cannabis use (young),no,Age onset,CannabisHistory,independent,extract_camera2012_psychFac_ageOnsetCan,pEstimate_camera2012_psychFac_ageOnsetCan,cohen,,Yes,Yes,
352,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,US,22.9,NA,NA,Can.PLE,psych_like,Family history of alcoholism,Alcoholism (fam. Hx),yes,AddictionLiability ,MentalHealthPersonality,independent,extract_camera2012_psych_alcFamHx,pEstimate_camera2012_psych_alcFamHx,cohen,,Yes,Yes,
353,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,US,22.9,NA,NA,Can.HAL,psych_like,Alcohol use,Alcohol use,no,Alcohol,OtherDrugs,independent,extracted_camera2012_hallucinations_alcUse,pEstimate_camera2012_psych_alcFamHx,cohen,,Yes,Yes,
354,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,US,22.9,NA,NA,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,camera2012_hallucinationsDF,NA,rates,,Yes,Yes,
355,Camera ,Camera ,"Camera, Ariella A., Veronica Tomaselli, Jerry Fleming, Gul A. Jabbar, Melissa Trachtenberg, Juan A. Galvez-Buccollini, Ashley C. Proal, Richard N. Rosenthal, and Lynn E. DeLisi. ""Correlates to the variable effects of cannabis in young adults: a preliminary study."" Harm reduction journal 9, no. 1 (2012): 15.",2012,NA,Observational,US,22.9,NA,NA,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,camera2012_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
357,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,UK,23.5,18,65,Can.PLE,psych_like,"FAAH (rs324420, risk allele: A)","FAAH (rs324420, risk allele: A)",no,FAAH,CandidateGene,independent,extract_hindocha2020_faah_psych,pEstimate_hindocha2020_faah_psych,cohen,,Yes,Yes,
358,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,UK,23.5,18,65,Can.PLE,psych_like,FAAH genotype (rs324420) x caseness (healhy vs psychosis),FAAH genotype (rs324420) x caseness (healhy vs psychosis),no,Other,Other,independent,extract_hindocha2020_faah_x_case_psych,pEstimate_hindocha2020_faah_x_case_psych,cohen,,Yes,Yes,
359,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,UK,23.5,18,65,Can.PLE,psych_like,"COMT (rs4680, risk allele: G)","COMT (rs4680, risk allele: G)",no,COMT,CandidateGene,independent,extract_hindocha2020_comt_psych,pEstimate_hindocha2020_comt_psych,cohen,,Yes,Yes,
360,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,UK,23.5,18,65,Can.PLE,psych_like,COMT genotype (rs4680) x caseness (healhy vs psychosis),COMT genotype (rs4680) x caseness (healhy vs psychosis),no,Other,Other,independent,extract_hindocha2020_comt_x_case_psych,pEstimate_hindocha2020_comt_x_case_psych,cohen,,Yes,Yes,
361,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,UK,23.5,18,65,Can.PLE,psych_like,"AKT1 (rs2494732, risk allele: C)","AKT (rs2494732, risk allele: C)",no,AKT1,CandidateGene,independent,extract_hindocha2020_akt1_psych,pEstimate_hindocha2020_akt1_x_case_psych,cohen,,Yes,Yes,
362,Hindocha,Morgan_Curran_MRC,"Hindocha, C., Quattrone, D., Freeman, T.P. et al. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?. Transl Psychiatry 10, 143 (2020). https://doi.org/10.1038/s41398-020-0823-9",2020,NA,Observational,UK,23.5,18,65,Can.PLE,psych_like,AKT1 genotype (rs2494732) x caseness (healhy vs psychosis),AKT genotype (rs2494732) x caseness (healhy vs psychosis),no,Other,Other,independent,extract_hindocha2020_akt1_x_case_psych,pEstimate_hindocha2020_akt1_x_case_psych,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
364,Kaufmann,Kaufmann,"Kaufmann RM, Kraft B, Frey R, et al. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry. 2010;43(1):24‐32. doi:10.1055/s-0029-1237397",2010,NA,Experiment,Austria,23.6,19,29,THC.PLE,psych_like,"Single dose oral THC  (0mg vs. 20 mg THC, CBD:THC = 1:2)",Single dose oral THC  (20 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_kaufmann2010_20mg_bprs_tot,pEstimate_kaufmann2010_20mg_bprs_tot,cohen,,Yes,Yes,
365,Kaufmann,Kaufmann,"Kaufmann RM, Kraft B, Frey R, et al. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry. 2010;43(1):24‐32. doi:10.1055/s-0029-1237397",2010,NA,Experiment,Austria,23.6,19,29,THC.PAR,psych_like,"Single dose oral THC  (0mg vs. 20 mg THC, CBD:THC = 1:2)",Single dose oral THC  (20 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_kaufmann2010_20mg_bprs_par,pEstimate_kaufmann2010_20mg_bprs_par,cohen,,Yes,Yes,
366,Kaufmann,Kaufmann,"Kaufmann RM, Kraft B, Frey R, et al. Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry. 2010;43(1):24‐32. doi:10.1055/s-0029-1237397",2010,NA,Experiment,Austria,23.6,19,29,THC.PLE,psych_like,rates,rates,no,rates,rates,NA,kaufmann2010_psychosisDF,NA,rates,kaufmann2010_psychosisControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
368,Hindocha,Curran_Hindocha,"Hindocha, Chandni, T. P. Freeman, J. X. Xia, Natacha DC Shaban, and Helen V. Curran. ""Acute memory and psychotomimetic effects of cannabis and tobacco both ‘joint’and individually: a placebo-controlled trial."" Psychological medicine 47, no. 15 (2017): 2708-2719.",2017,NA,Experiment,UK,24.5,NA,NA,THC.PLE,psych_like,Single dose smoked (0mg vs. 10mg THC),Single dose smoked THC  (10 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_hindocha2017_10mg_PSI,pEstimate_hindocha2017_10mg_PSI,cohen,,No,No,
369,Hindocha,Curran_Hindocha,"Hindocha, Chandni, T. P. Freeman, J. X. Xia, Natacha DC Shaban, and Helen V. Curran. ""Acute memory and psychotomimetic effects of cannabis and tobacco both ‘joint’and individually: a placebo-controlled trial."" Psychological medicine 47, no. 15 (2017): 2708-2719.",2017,NA,Experiment,UK,24.5,NA,NA,THC.PLE,psych_like,THC x nicotine interaction,THC x nicotine interaction,no,Nicotine,OtherDrugs,dependent,"pes(pValueNS_allStudies, n.1=n_effective_hindocha2017/2, n.2=n_effective_hindocha2017/2)",pEstimate_hindocha2017_nicotine_x_THC,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
371,Mokrysz,Curran_Mokrysz,"Mokrysz, Claire, Tom P. Freeman, Saana Korkki, Kirsty Griffiths, and H. Valerie Curran. ""Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males."" Translational psychiatry 6, no. 11 (2016): e961-e961.",2016,NA,Experiment,UK,21.3,16,28,THC.PAR,psych_like,Single dose smoked (0mg vs. 8mg THC),Single dose smoked THC  (8 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_mokrysz2016_8mg_paranoia_tot_sample,pEstimate_mokrysz2016_8mg_paranoia_tot_sample,cohen,,Yes,Yes,
372,Mokrysz,Curran_Mokrysz,"Mokrysz, Claire, Tom P. Freeman, Saana Korkki, Kirsty Griffiths, and H. Valerie Curran. ""Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males."" Translational psychiatry 6, no. 11 (2016): e961-e961.",2016,NA,Experiment,UK,21.3,16,28,THC.PAR,psych_like,Age (younger),Age (young),no,Age,Demographic,independent,extract_mokrysz2016_paranoia_ado_vs_adult,pEstimate_mokrysz2016_paranoia_ado_vs_adult,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
374,Dalzell,Dalzell,"Dalzell, A. M., H. Bartlett, and J. S. Lilleyman. ""Nabilone: an alternative antiemetic for cancer chemotherapy."" Archives of disease in childhood 61, no. 5 (1986): 502-505.",1986,NA,MedicalTrial,UK,8,10,17,Med.HAL,AE,Medical cannabis (Nabilone),Chemotherapy sample (children),no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extract_dalzell1986_nabilone_hallucinations,pEstimate_dalzell1986_nabilone_hallucinations,cohen,,Yes,Yes,
375,Dalzell,Dalzell,"Dalzell, A. M., H. Bartlett, and J. S. Lilleyman. ""Nabilone: an alternative antiemetic for cancer chemotherapy."" Archives of disease in childhood 61, no. 5 (1986): 502-505.",1986,NA,MedicalTrial,UK,8,10,17,Med.HAL,AE,Medical cannabis (Nabilone),Chemotherapy sample (children),no,rates,rates,NA,dalzell1986_nabilone_hallucinationsDF,NA,rates,dalzell1986_nabilone_hallucinationsControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
378,Laszilo,Laszilo,"LASZLO, JOHN, VIRGIL S. LUCAS JR, DEAN C. HANSON, CAROL M. CRONIN, and STEPHEN E. SALLAN. ""Levonantradol for Chemotherapy‐Induced Emesis: Phase I—II Oral Administration."" The Journal of Clinical Pharmacology 21, no. S1 (1981): 51S-56S.",1981,1980-1980,MedicalTrial,US,40,17,66,Med.HAL,AE,Medical cannabis (Drabinol),Cancer,no,rates,rates,NA,laszilo1981_dronabinol_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
380,Jain,Jain,"JAIN, A.K., RYAN, J.R., McMAHON, F.G. and SMITH, G., 1981. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. The Journal of Clinical Pharmacology, 21(S1), pp.320S-326S.",1981,NA,MedicalTrial,US,28,NA,NA,Med.HAL,AE,Medical cannabis (Drabinol),Pain,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_jain1981_drabinol_hallucinations,pEstimate_jain1981_drabinol_hallucinations,cohen,,Yes,Yes,
381,Jain,Jain,"JAIN, A.K., RYAN, J.R., McMAHON, F.G. and SMITH, G., 1981. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. The Journal of Clinical Pharmacology, 21(S1), pp.320S-326S.",1981,NA,MedicalTrial,US,28,NA,NA,Med.HAL,AE,Medical cannabis (Drabinol),Pain,no,rates,rates,NA,jain1981_drabinol_hallucinationsDF,NA,rates,jain1981_drabinol_hallucinationsControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
383,Herman,Herman,"Herman, Terence S., Lawrence H. Einhorn, Stephen E. Jones, Catherine Nagy, Aurelia B. Chester, Judith C. Dean, Becky Furnas et al. ""Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy."" New England Journal of Medicine 300, no. 23 (1979): 1295-1297.",1979,NA,MedicalTrial,US,33,15,73,Med.HAL,AE,Medical cannabis (Nabilone),Cancer,no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,"chies(chiSquEstimate_herman1979_nabilone_hallucinations, Ntot_herman1979_nabilone_hallucinations, dig=50)",pEstimate_herman1979_nabilone_hallucinations,cohen,,Yes,Yes,
384,Herman,Herman,"Herman, Terence S., Lawrence H. Einhorn, Stephen E. Jones, Catherine Nagy, Aurelia B. Chester, Judith C. Dean, Becky Furnas et al. ""Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy."" New England Journal of Medicine 300, no. 23 (1979): 1295-1297.",1979,NA,MedicalTrial,US,33,15,73,Med.HAL,AE,Medical cannabis (Nabilone),Cancer,no,rates,rates,NA,herman1979medCan_hallucinationsDF,NA,rates,herman1979medCan_hallucinationsControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
386,Dittrich,Dittrich,"Dittrich A, Bickel P, Schöpf J, Zimmer D. Vergleich veränderter Bewusstseinszustände unter den Halluzinogenen (--)-delta9-trans-Tetrahydrocannabinol (delta9-THC) und N,N-Dimethyltryptamin (DMT) [Comparison of altered states of consciousness induced by the hallucinogens (--)-delta9-trans-tetrahydrocannabinol (delta9-THC) and N,N-dimethyltryptamine (DMT) (author's transl)]. Arch Psychiatr Nervenkr (1970). 1976;223(1):77-87. doi:10.1007/BF00367455",1976,NA,Experiment,Germany,27,NA,NA,THC.HAL,psych_like,Single dose oral (0mg vs.0.25mg THC/kg),Single dose oral (0.25mg THC/kg),no,SingleDose,CannabisDynamics,independent,"mes(dittrich1976_THC_hallucinations_visual_m, dittrich1976_placebo_hallucinations_visual_m, dittrich1976_THC_hallucinations_visual_sd, dittrich1976_placebo_hallucinations_visual_sd, dittrich1976_THC_n, dittrich1976_placebo_n, dig=20)",pEstimate_dittrich1976_THC_hallucinations_visual,cohen,,Yes,Yes,
387,Dittrich,Dittrich,"Dittrich A, Bickel P, Schöpf J, Zimmer D. Vergleich veränderter Bewusstseinszustände unter den Halluzinogenen (--)-delta9-trans-Tetrahydrocannabinol (delta9-THC) und N,N-Dimethyltryptamin (DMT) [Comparison of altered states of consciousness induced by the hallucinogens (--)-delta9-trans-tetrahydrocannabinol (delta9-THC) and N,N-dimethyltryptamine (DMT) (author's transl)]. Arch Psychiatr Nervenkr (1970). 1976;223(1):77-87. doi:10.1007/BF00367455",1976,NA,Experiment,Germany,27,NA,NA,THC.HAL,psych_like,Single dose oral (0mg vs.0.25mg THC/kg),Single dose oral (0.25mg THC/kg),no,SingleDose,CannabisDynamics,independent,"mes(dittrich1976_THC_hallucinations_auditory_m, dittrich1976_placebo_hallucinations_auditory_m, dittrich1976_THC_hallucinations_auditory_sd, dittrich1976_placebo_hallucinations_auditory_sd, dittrich1976_THC_n, dittrich1976_placebo_n, dig=20)",pEstimate_dittrich1976_THC_hallucinations_auditory,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
389,Crescioli,Crescioli,"Crescioli, Giada, Niccolò Lombardi, Alessandra Bettiol, Francesca Menniti‐Ippolito, Roberto Da Cas, Maria Parrilli, Martina Del Lungo et al. ""Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database."" British Journal of Clinical Pharmacology 86, no. 1 (2020): 106-120.",2019,2006-2018,MedicalTrial,Italy,61.9,NA,NA,Med.HAL,AE,Medical cannabis (mixed),Mixed,no,rates,rates,NA,crescioli_medTrial_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
391,Milosev,Milosev,"Milosev, Leonie M., Nikolas Psathakis, Natalia Szejko, Ewgeni Jakubovski, and Kirsten R. Müller-Vahl. ""Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey."" Cannabis and Cannabinoid Research 4, no. 4 (2019): 265-274.",2019,2002-2017,MedicalTrial,Germany,35.8,18,79,Med.HAL,AE,Medical cannabis (mixed),Tourette syndrome,no,rates,rates,NA,milosev_medTrial_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
393,Zuurman,Kleinloog,"Zuurman, L., C. Roy, R. C. Schoemaker, A. Hazekamp, J. Den Hartigh, J. C. M. E. Bender, R. Verpoorte, J. L. Pinquier, A. F. Cohen, and J. M. A. Van Gerven. ""Effect of intrapulmonary tetrahydrocannabinol administration in humans."" Journal of psychopharmacology 22, no. 7 (2008): 707-716.",2008,NA,Experiment,Netherlands,23,21,27,THC.HAL,psych_like,Single dose inhaled in vaporizer (0mg vs 8mg THC),Single dose vaped THC  (8 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_zuurman2008_8mgTHCvaped_hallucinations,pEstimate_zuurman2008_8mgTHCvaped_hallucinations,cohen,,Yes,Yes,
394,Zuurman,Kleinloog,"Zuurman, L., C. Roy, R. C. Schoemaker, A. Hazekamp, J. Den Hartigh, J. C. M. E. Bender, R. Verpoorte, J. L. Pinquier, A. F. Cohen, and J. M. A. Van Gerven. ""Effect of intrapulmonary tetrahydrocannabinol administration in humans."" Journal of psychopharmacology 22, no. 7 (2008): 707-716.",2008,NA,Experiment,Netherlands,23,21,27,THC.PAR,psych_like,Single dose inhaled in vaporizer (0mg vs 8mg THC),Single dose vaped THC  (8 mg THC),no,SingleDose,CannabisDynamics,dependent,extract_zuurman2008_8mgTHCvaped_paranoia,pEstimate_zuurman2008_8mgTHCvaped_paranoia,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
396,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.HAL,psych_like,Single dose inhaled in vaporizer (0mg vs 2mg THC),Single dose vaped THC  (2 mg THC),no,SingleDose,CannabisDynamics,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_2mgTHC_hallucinations, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_2mgTHC_hallucinations,cohen,,Yes,Yes,
397,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.HAL,psych_like,Single dose inhaled in vaporizer (0mg vs 4mg THC),Single dose vaped THC  (4 mg THC),no,SingleDose,CannabisDynamics,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_4mgTHC_hallucinations, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_4mgTHC_hallucinations,cohen,,Yes,Yes,
398,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.HAL,psych_like,Single dose inhaled in vaporizer (0mg vs 6mg THC),Single dose vaped THC  (6 mg THC),no,SingleDose,CannabisDynamics,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_6mgTHC_hallucinations, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_6mgTHC_hallucinations,cohen,,Yes,Yes,
399,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.PAR,psych_like,Single dose inhaled in vaporizer (0mg vs 2mg THC),Single dose vaped THC  (6 mg THC),no,SingleDose,CannabisDynamics,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_2mgTHC_paranoia, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_2mgTHC_paranoia,cohen,,Yes,Yes,
400,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.PAR,psych_like,Single dose inhaled in vaporizer (0mg vs 4mg THC),Single dose vaped THC  (4 mg THC),no,SingleDose,CannabisDynamics,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_4mgTHC_paranoia, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_4mgTHC_paranoia,cohen,,Yes,Yes,
401,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.PAR,psych_like,Single dose inhaled in vaporizer (0mg vs 6mg THC),Single dose vaped THC  (6 mg THC),no,SingleDose,CannabisDynamics,dependent,"chies(chiSquEstimate_kleinloogMega_analysis2014_6mgTHC_paranoia, kleinloogMega_analysis2014_n, dig=50)",pEstimate_kleinloogMega_analysis2014_6mgTHC_paranoia,cohen,,Yes,Yes,
402,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.PAR,psych_like,DoseResponse,"DoseResponse (2mg, 4mg, 6mg)",no,DoseResponseTHC,CannabisDynamics,dependent,extract_kleinloogMega_analysis2014_doseResp_paranoia,pEstimate_kleinloogMega_analysis2014_doseResp_paranoia,cohen,,Yes,Yes,
403,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.PAR,psych_like,rates,rates,no,rates,rates,NA,kleinloogMega_analysis2014_paranoiaDF,NA,rates,kleinloogMega_analysis2014_paranoiaControl,Yes,Yes,
404,Kleinloog,Kleinloog,"Kleinloog, Daniël, Frits Roozen, Willem De Winter, Jan Freijer, and Joop Van Gerven. ""Profiling the subjective effects of Δ9‐tetrahydrocannabinol using visual analogue scales."" International journal of methods in psychiatric research 23, no. 2 (2014): 245-256.",2014,NA,Experiment,Netherlands,NA,NA,NA,THC.HAL,psych_like,rates,rates,no,rates,rates,NA,kleinloogMega_analysis2014_hallucinationsDF,NA,rates,kleinloogMega_analysis2014_hallucinationsControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
406,Ware,Ware,"Ware, Mark A., Tongtong Wang, Stan Shapiro, Jean-Paul Collet, Aline Boulanger, John M. Esdaile, Allan Gordon, Mary Lynch, Dwight E. Moulin, and Colleen O'Connell. ""Cannabis for the management of pain: assessment of safety study (COMPASS)."" The Journal of Pain 16, no. 12 (2015): 1233-1242.",2015,2004-2008,MedicalTrial,Canada,49,19,83,Med.PAR,AE,Medical cannabis (13% THC),Chronic pain,no,rates,rates,NA,ware2015medCan_paranoiaDF,NA,rates,,Yes,Yes,
407,Ware,Ware,"Ware, Mark A., Tongtong Wang, Stan Shapiro, Jean-Paul Collet, Aline Boulanger, John M. Esdaile, Allan Gordon, Mary Lynch, Dwight E. Moulin, and Colleen O'Connell. ""Cannabis for the management of pain: assessment of safety study (COMPASS)."" The Journal of Pain 16, no. 12 (2015): 1233-1242.",2015,2004-2008,MedicalTrial,Canada,49,19,83,Med.HAL,AE,Medical cannabis (13% THC),Chronic pain,no,rates,rates,NA,ware2015medCan_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
409,Cooper,Cooper,"Cooper, Ruth E., Emma Williams, Seth Seegobin, Charlotte Tye, Jonna Kuntsi, and Philip Asherson. ""Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial."" European Neuropsychopharmacology 27, no. 8 (2017): 795-808.",2017,2014-2015,MedicalTrial,UK,37.9,NA,NA,Med.PAR,psych_like,Medical cannabis (Sativex),ADHD,no,Medical cannabis (placebo controlled),excluded,independent,extractCooperADHD_paranoia,pEstimate_cooperADHD_sativex,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
411,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,US,25.3,NA,NA,THC.PLE,psych_like,DoseResponseTHC,Dose response IV (varying doses),no,DoseResponseTHC,CannabisDynamics,dependent,"chies(19.88, n_effective_ganesh2020_megaTHCdose, dig=50)",pEstimate_ganesh2020_megaTHCdose,cohen,,Yes,Yes,
412,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,US,25.3,NA,NA,THC.PLE,psych_like,Frequency of cannabis use,Cannabis frequency,yes,Tolerance,CannabisDynamics,independent,"chies( 18.13, ganesh2020_megaTHC_canFrq_n, dig=50) ",pEstimate_ganesh2020_megaTHCcanFrq,cohen,,Yes,Yes,
413,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,US,25.3,NA,NA,THC.PLE,psych_like,Age (younger age),Age (young),yes,Age,Demographic,independent,"chies( 5.05, ganesh2020_megaTHC_age_n, dig=50)",pEstimate_ganesh2020_megaTHCage,cohen,,Yes,Yes,
414,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,US,25.3,NA,NA,THC.PLE,psych_like,Gender (male vs. female),Gender (male),no,Gender,Demographic,independent,"pes(p=pValueNS_allStudies, n.1=ganesh2020_megaTHC_gender_n/2, n.2=ganesh2020_megaTHC_gender_n/2)",pEstimate_ganesh2020_megaTHCgender,cohen,,Yes,Yes,
415,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,US,25.3,NA,NA,THC.PLE,psych_like,Smoking statut (current smoked),Smoking statut (current smoked),no,Nicotine,OtherDrugs,independent,"mes(3, 4.32,  3.46, 3.46, ganesh2020_megaTHC_tobacooSmoker_n, ganesh2020_megaTHC_tobacooNonSmoker_n, dig = 20)",pEstimate_ganesh2020_megaTHC_tobacoo,cohen,,Yes,Yes,
416,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,US,25.3,NA,NA,THC.DEL,psych_like,rates,rates,no,rates,rates,NA,ganesh2020_mega_delusionsDF,NA,rates,,Yes,Yes,
417,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,US,25.3,NA,NA,THC.HAL,psych_like,rates,rates,no,rates,rates,NA,ganesh2020_mega_hallucinationDF,NA,rates,,Yes,Yes,
418,Ganesh,Dsouza_Ranganathan,"Ganesh, Suhas, Jose Cortes-Briones, Mohini Ranganathan, Rajiv Radhakrishnan, Patrick D. Skosnik, and Deepak Cyril D’Souza. ""Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol-A mega analysis of individual participant-data from human laboratory studies."" International Journal of Neuropsychopharmacology (2020).",2020,NA,Experiment,US,25.3,NA,NA,THC.PAR,psych_like,rates,rates,no,rates,rates,NA,ganesh2020_mega_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
420,Ranganathan,Ranganathan,"Ranganathan, Mohini, Michelle Carbuto, Gabriel Braley, Jaqueline Elander, Edward Perry, Brian Pittman, Rajiv Radhakrishnan, Richard A. Sewell, and Deepak C. D'Souza. ""Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans."" International Journal of Neuropsychopharmacology 15, no. 9 (2012): 1251-1264.",2012,NA,Experiment,US,27.14,18,55,THC.PLE,psych_like,Administration Naltrexone (25mg),Opioid receptor function (Naltrexone),no,Opioidergic function,Neurotransmission,dependent,extract_Ranganathan_PANSSpos_naltrexone,pEstimate_Ranganathan_PANSSpos_naltrexone,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
423,van Amerongen,van_Amerongen,"van Amerongen, G., P. Siebenga, M. L. de Kam, J. L. Hay, and G. J. Groeneveld. ""Effect profile of paracetamol, Δ9‐THC and promethazine using an evoked pain test battery in healthy subjects."" European Journal of Pain 22, no. 7 (2018): 1331-1342.",2018,NA,Experiment,Netherlands,24,18,45,THC.HAL,AE,rates,rates,no,rates,rates,NA,amerongen_oralTHC10mg_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
425,Patti,Patti,"Patti, Francesco, Silvia Messina, Claudio Solaro, Maria Pia Amato, Roberto Bergamaschi, Simona Bonavita, R. Bruno Bossio et al. ""Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity."" Journal of Neurology, Neurosurgery & Psychiatry 87, no. 9 (2016): 944-951.",2016,2014-2015,MedicalTrial,Italy,51,NA,NA,Med.HAL,AE,Medical cannabis (Sativex),MS,no,rates,rates,NA,patti2016Sativex_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
427,Freeman,Morgan_Curran_Experiment,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,UK,21.8,NA,NA,THC.PLE,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,"des(0.147, n.1=FreemanMega_Hindocha2015_effective/2, n.2=FreemanMega_Hindocha2015_effective/2)",pEstimate_FreemanMega_Hindocha2015_PSI,cohen,,Yes,Yes,
428,Freeman,Curran_Hindocha,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,UK,24.5,NA,NA,THC.PLE,psych_like,Single dose smoked (0mg vs. 10mg THC),Single dose smoked THC  (10 mg THC),no,SingleDose,CannabisDynamics,dependent,"des(0.520, n.1=FreemanMega_Hindocha2017_effective/2, n.2=FreemanMega_Hindocha2017_effective/2)",pEstimate_FreemanMega_Hindocha2017_PSI,cohen,,Yes,Yes,
429,Freeman,Lawn_experiment,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,UK,26.9,NA,NA,THC.PLE,psych_like,Single dose vaped (0.05mg vs. 8mg THC),Single dose vaped THC  (8 mg THC),no,SingleDose,CannabisDynamics,dependent,"des(0.313, n.1=FreemanMega_Lawn2016_effective/2, n.2=FreemanMega_Lawn2016_effective/2)",pEstimate_FreemanMega_Lawn2016_PSI,cohen,,Yes,Yes,
430,Freeman,Curran_Mokrysz,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,UK,21.3,16,28,THC.PLE,psych_like,Single dose vaped (0mg vs. 8mg THC),Single dose vaped THC  (8 mg THC),no,SingleDose,CannabisDynamics,dependent,"des(0.658, n.1=FreemanMega_Mokrysz_effective/2, n.2=FreemanMega_Mokrysz_effective/2)",pEstimate_FreemanMega_Mokrysz_PSI,cohen,,Yes,Yes,
431,Freeman,Morgan_Curran_Experiment__Curran_Hindocha__Lawn_experiment__Curran_Mokrysz,"Freeman, Abigail M., Claire Mokrysz, Chandni Hindocha, Will Lawn, Celia JA Morgan, Tom P. Freeman, Rob Saunders, and H. Valerie Curran. ""Does variation in trait schizotypy and frequency of cannabis use influence the acute subjective, cognitive and psychotomimetic effects of delta-9-tetrahydrocannabinol? A mega-analysis."" Journal of Psychopharmacology: 0269881120959601.",2021,NA,Experiment,UK,22.7,NA,NA,THC.PLE,psych_like,Frequency of cannabis use,Cannabis frequency,yes,Tolerance,CannabisDynamics,dependent,"pes(0.522, n.1=FreemanMega_PSI_freq_all_effective/2, n.2=FreemanMega_PSI_freq_all_effective/2)",pEstimate_FreemanMega_PSI_freq,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
433,Bonn-Miller,Bonn_Miller,"Bonn-Miller, Marcel O., Sue Sisley, Paula Riggs, Berra Yazar-Klosinski, Julie B. Wang, Mallory JE Loflin, Benjamin Shechet et al. ""The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial."" Plos one 16, no. 3 (2021): e0246990.",2021,NA,MedicalTrial,US,44.9,24.3,77.3,Med.PAR,AE,"Medical cannabis (smoked cannabis, 1) high THC = 12% THC; <0.05% CBD; 2) THC+-CBD =  7.9% THC, 8.1% CBD,)",PTSD,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_EstBonn_PAR,pvalEstBonn_PAR,cohen,,Yes,Yes,
434,Bonn-Miller,Bonn_Miller,"Bonn-Miller, Marcel O., Sue Sisley, Paula Riggs, Berra Yazar-Klosinski, Julie B. Wang, Mallory JE Loflin, Benjamin Shechet et al. ""The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial."" Plos one 16, no. 3 (2021): e0246990.",2021,NA,MedicalTrial,US,44.9,24.3,77.3,Med.HAL,AE,"Medical cannabis (smoked cannabis, 1) high THC = 12% THC; <0.05% CBD; 2) THC+-CBD =  7.9% THC, 8.1% CBD,)",PTSD,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_EstBonn_HAL,pvalEstBonn_HAL,cohen,,Yes,Yes,
435,Bonn-Miller,Bonn_Miller,"Bonn-Miller, Marcel O., Sue Sisley, Paula Riggs, Berra Yazar-Klosinski, Julie B. Wang, Mallory JE Loflin, Benjamin Shechet et al. ""The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial."" Plos one 16, no. 3 (2021): e0246990.",2021,NA,MedicalTrial,US,44.9,24.3,77.3,Med.PAR,AE,"Medical cannabis (smoked cannabis, 1) high THC = 12% THC; <0.05% CBD; 2) THC+-CBD =  7.9% THC, 8.1% CBD,)",PTSD,no,Medical cannabis,rates,NA,bonn2021HighTC_paranoiaDF,NA,rates,bonn2021HighTC_paranoiaControl,Yes,Yes,
436,Bonn-Miller,Bonn_Miller,"Bonn-Miller, Marcel O., Sue Sisley, Paula Riggs, Berra Yazar-Klosinski, Julie B. Wang, Mallory JE Loflin, Benjamin Shechet et al. ""The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial."" Plos one 16, no. 3 (2021): e0246990.",2021,NA,MedicalTrial,US,44.9,24.3,77.3,Med.HAL,AE,"Medical cannabis (smoked cannabis, 1) high THC = 12% THC; <0.05% CBD; 2) THC+-CBD =  7.9% THC, 8.1% CBD,)",PTSD,no,Medical cannabis,rates,NA,bonn2021HighTC_hallucinationsDF,NA,rates,bonn2021HighTC_hallucinationsControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
438,Aviram,Aviram,"Aviram, Joshua, Dorit Pud, Tamar Gershoni, Bareket Schiff‐Keren, Miriam Ogintz, Simon Vulfsons, Tamar Yashar et al. ""Medical cannabis treatment for chronic pain: Outcomes and prediction of response."" European Journal of Pain 25, no. 2 (2021): 359-374.",2021,2015-2019,MedicalTrial,Israel,47,37,60,Med.PAR,AE,Medical cannabis,Chronic pain,no,Medical cannabis,rates,NA,aviramMedCanT1_ParanoiaDF,NA,rates,,Yes,Yes,
439,Aviram,Aviram,"Aviram, Joshua, Dorit Pud, Tamar Gershoni, Bareket Schiff‐Keren, Miriam Ogintz, Simon Vulfsons, Tamar Yashar et al. ""Medical cannabis treatment for chronic pain: Outcomes and prediction of response."" European Journal of Pain 25, no. 2 (2021): 359-374.",2021,2015-2019,MedicalTrial,Israel,47,37,60,Med.HAL,AE,Medical cannabis,Chronic pain,no,Medical cannabis,rates,NA,aviramMedCanT1_HallucinationsDF,NA,rates,,Yes,Yes,
440,Aviram,Aviram,"Aviram, Joshua, Dorit Pud, Tamar Gershoni, Bareket Schiff‐Keren, Miriam Ogintz, Simon Vulfsons, Tamar Yashar et al. ""Medical cannabis treatment for chronic pain: Outcomes and prediction of response."" European Journal of Pain 25, no. 2 (2021): 359-374.",2021,2015-2019,MedicalTrial,Israel,47,37,60,Med.PLE,full_episode,Medical cannabis,Chronic pain,no,Medical cannabis,rates,NA,aviramMedCanT1_PsychosisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
442,Gustavsen,Gustavsen,"Gustavsen, S., H. B. Søndergaard, K. Linnet, R. Thomsen, B. S. Rasmussen, P. S. Sorensen, F. Sellebjerg, and A. B. Oturai. ""Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis."" Multiple sclerosis and related disorders 48 (2021): 102708.",2021,2019-2020,MedicalTrial,Denmark,50,27,74,Med.PAR,AE,Medical cannabis,MS,no,Medical cannabis,rates,NA,gustavsen2021MedCanMS_ParanoiaDF,NA,rates,,Yes,Yes,
443,Gustavsen,Gustavsen,"Gustavsen, S., H. B. Søndergaard, K. Linnet, R. Thomsen, B. S. Rasmussen, P. S. Sorensen, F. Sellebjerg, and A. B. Oturai. ""Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis."" Multiple sclerosis and related disorders 48 (2021): 102708.",2021,2019-2020,MedicalTrial,Denmark,50,27,74,Med.HAL,AE,Medical cannabis,MS,no,Medical cannabis,rates,NA,gustavsen2021MedCanMS_HallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
445,Theunissen,Theunissen,"Theunissen, Eef L., Johannes T. Reckweg, Nadia RPW Hutten, Kim PC Kuypers, Stefan W. Toennes, Merja A. Neukamm, Sebastian Halter, and Johannes G. Ramaekers. ""Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis."" Psychopharmacology (2021): 1-11.",2021,NA,Experiment,Netherlands,22.8,19,34,THC.PAR,AE,Single dose inhaled (0mg vs 5.52mg THC),Single dose inhaled (5.52mg THC),no,SingleDose,CannabisDynamics,dependent,extracted_theunissen2021_JWH_018_paranoia,pEstimate_theunissen2021_JWH_018_paranoia,cohen,,Yes,Yes,
446,Theunissen,Theunissen,"Theunissen, Eef L., Johannes T. Reckweg, Nadia RPW Hutten, Kim PC Kuypers, Stefan W. Toennes, Merja A. Neukamm, Sebastian Halter, and Johannes G. Ramaekers. ""Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis."" Psychopharmacology (2021): 1-11.",2021,NA,Experiment,Netherlands,22.8,19,34,THC.PAR,AE,rates,rates,no,Medical cannabis,rates,NA,theunissen2021_JWH_018_paranoiaDF,NA,rates,theunissen2021_JWH_018_paranoiaDF,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
448,Aran,Aran,"Aran, Adi, Moria Harel, Hanoch Cassuto, Lola Polyansky, Aviad Schnapp, Nadia Wattad, Dorit Shmueli, Daphna Golan, and F. Xavier Castellanos. ""Cannabinoid treatment for autism: a proof-of-concept randomized trial."" Molecular autism 12, no. 1 (2021): 1-11.",2021,2017-2018,MedicalTrial,Israel,11.8,5,21,Med.HAL,AE,Medical cannabis,Autism,yes,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extractedAran2021_medCan_autism_hallucination,pEstimate_aran2021_medCan_autism_hallucination,cohen,,Yes,Yes,
449,Aran,Aran,"Aran, Adi, Moria Harel, Hanoch Cassuto, Lola Polyansky, Aviad Schnapp, Nadia Wattad, Dorit Shmueli, Daphna Golan, and F. Xavier Castellanos. ""Cannabinoid treatment for autism: a proof-of-concept randomized trial."" Molecular autism 12, no. 1 (2021): 1-11.",2021,2017-2018,MedicalTrial,Israel,11.8,5,21,Med.HAL,AE,Medical cannabis,Autism,no,Medical cannabis (rate),rates,NA,aran2021_medCan_autism_hallucination_HallucinationsDF,NA,rates,aran2021_medCan_autism_HallucinationsControl,Yes,Yes,
674,Aran,Aran,"Aran, Adi, Moria Harel, Hanoch Cassuto, Lola Polyansky, Aviad Schnapp, Nadia Wattad, Dorit Shmueli, Daphna Golan, and F. Xavier Castellanos. ""Cannabinoid treatment for autism: a proof-of-concept randomized trial."" Molecular autism 12, no. 1 (2021): 1-11.",2021,2017-2018,MedicalTrial,Israel,11.8,5,21,Med.DEL,AE,Medical cannabis,Autism,yes,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extractedAran2021_medCan_autism_delusions,pEstimate_aran2021_medCan_autism_delusions,cohen,,Yes,Yes,
675,Aran,Aran,"Aran, Adi, Moria Harel, Hanoch Cassuto, Lola Polyansky, Aviad Schnapp, Nadia Wattad, Dorit Shmueli, Daphna Golan, and F. Xavier Castellanos. ""Cannabinoid treatment for autism: a proof-of-concept randomized trial."" Molecular autism 12, no. 1 (2021): 1-11.",2021,2017-2018,MedicalTrial,Israel,11.8,5,21,Med.DEL,AE,Medical cannabis,Autism,no,Medical cannabis (rate),rates,NA,aran2021_medCan_autism_delusionsDF,NA,rates,aran2021_medCan_autism_delusionsControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
451,Schmidt,Schmidt,"Schmidt-Wolf, Gabriele, and Peter Cremer-Schaeffer. ""3 Jahre Cannabis als Medizin–Zwischenergebnisse der Cannabisbegleiterhebung."" Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 64, no. 3 (2021): 368-377.",2021,2017-2020,MedicalTrial,Germnany,54,NA,NA,Med.PAR,AE,Medical cannabis (Dronabinol/Sativex),Pain/spasticity,no,Medical cannabis (rate),rates,NA,schmidtMedCanGermany202_ParanoiaDF,NA,rates,,Yes,Yes,
452,Schmidt,Schmidt,"Schmidt-Wolf, Gabriele, and Peter Cremer-Schaeffer. ""3 Jahre Cannabis als Medizin–Zwischenergebnisse der Cannabisbegleiterhebung."" Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 64, no. 3 (2021): 368-377.",2021,2017-2020,MedicalTrial,Germnany,54,NA,NA,Med.HAL,AE,Medical cannabis (Dronabinol/Sativex),Pain/spasticity,no,Medical cannabis (rate),rates,NA,schmidtMedCanGermany202_HallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
454,Fairhurst,Fairhurst,"Fairhurst, Charlie, Ram Kumar, Daniel Checketts, Bola Tayo, and Susie Turner. ""Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial."" Developmental Medicine & Child Neurology 62, no. 9 (2020): 1031-1039.",2020,2013-2017,MedicalTrial,"UK,Israel,Czech Republic",12,8,18,Med.HAL,AE,Medical cannabis (Nabiximols),Spacsticity,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_EstfairhurstNabiximols_HAL,pvalEstfairhurstNabiximols_HAL,cohen,,Yes,Yes,
455,Fairhurst,Fairhurst,"Fairhurst, Charlie, Ram Kumar, Daniel Checketts, Bola Tayo, and Susie Turner. ""Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial."" Developmental Medicine & Child Neurology 62, no. 9 (2020): 1031-1039.",2020,2013-2017,MedicalTrial,"UK,Israel,Czech Republic",12,8,18,Med.HAL,AE,Medical cannabis (Nabiximols),Spacsticity,no,Medical cannabis (rate),rates,NA,fairhurstNabiximols_HALDF,NA,rates,fairhurstNabiximols_HALControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
457,Habib,Habib,"Habib, G., & Levinger, U. (2020). CHARACTERISTICS OF MEDICAL CANNABIS USAGE AMONG PATIENTS WITH FIBROMYALGIA. Harefuah, 159(5), 343-348.",2020,NA,MedicalTrial,Israel,45,NA,NA,Med.PLE,full_episode,Medical cannabis,Fibromyalgia,no,Medical cannabis (rate),rates,NA,Habib_medCan_psychDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
459,Okey,Okey,"Okey, Sarah A., and Madeline H. Meier. ""A within-person comparison of the subjective effects of higher vs. lower-potency cannabis."" Drug and alcohol dependence 216 (2020): 108225.",2020,NA,Observational,US,32.2,18,NA,Can.PLE,psych_like,CannabisType (high vs. low potency),CannabisType (concentrates vs. dried buds),no,THCcontent,CannabisStrain,dependent,extract_okey2020_within_CEQ,pEstimate_okey2020_within_CEQ,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
461,Safakish,Safakish,"Safakish, Ramin, Gordon Ko, Vahid Salimpour, Bryan Hendin, Imrat Sohanpal, Gena Loheswaran, and Sun Young Rosalia Yoon. ""Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study."" Pain Medicine 21, no. 11 (2020): 3073-3086.",2020,2015-2019,MedicalTrial,Canada,49.6,25,88,Med.HAL,AE,Medical cannabis,Mixed conditions,no,Medical cannabis (rate),rates,NA,safakish_medCan_hallucinationsDF,NA,rates,,Yes,Yes,
462,Safakish,Safakish,"Safakish, Ramin, Gordon Ko, Vahid Salimpour, Bryan Hendin, Imrat Sohanpal, Gena Loheswaran, and Sun Young Rosalia Yoon. ""Medical Cannabis for the Management of Pain and Quality of Life in Chronic Pain Patients: A Prospective Observational Study."" Pain Medicine 21, no. 11 (2020): 3073-3086.",2020,2015-2019,MedicalTrial,Canada,49.6,25,88,Med.PAR,AE,Medical cannabis,Mixed conditions,no,Medical cannabis (rate),rates,NA,safakish_medCan_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
464,Abrams,Abrams1,"Abrams, Donald I., Paul Couey, Niharika Dixit, Varun Sagi, Ward Hagar, Elliott Vichinsky, Mary Ellen Kelly, John E. Connett, and Kalpna Gupta. ""Effect of Inhaled Cannabis for Pain in Adults With Sickle Cell Disease: A Randomized Clinical Trial."" JAMA network open 3, no. 7 (2020): e2010874-e2010874.",2020,2014-2019,MedicalTrial,US,37.6,NA,NA,Med.PAR,AE,"Medical cannabis (4.4% THC, 4.9% CBD)",Sickle cell disease,no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extract_abramsMedCan_paranoia,pEstimate_abramsMedCan_paranoia,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
466,Grimison,Grimison,"Grimison, P., A. Mersiades, A. Kirby, N. Lintzeris, R. Morton, P. Haber, I. Olver et al. ""Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial."" Annals of Oncology 31, no. 11 (2020): 1553-1560.# 19 patients received either nabilone (median dose = 0.75 mg) or pla- cebo",2020,2016-2019,MedicalTrial,Australia,55,29,80,Med.HAL,AE,"Medical cannabis (2.5mg THC, 2.5mg CBD)",Cancer,no,Medical cannabis (placebo controlled),Excluded,dependent,extract_grimison2020Cancer_hallucinations,pEstimate_grimison2020Cancer_hallucinations,cohen,,Yes,Yes,
467,Grimison,Grimison,"Grimison, P., A. Mersiades, A. Kirby, N. Lintzeris, R. Morton, P. Haber, I. Olver et al. ""Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial."" Annals of Oncology 31, no. 11 (2020): 1553-1560.# 19 patients received either nabilone (median dose = 0.75 mg) or pla- cebo",2020,2016-2019,MedicalTrial,Australia,55,29,80,Med.HAL,AE,"Medical cannabis (2.5mg THC, 2.5mg CBD)",Cancer,no,Medical cannabis (rate),rates,NA,grimison2020Cancer_hallucinationsDF,NA,rates,grimison2020Cancer_hallucinationsControls,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
469,Martin-Santos,Martin-Santos,"Martin-Santos, R., J. a Crippa, A. Batalla, S. Bhattacharyya, Z. Atakan, S. Borgwardt, P. Allen et al. ""Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers."" Current pharmaceutical design 18, no. 32 (2012): 4966-4979.",2012,2012,Experiment,UK,26.4,20,42,THC.PLE,psych_like,rates,rates,no,rates,rates,NA,marSan2012acute_paranoiaDF,NA,rates,,Yes,Yes,
470,Martin-Santos,Martin-Santos,"Martin-Santos, R., J. a Crippa, A. Batalla, S. Bhattacharyya, Z. Atakan, S. Borgwardt, P. Allen et al. ""Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers."" Current pharmaceutical design 18, no. 32 (2012): 4966-4979.",2012,2012,Experiment,UK,26.4,20,42,High.PLE,psych_like,THC in blood [(THC-COOH) whole blood concentration],Cannabis in system (high),no,THC-COOH levels,CannabisDynamics,independent,cohen_marSan2012THC_COOH_panssTS,pEstimate_marSan2012THC_COOH_panssTS,cohen,,no,no,
,,,,,,,,,,,,,,,,,,,,,,,,,
472,Favrat,GiroudDronabinol,"Favrat, Bernard, Annick Ménétrey, Marc Augsburger, Laura E. Rothuizen, Monique Appenzeller, Thierry Buclin, Marie Pin, Patrice Mangin, and Christian Giroud. ""Two cases of"" cannabis acute psychosis"" following the administration of oral cannabis."" BMC psychiatry 5, no. 1 (2005): 1-6.",2005,NA,Experiment,Switzerland,26.4,22,30,THC.PLE,full_episode,rates,rates,no,rates,rates,NA,favrat2005oralTHC_psychosisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
474,Cavazos-Rehg,Cavazos-Rehg,"Cavazos-Rehg, Patricia A., Melissa J. Krauss, Shaina J. Sowles, Glennon M. Floyd, Elizabeth S. Cahn, Veronica L. Chaitan, and Marisel Ponton. ""Leveraging user perspectives for insight into cannabis concentrates."" The American journal of drug and alcohol abuse 44, no. 6 (2018): 628-641.",2018,2015,Observational,US,25,18,35,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,cavazos_rehgCanConcentrates_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
476,Morvan,Morvan,"Morvan, Y., J. Rouvier, J-P. Olié, H. Lôo, and M-O. Krebs. ""Consommations de substances illicites chez les étudiants: une enquête en service de médecine préventive."" L'Encéphale 35 (2009): S202-S208.",2009,NA,Observational,France,20,NA,NA,Can.PLE,psych_like,rates,rates,no,rates,rates,NA,morvan2009_PLEDF,NA,rates,,Yes,Yes,
477,Morvan,Morvan,"Morvan, Y., J. Rouvier, J-P. Olié, H. Lôo, and M-O. Krebs. ""Consommations de substances illicites chez les étudiants: une enquête en service de médecine préventive."" L'Encéphale 35 (2009): S202-S208.",2009,NA,Observational,France,20,NA,NA,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,morvan2009_hallucinationDF,NA,rates,,Yes,Yes,
478,Morvan,Morvan,"Morvan, Y., J. Rouvier, J-P. Olié, H. Lôo, and M-O. Krebs. ""Consommations de substances illicites chez les étudiants: une enquête en service de médecine préventive."" L'Encéphale 35 (2009): S202-S208.",2009,NA,Observational,France,20,NA,NA,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,morvan2009_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
480,Costiniuk,Costiniuk,"Costiniuk, Cecilia T., Zahra Saneei, Syim Salahuddin, Joseph Cox, Jean-Pierre Routy, Sergio Rueda, Sara J. Abdallah et al. ""Cannabis consumption in people living with HIV: Reasons for use, secondary effects, and opportunities for health education."" Cannabis and cannabinoid research 4, no. 3 (2019): 204-213.",2019,2018,Observational,Canada,54,NA,NA,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,costiniuk2019_HIVparanoiaDF,NA,rates,,No,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
482,Barratt,Barratt,"Barratt, Monica J., Vince Cakic, and Simon Lenton. ""Patterns of synthetic cannabinoid use in A ustralia."" Drug and alcohol review 32, no. 2 (2013): 141-146.",2013,2011-2012,Observational,Australia,27,NA,NA,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,barratt2016_synthetic_paranoiaDF,NA,rates,,Yes,Yes,
483,Barratt,Barratt,"Barratt, Monica J., Vince Cakic, and Simon Lenton. ""Patterns of synthetic cannabinoid use in A ustralia."" Drug and alcohol review 32, no. 2 (2013): 141-146.",2013,2011-2012,Observational,Australia,27,NA,NA,Can.PLE,psych_like,rates,rates,no,rates,rates,NA,barratt2016_synthetic_psychosisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
485,Contreras,Contreras,"Contreras, Alexandra Elyse, Katelyn E. Hall, Daniel I. Vigil, Allison Rosenthal, Alejandro Azofeifa, and Michael Van Dyke. ""Results from the Colorado Cannabis Users Survey on Health (CUSH), 2016."" International Journal of Mental Health and Addiction 18, no. 1 (2020): 1-13.",2020,2016,Observational,US,NA,21,NA,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,contreras2020Colorado_paranoiaDF,NA,rates,,Yes,Yes,
486,Contreras,Contreras,"Contreras, Alexandra Elyse, Katelyn E. Hall, Daniel I. Vigil, Allison Rosenthal, Alejandro Azofeifa, and Michael Van Dyke. ""Results from the Colorado Cannabis Users Survey on Health (CUSH), 2016."" International Journal of Mental Health and Addiction 18, no. 1 (2020): 1-13.",2020,2016,Observational,US,NA,21,NA,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,contreras2020Colorado_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
488,LaFrance,LaFrance,"LaFrance, Emily M., Amanda Stueber, Nicholas C. Glodosky, Dakota Mauzay, and Carrie Cuttler. ""Overbaked: assessing and predicting acute adverse reactions to Cannabis."" Journal of Cannabis Research 2, no. 1 (2020): 1-10.",2020,NA,Observational,US,20.9,18,61,Can.PAR,psych_like,rates,rates,no,rates,rates,NA,laFrance2020arc_paranoiaDF,NA,rates,,Yes,Yes,
489,LaFrance,LaFrance,"LaFrance, Emily M., Amanda Stueber, Nicholas C. Glodosky, Dakota Mauzay, and Carrie Cuttler. ""Overbaked: assessing and predicting acute adverse reactions to Cannabis."" Journal of Cannabis Research 2, no. 1 (2020): 1-10.",2020,NA,Observational,US,20.9,18,61,Can.HAL,psych_like,rates,rates,no,rates,rates,NA,laFrance2020arc_hallucinationDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
491,Naef,Naef,"Naef, Myrtha, Michele Curatolo, Steen Petersen-Felix, Lars Arendt-Nielsen, Alex Zbinden, and Rudolf Brenneisen. ""The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions."" Pain 105, no. 1-2 (2003): 79-88.",2003,NA,Experiment,Switzerland,26,NA,NA,THC.HAL,psych_like,Single dose oral (0mg vs 20mg THC),Single dose oral (20mg THC),no,SingleDose,CannabisDynamics,dependent,extract_naef2003analgesic_THC_hallucinations,pEstimate_naef2003analgesic_THC_hallucinations,cohen,,Yes,Yes,
492,Naef,Naef,"Naef, Myrtha, Michele Curatolo, Steen Petersen-Felix, Lars Arendt-Nielsen, Alex Zbinden, and Rudolf Brenneisen. ""The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions."" Pain 105, no. 1-2 (2003): 79-88.",2003,,Experiment,Switzerland,26,NA,NA,THC.HAL,psych_like,rates,rates,no,rates,rates,NA,naef2003analgesic_THC_hallucinationsDF,NA,rates,naef2003analgesic_THC_hallucinationsControl,Yes,Yes,
493,Naef,Naef,"Naef, Myrtha, Michele Curatolo, Steen Petersen-Felix, Lars Arendt-Nielsen, Alex Zbinden, and Rudolf Brenneisen. ""The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions."" Pain 105, no. 1-2 (2003): 79-88.",2003,NA,Experiment,Switzerland,26,NA,NA,THC.HAL,psych_like,THC combined with morphine vs THC alone,Opioidergic function,no,Opioidergic function,Neurotransmission,dependent,extract_naef2003analgesic_THC_morphine_hallucinations,pEstimate_naef2003analgesic_THC_morphine_hallucinations,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
495,Zeiger,Zeiger,"Zeiger, Joanna S., William S. Silvers, Tonya A. Winders, Mary K. Hart, and Robert S. Zeiger. ""Cannabis attitudes and patterns of use among followers of the Allergy & Asthma Network."" Annals of Allergy, Asthma & Immunology 126, no. 4 (2021): 401-410.",2021,2020,Observational,US,NA,NA,NA,Can.PAR,AE,rates,rates,no,rates,rates,NA,zeiger2021_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
497,Sholler,MEGA_Vandrey_Schlienz_Spindle,"Sholler, D.J., Strickland, J.C., Spindle, T.R., Weerts, E.M. and Vandrey, R., 2020. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addiction biology, p.e12968.",2020,NA,Experiment,US,27,18,45,THC.PAR,psych_like,Dose response oral (0mg/10mg/25mf/ 50mg THC),Dose response oral (0mg/10mg/25mf/ 50mg THC),no,DoseResponseTHC,CannabisDynamics,dependent,extract_shollerMEGA_THC_doseresponse,pEstimate_shollerMEGA_THC_doseresponse,cohen,,Yes,Yes,
498,Sholler,MEGA_Vandrey_Schlienz_Spindle,"Sholler, D.J., Strickland, J.C., Spindle, T.R., Weerts, E.M. and Vandrey, R., 2020. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addiction biology, p.e12968.",2020,NA,Experiment,US,27,18,45,THC.PAR,psych_like,Route (0:oral; 1:vaporized),Route (vaporized),no,Route (vaporized),CannabisDynamics,dependent,extract_shollerMEGA_THC_route,pEstimate_shollerMEGA_THC_route,cohen,,Yes,Yes,
499,Sholler,MEGA_Vandrey_Schlienz_Spindle,"Sholler, D.J., Strickland, J.C., Spindle, T.R., Weerts, E.M. and Vandrey, R., 2020. Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addiction biology, p.e12968.",2020,NA,Experiment,US,27,18,45,THC.PAR,psych_like,Gender,Gender,yes,Gender,Demographic,dependent,extract_shollerMEGA_THC_sex,pEstimate_shollerMEGA_THC_sex,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
501,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, David J. Lythgoe, Steve CR Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol."" Psychological Medicine 52, no. 11 (2022): 2024-2031.",2019,NA,Experiment,UK,24.44,NA,NA,THC.PLE,psych_like,THC-induced change in myo-inositol levels,THC-induced change in myo-inositol levels,no,Other,Other,independent,extract_colizzi2020_THCmyoinositol,pEstimate_colizzi2020_THCmyoinositol,cohen,,Yes,Yes,
502,Colizzi,Bhattacharyya1,"Colizzi, Marco, Nathalie Weltens, David J. Lythgoe, Steve CR Williams, Lukas Van Oudenhove, and Sagnik Bhattacharyya. ""Differential sensitivity to the acute psychotomimetic effects of delta-9-tetrahydrocannabinol associated with its differential acute effects on glial function and cortisol."" Psychological Medicine 52, no. 11 (2022): 2024-2031.",2019,NA,Experiment,UK,24.44,NA,NA,THC.PLE,psych_like,THC-induced change in cortisol levels,THC-induced change in cortisol levels,no,Other,Other,independent,extract_colizzi2020_THCcortisol,pEstimate_colizzi2020_THCcortisol,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
504,Mathews,Mathews,"Mathews, Eva M., Emily Jeffries, Chenen Hsieh, Glenn Jones, and Julia D. Buckner. ""Synthetic cannabinoid use among college students."" Addictive behaviors 93 (2019): 219-224.",2019,NA,Observational,US,20,NA,NA,Can.PAR,AE,rates,rates,no,rates,rates,NA,mathews2019synthetic_paranoiaDF,NA,rates,,Yes,Yes,
505,Mathews,Mathews,"Mathews, Eva M., Emily Jeffries, Chenen Hsieh, Glenn Jones, and Julia D. Buckner. ""Synthetic cannabinoid use among college students."" Addictive behaviors 93 (2019): 219-224.",2019,NA,Observational,US,20,NA,NA,Can.HAL,AE,rates,rates,no,rates,rates,NA,mathews2019synthetic_hallucinationDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
507,Gilman,Gilman,"Gilman, Jodi M., Meryem A. Yücel, Gladys N. Pachas, Kevin Potter, Nina Levar, Hannah Broos, Eve M. Manghis, Randi M. Schuster, and A. Eden Evins. ""Delta-9-tetrahydrocannabinol intoxication is associated with increased prefrontal activation as assessed with functional near-infrared spectroscopy: A report of a potential biomarker of intoxication."" Neuroimage 197 (2019): 575-585.",2019,NA,Experiment,US,26,18,55,THC.PAR,AE,rates,rates,no,rates,rates,NA,gilman2019_dronabinol_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
509,Li,ReleafApp_2018,"Li, Xiaoxue, Jacob M. Vigil, Sarah S. Stith, Franco Brockelman, Keenan Keeling, and Branden Hall. ""The effectiveness of self-directed medical cannabis treatment for pain."" Complementary therapies in medicine 46 (2019): 123-130.",2019,2016-2018,MedicalSample,US,NA,NA,NA,Med.PAR,AE,Medical cannabis,Pain,no,rates,rates,NA,li2019_ReleafApp_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
511,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Hippocampal activation,Hippocampal activation,no,Other,Other,independent,bhattacharyya2018_THCsens_hippoActivation,pEstimate_bhattacharyya2018_THCsens_hippoActivation,cohen,,Yes,Yes,
512,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Age (younger),Age ,no,Age,Demographic,independent,bhattacharyya2018_THCsens_age,pEstimate_bhattacharyya2018_THCsens_age,cohen,,Yes,Yes,
513,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Intellectual functioning (poorer performance),Intellectual functioning,no,Other,Other,independent,bhattacharyya2018_THCsens_IF,pEstimate_bhattacharyya2018_THCsens_IF,cohen,,Yes,Yes,
514,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Years in education (more years),Years in education (more years),no,Education,Demographic,independent,bhattacharyya2018_THCsens_education,pEstimate_bhattacharyya2018_THCsens_education,cohen,,Yes,Yes,
515,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,CigaretteUse,Cigarette use,no,Nicotine,OtherDrugs,independent,bhattacharyya2018_THCsens_cigarettes,pEstimate_bhattacharyya2018_THCsens_cigarettes,cohen,,Yes,Yes,
516,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Previous cannabis use,Previous cannabis use,no,Tolerance,CannabisDynamics,independent,bhattacharyya2018_THCsens_cannabis,pEstimate_bhattacharyya2018_THCsens_cannabis,cohen,,Yes,Yes,
517,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Caffeine use,Caffeine use,no,Caffeine,OtherDrugs,independent,bhattacharyya2018_THCsens_caffeine,pEstimate_bhattacharyya2018_THCsens_caffeine,cohen,,Yes,Yes,
518,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Alcohol use,Alcohol use,yes,Alcohol,OtherDrugs,independent,extract_bhattacharyya2018_THCsens_alc,pEstimate_bhattacharyya2018_THCsens_alc,cohen,,Yes,Yes,
519,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Amphetamine use,Amphetamine use,no,Stimulants,OtherDrugs,independent,extract_bhattacharyya2018_THCsens_amphetamine,pEstimate_bhattacharyya2018_THCsens_amphetamine,cohen,,Yes,Yes,
520,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,LSD use,LSD use,yes,Hallucinogens,OtherDrugs,independent,extract_bhattacharyya2018_THCsens_LSD,pEstimate_bhattacharyya2018_THCsens_LSD,cohen,,Yes,Yes,
521,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Cocaine use,Cocaine use,yes,Cocaine,OtherDrugs,independent,extract_bhattacharyya2018_THCsens_cocaine,pEstimate_bhattacharyya2018_THCsens_cocaine,cohen,,Yes,Yes,
522,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,MDMA use,MDMA use,yes,MDMA,OtherDrugs,independent,extract_bhattacharyya2018_THCsens_mdma,pEstimate_bhattacharyya2018_THCsens_mdma,cohen,,Yes,Yes,
523,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Opiate use,Opiate use,no,Opioid,OtherDrugs,independent,extract_bhattacharyya2018_THCsens_opioid,pEstimate_bhattacharyya2018_THCsens_opioid,cohen,,Yes,Yes,
524,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Thomas Sainsbury, Paul Allen, Chiara Nosarti, Zerrin Atakan, Vincent Giampietro, Michael Brammer, and P. K. McGuire. ""Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC."" Psychological medicine 48, no. 16 (2018): 2748-2756.",2018,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,rates,rates,no,rates,rates,NA,bhattacharyya2018_THCsens_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
526,Abdallah,Abdallah,"Abdallah, Sara J., Benjamin M. Smith, Mark A. Ware, Michelle Moore, Pei Zhi Li, Jean Bourbeau, and Dennis Jensen. ""Effect of vaporized cannabis on exertional breathlessness and exercise endurance in advanced chronic obstructive pulmonary disease. A randomized controlled trial."" Annals of the American Thoracic Society 15, no. 10 (2018): 1146-1158.",2018,,MedicalTrial,Canada,65,47,77,Med.PAR,psych_like,Medical cannabis,COPD,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,abdallah2018_COPD_paranoiaChange,pEstimate_abdallah2018_COPD_paranoiaChange,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
528,Bloomfield,Morgan_Curran_MRC,"Bloomfield, M. A. P., E. Mouchlianitis, C. J. A. Morgan, T. P. Freeman, H. V. Curran, J. P. Roiser, and O. D. Howes. ""Salience attribution and its relationship to cannabis-induced psychotic symptoms."" Psychological medicine 46, no. 16 (2016): 3383-3395.",2016,NA,QuasiExperimental,UK,22.4,18,NA,THC.PLE,psych_like,Aberrant salience (explicit),Aberrant salience (explicit),no,Other,Other,independent,"res(bloomberg_explicitSalience_psych_r, n=bloomberg_salience_can_user, dig=20)",pEstimate_bloomberg_explicitSalience_psych,cohen,,Yes,Yes,
529,Bloomfield,Morgan_Curran_MRC,"Bloomfield, M. A. P., E. Mouchlianitis, C. J. A. Morgan, T. P. Freeman, H. V. Curran, J. P. Roiser, and O. D. Howes. ""Salience attribution and its relationship to cannabis-induced psychotic symptoms."" Psychological medicine 46, no. 16 (2016): 3383-3395.",2016,NA,QuasiExperimental,UK,22.4,18,NA,THC.PLE,psych_like,Aberrant salience (implicit),Aberrant salience (implicit),no,Other,Other,independent,"pes(pValueNS_allStudies, bloomberg_salience_can_user/2, bloomberg_salience_can_user/2, dig=20)",pEstimate_bloomberg_implicitSalience_psych,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
531,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Z. Atakan, R. Martin-Santos, J. A. Crippa, J. Kambeitz, S. Malhi, V. Giampietro et al. ""Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis."" European Neuropsychopharmacology 25, no. 1 (2015): 26-37.",2015,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Single dose oral (0mg vs 10mg THC),Single dose oral (10mg THC),no,SingleDose,CannabisDynamics,dependent,extract_bhattacharyya2015_10mgTHC_PANSS_pos,pEstimate_bhattacharyya2015_10mgTHC_PANSS_pos,cohen,,Yes,Yes,
532,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Z. Atakan, R. Martin-Santos, J. A. Crippa, J. Kambeitz, S. Malhi, V. Giampietro et al. ""Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis."" European Neuropsychopharmacology 25, no. 1 (2015): 26-37.",2015,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,Inhibitory processing,Inhibitory processing,no,Other,Other,independent,bhattacharyya2015_10mgTHC_inhibit_processing,pEstimate_bhattacharyya2015_10mgTHC_inhibit_processing,cohen,,Yes,Yes,
533,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Z. Atakan, R. Martin-Santos, J. A. Crippa, J. Kambeitz, S. Malhi, V. Giampietro et al. ""Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis."" European Neuropsychopharmacology 25, no. 1 (2015): 26-37.",2015,2012,Experiment,UK,25.97,NA,NA,THC.PLE,psych_like,THC-induced inhibitory impairment,THC-induced inhibitory impairment,no,Other,Other,independent,bhattacharyya2015_10mgTHC_frontal_activation,pEstimate_bhattacharyya2015_10mgTHC_frontal_activation,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
535,Cortes-Briones,DSouza_2,"Cortes-Briones, Jose A., John D. Cahill, Patrick D. Skosnik, Daniel H. Mathalon, Ashley Williams, R. Andrew Sewell, Brian J. Roach, Judith M. Ford, Mohini Ranganathan, and Deepak Cyril D’Souza. ""The psychosis-like effects of Δ9-tetrahydrocannabinol are associated with increased cortical noise in healthy humans."" Biological psychiatry 78, no. 11 (2015): 805-813.",2015,NA,Experiment,US,26.21,NA,NA,THC.PLE,psych_like,Single dose IV (0mg vs 0.015 mg/kg THC),Single dose IV (0.015 mg/kg THC),no,SingleDose,CannabisDynamics,dependent,extract_cortes_singledose_THC15mg,pEstimate_cortes_singledose_THC15mg,cohen,,Yes,Yes,
536,Cortes-Briones,DSouza_2,"Cortes-Briones, Jose A., John D. Cahill, Patrick D. Skosnik, Daniel H. Mathalon, Ashley Williams, R. Andrew Sewell, Brian J. Roach, Judith M. Ford, Mohini Ranganathan, and Deepak Cyril D’Souza. ""The psychosis-like effects of Δ9-tetrahydrocannabinol are associated with increased cortical noise in healthy humans."" Biological psychiatry 78, no. 11 (2015): 805-813.",2015,NA,Experiment,US,26.21,NA,NA,THC.PLE,psych_like,Single dose IV (0mg vs 0.015 mg/kg THC),Single dose IV (0.015 mg/kg THC),no,SingleDose,CannabisDynamics,dependent,extract_cortes_singledose_THC30mg,pEstimate_cortes_singledose_THC30mg,cohen,,Yes,Yes,
537,Cortes-Briones,DSouza_2,"Cortes-Briones, Jose A., John D. Cahill, Patrick D. Skosnik, Daniel H. Mathalon, Ashley Williams, R. Andrew Sewell, Brian J. Roach, Judith M. Ford, Mohini Ranganathan, and Deepak Cyril D’Souza. ""The psychosis-like effects of Δ9-tetrahydrocannabinol are associated with increased cortical noise in healthy humans."" Biological psychiatry 78, no. 11 (2015): 805-813.",2015,NA,Experiment,US,26.21,NA,NA,THC.PLE,psych_like,Neural noise (Lempel-Ziv Complexity),Neural noise,no,Other,Other,independent,extract_cortes_neuralNoise,pEstimate_extract_cortes_neuralNoise,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
539,D'Souza,DSouza_2,"D'Souza, Deepak Cyril, Daniel J. Fridberg, Patrick D. Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto et al. ""Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ 9-THC in humans."" Neuropsychopharmacology 37, no. 7 (2012): 1632-1646.",2012,NA,Experiment,US,25.9,NA,NA,THC.PLE,psych_like,P3b amplitude,P3b amplitude,no,Other,Other,independent,extract_dsouza_eeg2012_P3bamplitude,pEstimate_dsouza_eeg2012,cohen,,Yes,Yes,
540,D'Souza,DSouza_2,"D'Souza, Deepak Cyril, Daniel J. Fridberg, Patrick D. Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto et al. ""Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ 9-THC in humans."" Neuropsychopharmacology 37, no. 7 (2012): 1632-1646.",2012,NA,Experiment,US,25.9,NA,NA,THC.PLE,psych_like,P3a amplitude,P3b amplitude,no,Other,Other,independent,extract_dsouza_eeg2012_P3aamplitude,pEstimate_dsouza_eeg2012,cohen,,Yes,Yes,
541,D'Souza,DSouza_2,"D'Souza, Deepak Cyril, Daniel J. Fridberg, Patrick D. Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto et al. ""Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ 9-THC in humans."" Neuropsychopharmacology 37, no. 7 (2012): 1632-1646.",2012,NA,Experiment,US,25.9,NA,NA,THC.PLE,psych_like,P3b latency,P3b latency,no,Other,Other,independent,extract_dsouza_eeg2012_P3alatency,pEstimate_dsouza_eeg2012,cohen,,Yes,Yes,
542,D'Souza,DSouza_2,"D'Souza, Deepak Cyril, Daniel J. Fridberg, Patrick D. Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto et al. ""Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ 9-THC in humans."" Neuropsychopharmacology 37, no. 7 (2012): 1632-1646.",2012,NA,Experiment,US,25.9,NA,NA,THC.PLE,psych_like,P3a latency,P3a latency,no,Other,Other,independent,extract_dsouza_eeg2012_P3blatency,pEstimate_dsouza_eeg2012,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
544,Flachenecker,Flachenecker,"Flachenecker, Peter, Thomas Henze, and Uwe K. Zettl. ""Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice."" European neurology 72, no. 1-2 (2014): 95-102.",2014,NA,MedicalSample,US,NA,NA,NA,Med.PAR,AE,Medical cannabis,MS,no,rates,rates,NA,flachenecker2014_medCan_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
546,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,Netherlands,22,NA,NA,THC.PLE,psych_like,Novelty seeking,Novelty seeking,no,Personality,MentalHealthPersonality,independent,extract_kleinloog2014THC_noveltyseeking,pEstimate_kleinloog2014THC_noveltyseeking,cohen,,Yes,Yes,
547,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,Netherlands,22,NA,NA,THC.PLE,psych_like,Harm avoidance,Harm avoidance,no,Personality,MentalHealthPersonality,independent,extract_kleinloog2014THC_harmavoidance,pEstimate_kleinloog2014THC_harmavoidance,cohen,,Yes,Yes,
548,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,Netherlands,22,NA,NA,THC.PLE,psych_like,Reward dependence,Reward dependence,no,Personality,MentalHealthPersonality,independent,extract_kleinloog2014THC_rewarddependence,pEstimate_kleinloog2014THC_rewarddependence,cohen,,Yes,Yes,
549,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,Netherlands,22,NA,NA,THC.PLE,psych_like,Persistence,Persistence,no,Personality,MentalHealthPersonality,independent,extract_kleinloog2014THC_persistence,pEstimate_kleinloog2014THC_persistence,cohen,,Yes,Yes,
550,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,Netherlands,22,NA,NA,THC.PLE,psych_like,Self-directedness,Self-directedness,no,Personality,MentalHealthPersonality,independent,extract_kleinloog2014THC_selfdirectedness,pEstimate_kleinloog2014THC_selfdirectedness,cohen,,Yes,Yes,
551,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,Netherlands,22,NA,NA,THC.PLE,psych_like,Cooperativeness,Cooperativeness,no,Personality,MentalHealthPersonality,independent,extract_kleinloog2014THC_cooperativeness,pEstimate_kleinloog2014THC_cooperativeness,cohen,,Yes,Yes,
552,Kleinloog,Kleinloog,"Kleinloog, Daniël, Jasper Stevens, Jules Heuberger, Philip Spinhoven, and Joop van Gerven. ""The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol."" Psychiatry research 220, no. 3 (2014): 945-953.",2014,NA,Experiment,Netherlands,22,NA,NA,THC.PLE,psych_like,Self-transcendence,Self-transcendence,no,Personality,MentalHealthPersonality,independent,extract_kleinloog2014THC_selftranscendence,pEstimate_kleinloog2014THC_selftranscendence,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
554,Cameron,Cameron,"Cameron, C., Watson, D., & Robinson, J. (2014). Use of a Synthetic Cannabinoid in a Correctional Population for Posttraumatic Stress Disorder–Related Insomnia and Nightmares, Chronic Pain, Harm Reduction, and Other Indications. Journal of Clinical Psychopharmacology, 34(5), 559–564.",2014,NA,MedicalSample,Canada,32.7,19,55,Med.PAR,AE,Medical cannabis (Nabilone),PTSD,no,rates,rates,NA,cameron2014_medCanNabilone_psychosisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
556,Ahmed,Ahmed,"Ahmed, Amir IA, Geke AH van den Elsen, Angela Colbers, Marjolein A. van der Marck, David M. Burger, Ton B. Feuth, Marcel GM Olde Rikkert, and Cornelis Kramers. ""Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial."" European Neuropsychopharmacology 24, no. 9 (2014): 1475-1482.",2014,NA,MedicalTrial,Netherlands,72,65,NA,Med.HAL,AE,Medical cannabis (Namisol),safety test in heathy,no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extract_ahmed2014namisol_hallucinations,pEstimate_ahmed2014namisol_hallucinations,cohen,,Yes,Yes,
557,Ahmed,Ahmed,"Ahmed, Amir IA, Geke AH van den Elsen, Angela Colbers, Marjolein A. van der Marck, David M. Burger, Ton B. Feuth, Marcel GM Olde Rikkert, and Cornelis Kramers. ""Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial."" European Neuropsychopharmacology 24, no. 9 (2014): 1475-1482.",2014,NA,MedicalTrial,Netherlands,72,65,NA,Med.HAL,AE,Medical cannabis (Namisol),safety test in heathy,no,rates,rates,NA,ahmed2014namisol_hallucinationsDF,NA,rates,ahmed2014namisol_hallucinationsControls,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
559,Fernandez,Fernandez,"Fernández, L. Lorente, E. Monte Boquet, F. Perez-Miralles, I. Gil Gomez, M. Escutia Roig, I. Bosca Blasco, JL Poveda Andrés, and B. Casanova-Estruch. ""Clinical experiences with cannabinoids in spasticity management in multiple sclerosis."" Neurología (English Edition) 29, no. 5 (2014): 257-260.",2014,2008-2012,MedicalSample,Spain,25.6,76.8,NA,Med.PAR,AE,Medical cannabis (Sativex),MS,no,rates,rates,NA,fernandezSativex_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
561,Portenoy,Portenoy,"Portenoy, R.K., Ganae-Motan, E.D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S. and Fallon, M.T., 2012. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. The Journal of Pain, 13(5), pp.438-449.",2012,NA,MedicalTrial,US,NA,NA,NA,Med.HAL,AE,Medical cannabis (Nabiximols),Cancer,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_portenoyNabiximols_hallucinations,pvalportenoyNabiximols_HAL,cohen,,Yes,Yes,
562,Portenoy,Portenoy,"Portenoy, R.K., Ganae-Motan, E.D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S. and Fallon, M.T., 2012. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. The Journal of Pain, 13(5), pp.438-449.",2012,NA,MedicalTrial,US,NA,NA,NA,Med.HAL,AE,Medical cannabis (Nabiximols),Cancer,no,rates,rates,NA,portenoyNabiximols_HALDF,NA,rates,portenoyNabiximols_HALControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
564,Morrison,Morrison_1.25mg,"Morrison, Paul D., Judith Nottage, James M. Stone, Sagnik Bhattacharyya, Nigel Tunstall, Rudolf Brenneisen, David Holt et al. ""Disruption of frontal theta coherence by Δ 9-tetrahydrocannabinol is associated with positive psychotic symptoms."" Neuropsychopharmacology 36, no. 4 (2011): 827-836.",2011,NA,Experiment,UK,26,NA,NA,THC.PLE,psych_like,Theta power (EEG),Theta power (EEG),no,Other,Other,independent,extract_morrison_theta_PLE,pEstimate_morrison_theta_PLE,cohen,,Yes,Yes,
565,Morrison,Morrison_1.25mg,"Morrison, Paul D., Judith Nottage, James M. Stone, Sagnik Bhattacharyya, Nigel Tunstall, Rudolf Brenneisen, David Holt et al. ""Disruption of frontal theta coherence by Δ 9-tetrahydrocannabinol is associated with positive psychotic symptoms."" Neuropsychopharmacology 36, no. 4 (2011): 827-836.",2011,NA,Experiment,UK,26,NA,NA,THC.PLE,psych_like,Theta coherence (EEG),Theta coherence (EEG),no,Other,Other,independent,extract_morrison_theta_coherence_PLE,pEstimate_morrison_theta_coherence_PLE,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
567,Ware,Ware_RCT,"Ware, Mark A., Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, Ann Gamsa, Gary J. Bennett, and Jean-Paul Collet. ""Smoked cannabis for chronic neuropathic pain: a randomized controlled trial."" Cmaj 182, no. 14 (2010): E694-E701.",2010,NA,MedicalTrial,Canada,45.4,NA,NA,Med.PAR,AE,Medical cannabis (Namisol),Pain,no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extract_ware2010RCT_paranoia,pEstimate_ware2010RCT_paranoia,cohen,,Yes,Yes,
568,Ware,Ware_RCT,"Ware, Mark A., Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, Ann Gamsa, Gary J. Bennett, and Jean-Paul Collet. ""Smoked cannabis for chronic neuropathic pain: a randomized controlled trial."" Cmaj 182, no. 14 (2010): E694-E701.",2010,NA,MedicalTrial,Canada,45.4,NA,NA,Med.PAR,AE,Medical cannabis,Pain,no,Medical cannabis (rate),rates,NA,ware2010RCT_paranoiaDF,NA,rates,ware2010RCT_paranoiaControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
570,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Paul D. Morrison, Paolo Fusar-Poli, Rocio Martin-Santos, Stefan Borgwardt, Toby Winton-Brown, Chiara Nosarti et al. ""Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology."" Neuropsychopharmacology 35, no. 3 (2010): 764-774.",2010,NA,Experiment,UK,26,NA,NA,THC.PLE,psych_like,THC-induced changes in striatum,THC-induced changes in striatum,no,Other,Other,independent,bhattacharyya2010_10mgTHC_striatum,pEstimate_bhattacharyya2010_10mgTHC_striatum,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
572,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Paolo Fusar-Poli, Stefan Borgwardt, Rocio Martin-Santos, Chiara Nosarti, Colin O’Carroll, Paul Allen et al. ""Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis."" Archives of general psychiatry 66, no. 4 (2009): 442-451.",2009,NA,Experiment,UK,26,NA,NA,THC.PLE,psych_like,THC-induced changes in ventral stiatum,THC-induced changes in ventral stiatum,no,Other,Other,independent,bhattacharyya2009_10mgTHC_fmri_ventral_striatum,pEstimate_bhattacharyya2009_10mgTHC_fmri_ventral_striatum,cohen,,Yes,Yes,
573,Bhattacharyya,Bhattacharyya_CBD,"Bhattacharyya, Sagnik, Paolo Fusar-Poli, Stefan Borgwardt, Rocio Martin-Santos, Chiara Nosarti, Colin O’Carroll, Paul Allen et al. ""Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis."" Archives of general psychiatry 66, no. 4 (2009): 442-451.",2009,NA,Experiment,UK,26,NA,NA,THC.PLE,psych_like,THC-induced changes in rostro-anterior cingulate cortex,THC-induced changes in rostro-anterior cingulate cortex,no,Other,Other,independent,bhattacharyya2009_10mgTHC_fmri_cingulate_cortex,pEstimate_bhattacharyya2009_10mgTHC_fmri_cingulate_cortex,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
575,Cooper,Cooper,"Cooper, Ziva D., and Margaret Haney. ""Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts."" Drug and alcohol dependence 103, no. 3 (2009): 107-113.",2009,NA,Experiment,US,25.5,NA,NA,THC.PAR,AE,rates,rates,no,rates,rates,NA,cooper2005joints_ParanoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
577,Abrams,Abrams2,"Abrams, Donald I., C. A. Jay, S. B. Shade, H. Vizoso, H. Reda, S. Press, M. E. Kelly, M. C. Rowbotham, and K. L. Petersen. ""Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial."" Neurology 68, no. 7 (2007): 515-521.",2007,NA,MedicalTrial,US,49,NA,NA,Med.PAR,AE,Medical cannabis (Namisol),HIV,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_abrams_HIVmedcan_paranoia,pEstimate_abrams_HIVmedcan_paranoia,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
579,Haney,Haney,"Haney, Margaret. ""Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers."" Neuropsychopharmacology 32, no. 6 (2007): 1391-1403.",2007,NA,Experiment,US,29.7,NA,NA,THC.PAR,AE,Administration Naltrexone (12mg),Opioid receptor function (Naltrexone),yes,Opioidergic function,Neurotransmission,dependent,extract_haney2007THCopioid_10mgTHC_naltrexone,pEstimate_haney2007THCopioid_paranoia,cohen,,Yes,Yes,
580,Haney,Haney,"Haney, Margaret. ""Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers."" Neuropsychopharmacology 32, no. 6 (2007): 1391-1403.",2007,NA,Experiment,US,29.7,NA,NA,THC.PAR,AE,Single dose inhaled (0mg vs 2.5mg THC),Single dose inhaled (2.5mg THC),no,SingleDose,CannabisDynamics,dependent,extract_haney2007THCopioid_2.5mgTHC,pEstimate_haney2007THCopioid_paranoia,cohen,,No,No,
581,Haney,Haney,"Haney, Margaret. ""Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers."" Neuropsychopharmacology 32, no. 6 (2007): 1391-1403.",2007,NA,Experiment,US,29.7,NA,NA,THC.PAR,AE,Single dose inhaled (0mg vs 5mg THC),Single dose inhaled (5mg THC),no,SingleDose,CannabisDynamics,dependent,extract_haney2007THCopioid_5mgTHC,pEstimate_haney2007THCopioid_paranoia,cohen,,Yes,Yes,
582,Haney,Haney,"Haney, Margaret. ""Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers."" Neuropsychopharmacology 32, no. 6 (2007): 1391-1403.",2007,NA,Experiment,US,29.7,NA,NA,THC.PAR,AE,Single dose inhaled (0mg vs 10mg THC),Single dose inhaled (10mg THC),no,SingleDose,CannabisDynamics,dependent,extract_haney2007THCopioid_10mgTHC_naltrexone,pEstimate_haney2007THCopioid_paranoia,cohen,,No,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
584,Brady,Brady,"Brady, C. M., R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, and C. J. Fowler. ""An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis."" Multiple Sclerosis Journal 10, no. 4 (2004): 425-433.",2004,NA,MedicalTrial,UK,48,31,64,Med.HAL,AE,Medical cannabis,MS,no,rates,rates,NA,brady2004MedCanMS_HallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
586,Menetrey,GiroudDronabinol,"Ménétrey, Annick, Marc Augsburger, Bernard Favrat, Marie A. Pin, Laura E. Rothuizen, Monique Appenzeller, Thierry Buclin, Patrice Mangin, and Christian Giroud. ""Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Δ9-THC."" Journal of analytical toxicology 29, no. 5 (2005): 327-338.",2005,NA,Experiment,Switzerland,26.4,22,30,THC.PAR,AE,rates,rates,no,rates,rates,NA,menetrey2005oralTHC_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
588,Beaulieu,Beaulieu,"Beaulieu, Pierre. ""Effects of nabilone, a synthetic cannabinoid, on postoperative pain."" Canadian Journal of Anesthesia 53, no. 8 (2006): 769-775.",2006,NA,MedicalTrial,Canada,52,NA,NA,Med.PLE,full_episode,rates,rates,no,rates,rates,NA,beaulieu2006medPain_psychosisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
590,Holdcroft,Holdcroft,"Holdcroft, Anita, Mervyn Maze, Caroline Dore, Susan Tebbs, and Simon Thompson. ""A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management."" The Journal of the American Society of Anesthesiologists 104, no. 5 (2006): 1040-1046.",2006,NA,MedicalTrial,UK,53,NA,NA,Med.PAR,AE,rates,rates,no,rates,rates,NA,holdcroft2006medPain_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
592,Buggy,Buggy,"Buggy, Donal J., Lynn Toogood, Shelagh Maric, Paul Sharpe, David G. Lambert, and David J. Rowbotham. ""Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain."" Pain 106, no. 1-2 (2003): 169-172.",2003,NA,MedicalTrial,UK,45,NA,NA,Med.HAL,AE,Medical cannabis (Namisol),Pain,yes,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_Buggy200_HAL,pvalBuggy200_HAL,cohen,,Yes,Yes,
593,Buggy,Buggy,"Buggy, Donal J., Lynn Toogood, Shelagh Maric, Paul Sharpe, David G. Lambert, and David J. Rowbotham. ""Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain."" Pain 106, no. 1-2 (2003): 169-172.",2003,NA,MedicalTrial,UK,45,NA,NA,Med.HAL,AE,Medical cannabis (Namisol),Pain,no,rates,rates,NA,buggy200_HAL_DF,NA,rates,buggy200_HAL_Control,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
595,Niederle,Niederle,"Niederle, N., J. Schütte, and C. G. Schmidt. ""Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy."" Klinische Wochenschrift 64, no. 8 (1986): 362-365.",1986,1982-1984,MedicalTrial,Germany,25,19,45,Med.HAL,AE,Nabilone (4mg daily) ,rates,no,rates,rates,NA,niederleNabilone1986_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
597,Pomeroy,Pomeroy,"Pomeroy, Mauve, James J. Fennelly, and Mark Towers. ""Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis."" Cancer chemotherapy and pharmacology 17, no. 3 (1986): 285-288.",1986,NA,MedicalTrial,Ireland,42,21,66,Med.HAL,AE,Nabilone,rates,no,rates,rates,NA,pomeroyNabilone1986_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
599,Niiranen,Niiranen,"Niiranen, Aila, and Karin Mattson. ""A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy."" American journal of clinical oncology 8, no. 4 (1985): 336-340.",1985,NA,MedicalTrial,Finnland,61,48,78,Med.HAL,AE,Nabilone (2mg daily),rates,no,rates,rates,NA,niiranenNabilone1985_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
601,Ahmedzai,Ahmedzai,"Ahmedzai, S., D. L. Carlyle, I. T. Calder, and F. Moran. ""Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy."" British Journal of Cancer 48, no. 5 (1983): 657-663.",1983,NA,MedicalTrial,UK,58,NA,NA,Med.HAL,AE,Nabilone,rates,no,rates,rates,NA,ahmedzaiNabilone1983_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
603,Sweet,Sweet,"Sweet, Donald L., Nancy J. Miller, William Wellington, Edward Senay, and Lisa Sushelsky. ""Δ9‐tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study."" The Journal of Clinical Pharmacology 21, no. S1 (1981): 70S-75S.",1981,NA,MedicalTrial,US,51.5,22,67,Med.HAL,AE,THC (oral dose 5mg/m2),rates,no,rates,rates,NA,sheetTHC1981_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
605,Noyes,Noyes,"Noyes, Russell, S. Fred Brunk, David H. Avery, and Arthur Canter. ""Psychologic effects of oral delta-9-tetrahydrocannabinol in advanced cancer patients."" Comprehensive psychiatry (1976).",1976,NA,MedicalTrial,US,51,NA,NA,Med.HAL,psych_like,Medical cannabis (5mg THC),Cancer,no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extract_noyesCancerTHC_hallucinations,pEstimate_noyesCancerTHC_hallucinations,cohen,,Yes,Yes,
606,Noyes,Noyes,"Noyes, Russell, S. Fred Brunk, David H. Avery, and Arthur Canter. ""Psychologic effects of oral delta-9-tetrahydrocannabinol in advanced cancer patients."" Comprehensive psychiatry (1976).",1976,NA,MedicalTrial,US,51,NA,NA,Med.HAL,psych_like,rates,rates,no,rates,rates,NA,noyesCancerTHC_hallucinationsDF,NA,rates,noyesCancerTHC_hallucinationsControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
608,Marcus,Marcus,"Marcus, Anthony M., Harry Klonoff, and Morton Low. ""Psychiatric status of the marihuana user."" Canadian Psychiatric Association Journal 19, no. 1 (1974): 31-39.",1974,1971-1972,Observational,Canada,22.5,19,31,Can.HAL,AE,rates,rates,no,rates,rates,NA,marcus1974_hallucinationsDF,NA,rates,,Yes,Yes,
609,Marcus,Marcus,"Marcus, Anthony M., Harry Klonoff, and Morton Low. ""Psychiatric status of the marihuana user."" Canadian Psychiatric Association Journal 19, no. 1 (1974): 31-39.",1974,1971-1972,Observational,Canada,22.5,19,31,Can.PAR,AE,rates,rates,no,rates,rates,NA,marcus1974_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
611,Kassim,Kassim,"Kassim, Faiz M., Sophie Tod, Jennifer Rodger, Sean D. Hood, Joseph WY Lee, Matthew A. Albrecht, and Mathew T. Martin-Iverson. ""Nabilone Impairs Spatial and Verbal Working Memory in Healthy Volunteers."" Cannabis and Cannabinoid Research (2022).",2022,NA,Experiment,Australia,25.9,17,60,Can.PLE,psych_like,Single dose oral (0mg vs 1mg THC),Single dose oral (1mg THC),no,SingleDose,CannabisDynamics,dependent,extract_kassimNabilone,pEstimate_kassimNabilone,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
613,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Gender,Gender,yes,Gender,Demographic,independent,extract_Schoeler_gender,pEstimate_Schoeler_gender,cohen,,Yes,Yes,
614,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Age,Age,yes,Age,Demographic,independent,extract_Schoeler_age,pEstimate_Schoeler_age,cohen,,Yes,Yes,
615,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Exercise,Exercise,yes,Other,Other,independent,extract_Schoeler_exercise,pEstimate_Schoeler_exercise,cohen,,Yes,Yes,
616,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Education (more),Education (more),no,Education,Demographic,independent,extract_Schoeler_edu,pEstimate_Schoeler_edu,cohen,,Yes,Yes,
617,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,BMI (underweight),Underweight,no,Other,Other,independent,extract_Schoeler_underW,pEstimate_Schoeler_underW,cohen,,Yes,Yes,
618,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,BMI (overweight),Overweight,yes,Other,Other,independent,extract_Schoeler_overW,pEstimate_Schoeler_overW,cohen,,Yes,Yes,
619,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Recreational use (vs. medical),Recreational use (vs. medical),yes,Reason (medicinal vs. recreational),CannabisHistory,independent,extract_Schoeler_reason,pEstimate_Schoeler_reason,cohen,,Yes,Yes,
620,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,CannabisType (high vs. low potency),Cannabis type (high potency),yes,THCcontent,CannabisStrain,independent,extract_Schoeler_potency,pEstimate_Schoeler_potency,cohen,,Yes,Yes,
621,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Frequency (heavy vs. light),Frequency (heavy),yes,CannabisSeverity,CannabisHistory,independent,extract_Schoeler_frequency,pEstimate_Schoeler_frequency,cohen,,Yes,Yes,
622,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Mix cannabis with tobacco,Mix cannabis with tobacco,no,Nicotine,OtherDrugs,independent,extract_Schoeler_tobacco,pEstimate_Schoeler_tobacco,cohen,,Yes,Yes,
623,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,ROA (eaten),ROA (eaten),yes,Other,Other,independent,extract_Schoeler_eaten,pEstimate_Schoeler_eaten,cohen,,Yes,Yes,
624,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,ROA (knife),ROA (knife),yes,Other,Other,independent,extract_Schoeler_knife,pEstimate_Schoeler_knife,cohen,,Yes,Yes,
625,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,ROA (pipe),ROA (pipe),yes,Other,Other,independent,extract_Schoeler_pipe,pEstimate_Schoeler_pipe,cohen,,Yes,Yes,
626,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,ROA (vape),ROA (vape),yes,Other,Other,independent,extract_Schoeler_vape,pEstimate_Schoeler_vape,cohen,,Yes,Yes,
627,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Alcohol use,Alcohol use,yes,Alcohol,OtherDrugs,independent,extract_Schoeler_alc,pEstimate_Schoeler_alc,cohen,,Yes,Yes,
628,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Cocaine use,Cocaine use,yes,Cocaine,OtherDrugs,independent,extract_Schoeler_cocaine,pEstimate_Schoeler_cocaine,cohen,,Yes,Yes,
629,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,MDMA use,MDMA use,no,MDMA,OtherDrugs,independent,extract_Schoeler_mdma,pEstimate_Schoeler_mdma,cohen,,Yes,Yes,
630,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Amphetamine use,Amphetamine use,no,Stimulants,OtherDrugs,independent,extract_Schoeler_amphetamine,pEstimate_Schoeler_amphetamine,cohen,,Yes,Yes,
631,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Methamphetamine use,Methamphetamine use,no,Stimulants,OtherDrugs,independent,extract_Schoeler_methamphetamine,pEstimate_Schoeler_methamphetamine,cohen,,Yes,Yes,
632,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Ketamine use,Ketamine use,yes,Ketamine,OtherDrugs,independent,extract_Schoeler_ketamine,pEstimate_Schoeler_ketamine,cohen,,Yes,Yes,
633,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,LSD use,LSD use,yes,Hallucinogens,OtherDrugs,independent,extract_Schoeler_lsd,pEstimate_Schoeler_lsd,cohen,,Yes,Yes,
634,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Diagnosis depression,Diagnosis depression,no,Depression,MentalHealthPersonality,independent,extract_Schoeler_depression,pEstimate_Schoeler_depression,cohen,,Yes,Yes,
635,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Diagnosis anxiety,Diagnosis anxiety,no,Anxiety,MentalHealthPersonality,independent,extract_Schoeler_anxiety,pEstimate_Schoeler_anxiety,cohen,,Yes,Yes,
636,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Diagnosis bipolar,Diagnosis bipolar,no,Bipolar,MentalHealthPersonality,independent,extract_Schoeler_bipolar,pEstimate_Schoeler_bipolar,cohen,,Yes,Yes,
637,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Diagnosis psychosis,Diagnosis psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extract_Schoeler_psychosis,pEstimate_Schoeler_psychosis,cohen,,Yes,Yes,
638,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,Diagnosis ADHD,Diagnosis ADHD,no,ADHD,MentalHealthPersonality,independent,extract_Schoeler_adhd,pEstimate_Schoeler_adhd,cohen,,Yes,Yes,
639,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PLE,full_episode,rates,rates,no,rates,rates,independent,schoelerRatesEver_psychosisDF,NA,rates,,Yes,Yes,
640,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.PAR,full_episode,rates,rates,no,rates,rates,independent,schoelerRatesEver_paranoiaDF,NA,rates,,No,No,
641,Schoeler,Winstock,"Schoeler, Tabea, Jason Ferris, and Adam R. Winstock. ""Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis."" Translational psychiatry 12, no. 1 (2022): 1-8.",2022,2014-2019,Observational,Wordwide,NA,18,NA,Can.HAL,full_episode,rates,rates,no,rates,rates,independent,schoelerRatesEver_hallucinationsDF,NA,rates,,No,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
643,Bassir,DSouza_2,"Bassir Nia, Anahita, Maria J. Orejarena, Leigh Flynn, Christina Luddy, Deepak Cyril D’Souza, Patrick D. Skosnik, Brian Pittman, and Mohini Ranganathan. ""Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)."" Psychopharmacology 239, no. 5 (2022): 1621-1628.",2022,NA,Experiment,US,26,NA,NA,THC.PLE,psych_like,Gender,Gender,no,Gender,Demographic,independent,sexTHC_bassir2022,pEstimate_sexTHC_bassir2022,cohen,,no,already included in Ganesh mega analysis,
644,Bassir,DSouza_2,"Bassir Nia, Anahita, Maria J. Orejarena, Leigh Flynn, Christina Luddy, Deepak Cyril D’Souza, Patrick D. Skosnik, Brian Pittman, and Mohini Ranganathan. ""Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)."" Psychopharmacology 239, no. 5 (2022): 1621-1628.",2022,NA,Experiment,US,26,NA,NA,THC.PLE,psych_like,Single dose IV (0mg vs 0.015 mg/kg THC),Single dose IV (0.015 mg/kg THC),no,SingleDose,CannabisDynamics,dependent,mainTHC_bassir2022,pEstimate_mainTHC_bassir2022,cohen,,no,already included in Ganesh mega analysis,
,,,,,,,,,,,,,,,,,,,,,,,,,
646,Ganesh,DSouza_2,"Ganesh, Suhas, Jose Cortes-Briones, Ashley M. Schnakenberg Martin, Patrick D. Skosnik, Deepak C. D'Souza, and Mohini Ranganathan. ""Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior."" Cannabis and Cannabinoid Research (2022).",2022,NA,Experiment,US,25,NA,NA,THC.PLE,psych_like,THC vs CBD 7.5 mg,CBD (7.5mg),yes,CBDcontent,CannabisStrain,dependent,extraxted_cbdTHC_ganesh2022,pEstimate_cbdTHC_ganesh2022,cohen,,no,already included in Ganesh mega analysis,
,,,,,,,,,,,,,,,,,,,,,,,,,
648,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,Canada/US,21.4,16,65,Can.HAL,full_episode,rates,rates,no,rates,rates,NA,rupSurvey2022_hallucinationsDF,NA,rates,,Yes,Yes,
649,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,Canada/US,21.4,16,65,Can.HAL,full_episode,Diagnosis anxiety,Diagnosis anxiety,yes,Anxiety,MentalHealthPersonality,independent,extract_RupSurvey2022_anxiety,pEstimate_RupSurvey2022_anxiety,cohen,,Yes,Yes,
650,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,Canada/US,21.4,16,65,Can.HAL,full_episode,Diagnosis depression,Diagnosis depression,yes,Depression,MentalHealthPersonality,independent,extract_RupSurvey2022_depression,pEstimate_RupSurvey2022_depression,cohen,,Yes,Yes,
651,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,Canada/US,21.4,16,65,Can.HAL,full_episode,Diagnosis ptsd,Diagnosis ptsd,no,Anxiety,MentalHealthPersonality,independent,extract_RupSurvey2022_ptsd,pEstimate_RupSurvey2022_ptsd,cohen,,Yes,Yes,
652,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,Canada/US,21.4,16,65,Can.HAL,full_episode,Diagnosis bipolar,Diagnosis bipolar,no,Bipolar,MentalHealthPersonality,independent,extract_RupSurvey2022_bipolar,pEstimate_RupSurvey2022_bipolar,cohen,,Yes,Yes,
653,Rup,Rup,"Rup, Jennifer, Tom P. Freeman, Chris Perlman, and David Hammond. ""Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status."" Substance Use & Misuse 57, no. 5 (2022): 719-729.",2022,2018,Observational,Canada/US,21.4,16,65,Can.HAL,full_episode,Diagnosis psychosis,Diagnosis psychosis,no,PsychosisLiability,MentalHealthPersonality,independent,extract_RupSurvey2022_psychosis,pEstimate_RupSurvey2022_psychosis,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
655,Ueberall,Ueberall,"Ueberall, Michael A., Johannes Horlemann, Norbert Schuermann, Maja Kalaba, and Mark A. Ware. ""Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry."" Pain Medicine (2022).",2022,2017-2019,MedicalSample,Germany,57,24,88,Med.HAL,AE,Medical cannabis (Drabinol),Pain,no,rates,rates,NA,UeberallDrabinol_hallucinationsDF,NA,rates,,Yes,Yes,
656,Ueberall,Ueberall,"Ueberall, Michael A., Johannes Horlemann, Norbert Schuermann, Maja Kalaba, and Mark A. Ware. ""Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry."" Pain Medicine (2022).",2022,2017-2019,MedicalSample,Germany,57,24,88,Med.PAR,AE,Medical cannabis (Drabinol),Pain,no,rates,rates,NA,UeberallDrabinol_paranoiaDF,NA,rates,,Yes,Yes,
657,Ueberall,Ueberall,"Ueberall, Michael A., Johannes Horlemann, Norbert Schuermann, Maja Kalaba, and Mark A. Ware. ""Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry."" Pain Medicine (2022).",2022,2017-2019,MedicalSample,Germany,57,24,88,Med.DEL,AE,Medical cannabis (Drabinol),Pain,no,rates,rates,NA,UeberallDrabinol_delusionsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
659,Melen,Melen,"Melén, Christopher M., Magali Merrien, Agata M. Wasik, Georgios Panagiotidis, Olof Beck, Kristina Sonnevi, Henna-Riikka Junlén, Birger Christensson, Birgitta Sander, and Björn Engelbrekt Wahlin. ""Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia."" Leukemia & Lymphoma 63, no. 6 (2022): 1387-1397.",2022,2019-2020,MedicalSample,Sweden,73,64,79,Med.HAL,AE,Medical cannabis,Cancer,no,rates,rates,NA,melenMedCan_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
661,Abi-Jaoude,Abi_Jaoude,"Abi-Jaoude, Elia, Tracy Bhikram, Ferdous Parveen, Jody Levenbach, Myriam Lafreniere-Roula, and Paul Sandor. ""A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome."" Cannabis and Cannabinoid Research (2022).",2022,2018-2020,MedicalTrial,Canada,NA,NA,NA,Med.HAL,AE,Medical cannabis,Tourette,no,rates,rates,NA,Abi_Jaoude_tourette_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
663,Peters,Peters,"Peters, Erica N., Irina Mosesova, Laura MacNair, Ryan Vandrey, M. Hunter Land, Mark A. Ware, Cynthia Turcotte, and Marcel O. Bonn-Miller. ""Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants."" Journal of Analytical Toxicology 46, no. 5 (2022): 528-539.",2022,2019-2020,MedicalTrial,Australia,28.1,18,55,Med.PAR,AE,Medical cannabis (Mixed THC condictiions: Treatment A: 5 mg total THC and 0.06 mg CBD daily; B: 10 mg total THC and 0.12 mg total CBD daily; C: 15 mg total THC and 0.18 mg total CBD daily; D: 20 mg total THC and 0.24 mg total CBD daily),Healthy,no,Medical cannabis (placebo controlled),CannabisDynamics,independent,extract_petersMedTrialHealthy_paranoia,pEstimate_petersMedTrialHealthy_paranoia,cohen,,Yes,Yes,
664,Peters,Peters,"Peters, Erica N., Irina Mosesova, Laura MacNair, Ryan Vandrey, M. Hunter Land, Mark A. Ware, Cynthia Turcotte, and Marcel O. Bonn-Miller. ""Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants."" Journal of Analytical Toxicology 46, no. 5 (2022): 528-539.",2022,2019-2020,MedicalTrial,Australia,28.1,18,55,Med.PAR,AE,Medical cannabis (Mixed THC condictiions: Treatment A: 5 mg total THC and 0.06 mg CBD daily; B: 10 mg total THC and 0.12 mg total CBD daily; C: 15 mg total THC and 0.18 mg total CBD daily; D: 20 mg total THC and 0.24 mg total CBD daily),Healthy,no,rates,rates,NA,petersMedTrialHealthy_paranoiaDF,NA,rates,petersMedTrialHealthy_paranoiaControl,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
666,Santarossa,Santarossa,"Santarossa, Talia M., Randy So, Penelope Smyth, Stefan Gustavsen, and Ross T. Tsuyuki. ""Medical cannabis use in Canadians with multiple sclerosis."" Multiple Sclerosis and Related Disorders 59 (2022): 103638.",2022,NA,MedicalSample,Canada,44,NA,NA,Med.HAL,AE,Medical cannabis (prescribed or unprescribed),MS,no,rates,rates,NA,nMS_Santarossa_hallucinationsDF,NA,rates,,Yes,Yes,
667,Santarossa,Santarossa,"Santarossa, Talia M., Randy So, Penelope Smyth, Stefan Gustavsen, and Ross T. Tsuyuki. ""Medical cannabis use in Canadians with multiple sclerosis."" Multiple Sclerosis and Related Disorders 59 (2022): 103638.",2022,NA,MedicalSample,Canada,44,NA,NA,Med.PAR,AE,Medical cannabis (prescribed or unprescribed),MS,no,rates,rates,NA,nMS_Santarossa_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
669,Tumati,Tumati,"Tumati, Shankar, Krista L. Lanctôt, RuoDing Wang, Abby Li, Andrew Davis, and Nathan Herrmann. ""Medical cannabis use among older adults in Canada: self-reported data on types and amount used, and perceived effects."" Drugs & aging 39, no. 2 (2022): 153-163.",2022,2014-2020,MedicalSample,Canada,73.2,NA,NA,Med.HAL,AE,rates,rates,no,rates,rates,NA,TumatiCanOil_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
671,Ergisi,MedicalCannabisRegistryUK,"Ergisi, Mehmet, Simon Erridge, Michael Harris, Michal Kawka, Devaki Nimalan, Oliver Salazar, Katerina Loupasaki et al. ""UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder."" Expert review of clinical pharmacology (2022): 1-9.",2022,2019-2022,MedicalSample,UK,37.42,NA,NA,Med.PAR,AE,rates,rates,no,rates,rates,NA,ErgisiCanMedPTSD_paranoiaDF,NA,rates,,No,No,
,,,,,,,,,,,,,,,,,,,,,,,,,
673,Tofthagen,Tofthagen,"Tofthagen, Cindy, Adam Perlman, Pooja Advani, Brenda Ernst, Judith Kaur, Winston Tan, Katharine Sheffield, John Crump, Joshua Henry, and Jason Starr. ""Medical Marijuana Use for Cancer-Related Symptoms among Floridians: A Descriptive Study."" Journal of Palliative Medicine 25, no. 10 (2022): 1563-1570.",2022,NA,MedicalSample,Canada,57.33,19,82,Med.PAR,AE,rates,rates,no,rates,rates,NA,TofthagenMedCanCancer_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
675,Gibson,Gibson,"Gibson, Laurel P., Hollis C. Karoly, Jarrod M. Ellingson, Jost Klawitter, Cristina Sempio, Julia E. Squeri, Angela D. Bryan, L. Cinnamon Bidwell, and Kent E. Hutchison. ""Effects of cannabidiol in cannabis flower: implications for harm reduction."" Addiction Biology 27, no. 1 (2022): e13092.",2021,NA,Experiment,US,36,NA,NA,THC.PLE,psych_like,THC vs CBD,THC vs CBD,yes,CBD (administration),CannabisDynamics,independent,Gibson2022CBD_paranoia,pEstimate_Gibson2022CBD_paranoia,cohen,,Yes,Yes,
676,Gibson,Gibson,"Gibson, Laurel P., Hollis C. Karoly, Jarrod M. Ellingson, Jost Klawitter, Cristina Sempio, Julia E. Squeri, Angela D. Bryan, L. Cinnamon Bidwell, and Kent E. Hutchison. ""Effects of cannabidiol in cannabis flower: implications for harm reduction."" Addiction Biology 27, no. 1 (2022): e13092.",2021,NA,Experiment,US,36,NA,NA,THC.PLE,psych_like,THCplasmaLevel,THCplasmaLevel,yes,THCplasmaLevel,CannabisDynamics,independent,Gibson2022plasmaTHC_paranoia,pEstimate_Gibson2022plasmaTHC_paranoia,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
678,Drennan,Drennan,"Drennan, M. L., H. C. Karoly, A. D. Bryan, K. E. Hutchison, and L. C. Bidwell. ""Acute objective and subjective intoxication effects of legal-market high potency THC-dominant versus CBD-dominant cannabis concentrates."" Scientific reports 11, no. 1 (2021): 1-10.",2021,NA,QuasiExperimental,US,29.8,21,60,THC.PAR,psych_like,THC (smoked),THC with and without THC (in a natural setting),yes,CBDcontent,CannabisStrain,independent,drennanColoradoTHC_CBD,pEstimate_drennanColoradoTHC_CBD,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
680,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,Australia,19.24,16,25,Can.PAR,psych_like,Childhood trauma,Childhood trauma,no,Other,Other,independent,carlyleSurveyCT_trauma,pEstimate_carlyleSurveyCT_trauma,cohen,,Yes,Yes,
681,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,Australia,19.24,16,25,Can.PAR,psych_like,Age,Age,no,Age,Demographic,independent,carlyleSurveyCT_age,pEstimate_carlyleSurveyCT_age,cohen,,Yes,Yes,
682,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,Australia,19.24,16,25,Can.PAR,psych_like,Indigenous Status ,Indigenous Status ,no,Other,Other,independent,carlyleSurveyCT_indigenous,pEstimate_carlyleSurveyCT_indigenous,cohen,,Yes,Yes,
683,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,Australia,19.24,16,25,Can.PAR,psych_like,GAD-7 - Generalised Anxiety Disorder-7,Anxiety,no,Anxiety,MentalHealthPersonality,independent,carlyleSurveyCT_anxiety,pEstimate_carlyleSurveyCT_anxiety,cohen,,Yes,Yes,
684,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,Australia,19.24,16,25,Can.PAR,psych_like,PHQ-9 - Patient Health Questionnaire-9 (depression severity),Depression,no,Depression,MentalHealthPersonality,independent,carlyleSurveyCT_depression,pEstimate_carlyleSurveyCT_depression,cohen,,Yes,Yes,
685,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,Australia,19.24,16,25,Can.PAR,psych_like,Mental Health Liability (Family History of Mental Illness),Mental Health Liability,no,MentalHealthLiability,MentalHealthPersonality,independent,carlyleSurveyCT_MHliability,pEstimate_carlyleSurveyCT_MHliability,cohen,,Yes,Yes,
686,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,Australia,19.24,16,25,Can.PAR,psych_like,AddictionLiability (Family History of Drug Dependence),Addiction Liability,no,AddictionLiability ,MentalHealthPersonality,independent,carlyleSurveyCT_AddictionLiability,pEstimate_carlyleSurveyCT_AddictionLiability,cohen,,Yes,Yes,
687,Carlyle,Hides,"Carlyle, Molly, Toby Constable, Zoe C. Walter, Joanna Wilson, Grace Newland, and Leanne Hides. ""Cannabis-induced dysphoria/paranoia mediates the link between childhood trauma and psychotic-like experiences in young cannabis users."" Schizophrenia Research 238 (2021): 178-184.",2021,NA,Observational,Australia,19.24,16,25,Can.PAR,psych_like,Male vs female,Male vs female,no,Gender,Demographic,independent,carlyleSurveyCT_gender,pEstimate_carlyleSurveyCT_gender,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
689,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,Spain,29.94,21,NA,THC.HAL,psych_like,Single dose vaped (0mg vs high potency THC),Single dose vaped (0mg vs high potency THC),no,SingleDose,CannabisDynamics,dependent,extract_bousoExpTHC_CBD_VAS_hallucinations,pEstimate_bousoExpTHC_CBD_VAS_hallucinations,cohen,,Yes,Yes,
690,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,Spain,29.94,21,NA,THC.PAR,psych_like,Single dose vaped (0mg vs high potency THC),Single dose vaped (0mg vs high potency THC),no,SingleDose,CannabisDynamics,dependent,extract_bousoExpTHC_CBD_VAS_paranoia,pEstimate_bousoExpTHC_CBD_VAS_paranoia,cohen,,Yes,Yes,
691,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,Spain,29.94,21,NA,THC.PAR,psych_like,Single dose vaped (0mg vs high potency THC),Single dose vaped (0mg vs high potency THC),no,SingleDose,CannabisDynamics,dependent,extract_bousoExpTHC_CBD_PSI_paranoia,pEstimate_bousoExpTHC_CBD_PSI_paranoia,cohen,,Yes,Yes,
692,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,Spain,29.94,21,NA,THC.DEL,psych_like,Single dose vaped (0mg vs high potency THC),Single dose vaped (0mg vs high potency THC),no,SingleDose,CannabisDynamics,dependent,extract_bousoExpTHC_CBD_PSI_delusions,pEstimate_bousoExpTHC_CBD_PSI_delusions,cohen,,Yes,Yes,
693,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,Spain,29.94,21,NA,THC.HAL,psych_like,THC vs CBD,THC vs CBD,yes,CBD (administration),CannabisDynamics,dependent,extract_bousoExpTHC_CBD_VAS_hallucinations_cbdAdmin,pEstimate_bousoExpTHC_CBD_VAS_hallucinations_cbdAdmin,cohen,,Yes,Yes,
694,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,Spain,29.94,21,NA,THC.PAR,psych_like,THC vs CBD,THC vs CBD,yes,CBD (administration),CannabisDynamics,dependent,extract_bousoExpTHC_CBD_VAS_paranoia_cbdAdmin,pEstimate_bousoExpTHC_CBD_VAS_paranoia_cbdAdmin,cohen,,Yes,Yes,
695,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,Spain,29.94,21,NA,THC.PAR,psych_like,THC vs CBD,THC vs CBD,yes,CBD (administration),CannabisDynamics,dependent,extract_bousoExpTHC_CBD_PSI_paranoia_cbdAdmin,pEstimate_bousoExpTHC_CBD_PSI_paranoia_cbdAdmin,cohen,,Yes,Yes,
696,Sainz-Cort,Bouso,"Sainz-Cort, Alberto, Daniel Jimenez-Garrido, Elena Muñoz-Marron, Raquel Viejo-Sobera, Joost Heeroma, and Jose Carlos Bouso. ""Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study."" Journal of Clinical Psychopharmacology 41, no. 5 (2021): 561-570.",2021,NA,Experiment,Spain,29.94,21,NA,THC.DEL,psych_like,THC vs CBD,THC vs CBD,yes,CBD (administration),CannabisDynamics,dependent,extract_bousoExpTHC_CBD_PSI_delusions_cbdAdmin,pEstimate_bousoExpTHC_CBD_PSI_delusions_cbdAdmin,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
698,Bloomfield,Freeman_Dronabinol_3325/002,"Bloomfield, Michael AP, Katherine Petrilli, Rachel Lees, Chandni Hindocha, Katherine Beck, Ryan J. Turner, Ellis Chika Onwordi et al. ""The effects of acute Δ9-tetrahydrocannabinol on striatal glutamatergic function: A proton magnetic resonance spectroscopy study."" Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 6, no. 6 (2021): 660-667.",2021,NA,Experiment,UK,23.5,19,35,THC.PLE,psych_like,Single dose oral (0mg vs 15mg THC),Single dose oral (0mg vs 15mg THC),no,SingleDose,CannabisDynamics,dependent,bloomfieldGlutamateTHC_dose,pEstimate_bloomfieldGlutamateTHC_dose,cohen,,Yes,Yes,
699,Bloomfield,Freeman_Dronabinol_3325/002,"Bloomfield, Michael AP, Katherine Petrilli, Rachel Lees, Chandni Hindocha, Katherine Beck, Ryan J. Turner, Ellis Chika Onwordi et al. ""The effects of acute Δ9-tetrahydrocannabinol on striatal glutamatergic function: A proton magnetic resonance spectroscopy study."" Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 6, no. 6 (2021): 660-667.",2021,NA,Experiment,UK,23.5,19,35,HIGH.PLE,psych_like,Glutamate (striatal Glx/Cre measures),Glutamate (striatal Glx/Cre measures),no,Glutamate,Neurotransmission,independent,bloomfieldGlutamateTHC_Gl,pEstimate_bloomfieldGlutamateTHC_Gl,cohen,,no,no,
,,,,,,,,,,,,,,,,,,,,,,,,,
670,Walsh,Walsh,"Walsh, Jennifer H., Kathleen J. Maddison, Tim Rankin, Kevin Murray, Nigel McArdle, Melissa J. Ree, David R. Hillman, and Peter R. Eastwood. ""Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo."" Sleep 44, no. 11 (2021): zsab149.",2021,2019-2019,MedicalTrial,Australia,53,25,70,Med.HAL,AE,rates,NA,no,rates,rates,NA,WalshInsomnia_2021_hallucinationsDF,NA,rates,WalshInsomnia_2021_hallucinationsControls,Yes,Yes,
671,Walsh,Walsh,"Walsh, Jennifer H., Kathleen J. Maddison, Tim Rankin, Kevin Murray, Nigel McArdle, Melissa J. Ree, David R. Hillman, and Peter R. Eastwood. ""Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo."" Sleep 44, no. 11 (2021): zsab149.",2021,2019-2019,MedicalTrial,Australia,53,25,70,Med.HAL,AE,Medical cannabis (placebo controlled),NA,no,Medical cannabis (placebo controlled),CannabisDynamics,dependent,extractWalshInsomnia_2021_hallucinations,pEstimate_walshInsomnia_2021_hallucinations,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
672,Halikas,Halikas,"Halikas, James A., Donald W. Goodwin, and Samuel B. Guze. ""Marihuana effects: a survey of regular users."" Jama 217, no. 5 (1971): 692-694.",1971,NA,Observational,US,22,18,31,Can.HAL,psych_like,rates,NA,no,rates,rates,NA,regularCan_Halikas1971_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
673,Greywoode,Greywoode,"Greywoode, Ruby, Chinazo Cunningham, Maegan Hollins, and Olga Aroniadis. ""Medical Cannabis Use Patterns and Adverse Effects in Inflammatory Bowel Disease."" Journal of Clinical Gastroenterology (2022): 10-1097.",2022,2020-2021,MedicalSample,US,40,18,NA,Med.PAR,AE,rates,NA,no,rates,rates,NA,greywoodeIBD_paranoiaDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
674,Stith,ReleafApp_2021,"Stith, Sarah See, Xiaoxue Li, Franco Brockelman, Keenan Keeling, Branden Hall, and Jacob Miguel Vigil. ""Understanding Feeling"" High"" and Its Role in Medical Cannabis Patient Outcomes."" Frontiers in Pharmacology 14: 1380.",2023,2016-2021,MedicalSample,US,NA,NA,NA,Med.PAR,AE,rates,NA,no,rates,rates,NA,StithReleaf_paranoiaDF,NA,rates,,Yes,Yes,
675,Stith,ReleafApp_2021,"Stith, Sarah See, Xiaoxue Li, Franco Brockelman, Keenan Keeling, Branden Hall, and Jacob Miguel Vigil. ""Understanding Feeling"" High"" and Its Role in Medical Cannabis Patient Outcomes."" Frontiers in Pharmacology 14: 1380.",2023,2016-2021,MedicalSample,US,NA,NA,NA,Med.PAR,AE,Subjective high,Subjective high,no,SubjectiveHigh,CannabisDynamics,independent,StithReleaf_paranoiaCor,pEstimate_StithReleaf_paranoia,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
676,Aladeen,Aladeen,"Aladeen, Traci S., Anna G. Mattle, Kory Zelen, Moustafa Mesha, Michelle M. Rainka, Tanya Geist, Bennett Myers, and Laszlo Mechtler. ""Medical Cannabis in the Treatment of Parkinson’s Disease."" Clinical neuropharmacology (2023): 10-1097.",2023,2016-2018,MedicalSample,US,72,NA,NA,Med.HAL,AE,rates,NA,no,rates,rates,NA,AladeenPD_psychosisDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
677,Arkell,EmeraldClinic,"Arkell, Thomas R., Luke A. Downey, Amie C. Hayley, and Sebastian Roth. ""Assessment of medical cannabis and health-related quality of life."" JAMA network open 6, no. 5 (2023): e2312522-e2312522.",2023,2018-2022,MedicalSample,Australia,55.9,NA,NA,Med.HAL,AE,rates,NA,no,rates,rates,NA,ArkellMed2023_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
678,Bassat,Bassat,"Kliuk-Ben Bassat, Orit, Meir Schechter, Natalia Ashtamker, Ilan Yanuv, Aliza Rozenberg, Boaz Hirshberg, Ayelet Grupper, Nachum Vaisman, Silviu Brill, and Ofri Mosenzon. ""Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study."" Clinical Kidney Journal 16, no. 4 (2023): 701-710.",2023,2018-2019,MedicalSample,Israel,64.1,NA,NA,Med.HAL,AE,rates,NA,no,rates,rates,NA,KliukWPE_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
679,Olsson,MedicalCannabisRegistryUK,"Olsson, F., Erridge, S., Tait, J., Holvey, C., Coomber, R., Beri, S., Hoare, J., Khan, S., Weatherall, M.W., Platt, M. and Rucker, J.J., 2023. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Review of Clinical Pharmacology, 16(3), pp.257-266.",2023,2019-2022,MedicalSample,UK,42.22,NA,NA,Med.PAR,AE,rates,NA,no,rates,rates,NA,OlssonMCR_paranoiaDF,NA,rates,,Yes,Yes,
680,Olsson,MedicalCannabisRegistryUK,"Olsson, F., Erridge, S., Tait, J., Holvey, C., Coomber, R., Beri, S., Hoare, J., Khan, S., Weatherall, M.W., Platt, M. and Rucker, J.J., 2023. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Review of Clinical Pharmacology, 16(3), pp.257-266.",2023,2019-2022,MedicalSample,UK,42.22,NA,NA,Med.PLE,AE,rates,NA,no,rates,rates,NA,OlssonMCR_psychosisDF,NA,rates,,Yes,Yes,
681,Olsson,MedicalCannabisRegistryUK,"Olsson, F., Erridge, S., Tait, J., Holvey, C., Coomber, R., Beri, S., Hoare, J., Khan, S., Weatherall, M.W., Platt, M. and Rucker, J.J., 2023. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Review of Clinical Pharmacology, 16(3), pp.257-266.",2023,2019-2022,MedicalSample,UK,42.22,NA,NA,Med.DEL,AE,rates,NA,no,rates,rates,NA,OlssonMCR_delusionsDF,NA,rates,,Yes,Yes,
682,Olsson,MedicalCannabisRegistryUK,"Olsson, F., Erridge, S., Tait, J., Holvey, C., Coomber, R., Beri, S., Hoare, J., Khan, S., Weatherall, M.W., Platt, M. and Rucker, J.J., 2023. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Review of Clinical Pharmacology, 16(3), pp.257-266.",2023,2019-2022,MedicalSample,UK,42.22,NA,NA,Med.HAL,AE,rates,NA,no,rates,rates,NA,OlssonMCR_hallucinationsDF,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
683,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.PLE,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,extract_lawn2023AdolAdultsTHC_PSI,pEstimate_lawn2023AdolAdults,cohen,,Yes,Yes,
684,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.PLE,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,extract_lawn2023AdolAdultsTHC_main_PANSS,pEstimate_lawn2023AdolAdults,cohen,,Yes,Yes,
685,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.PAR,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,extract_lawn2023AdolAdultsTHC_main_Paranoia,pEstimate_lawn2023AdolAdults,cohen,,Yes,Yes,
686,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.DEL,psych_like,Single dose inhaled (0mg vs 8mg THC),Single dose inhaled (8mg THC),no,SingleDose,CannabisDynamics,dependent,extract_lawn2023AdolAdultsTHC_main_Delusions,pEstimate_lawn2023AdolAdults,cohen,,Yes,Yes,
687,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.PLE,psych_like,CBD (24mg),CBD (24mg),no,CBD (administration),CannabisDynamics,dependent,extract_lawn2023AdolAdultsTHC_CBD_PSI,pEstimate_lawn2023AdolAdults,cohen,,Yes,Yes,
688,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.PLE,psych_like,CBD (24mg),CBD (24mg),no,CBD (administration),CannabisDynamics,dependent,extract_lawn2023AdolAdultsTHC_CBD_PANSS,pEstimate_lawn2023AdolAdults,cohen,,Yes,Yes,
689,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.PAR,psych_like,CBD (24mg),CBD (24mg),no,CBD (administration),CannabisDynamics,dependent,extract_lawn2023AdolAdultsTHC_CBD_Paranoia,pEstimate_lawn2023AdolAdults,cohen,,Yes,Yes,
690,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.DEL,psych_like,CBD (24mg),CBD (24mg),no,CBD (administration),CannabisDynamics,dependent,extract_lawn2023AdolAdultsTHC_CBD_Delusions,pEstimate_lawn2023AdolAdults,cohen,,Yes,Yes,
691,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.PLE,psych_like,Differences in acute effects between adults and adolescents,Age,no,Age,Demographic,dependent,extract_lawn2023AdolAdultsTHCxAge,pEstimate_lawn2023AdolAdultsTHCxAge,cohen,,Yes,Yes,
692,Lawn,CurranAdoAdult,"Lawn, W., Trinci, K., Mokrysz, C., Borissova, A., Ofori, S., Petrilli, K., Bloomfield, M., Haniff, Z.R., Hall, D., Fernandez‐Vinson, N. and Wang, S., 2023. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment. Addiction.",2023,2019-2021,Experiment,UK,22.47,16,29,THC.PLE,psych_like,rates,rates,no,rates,rates,NA,lawn2023AdolAdultsTHC_pseDF,NA,rates,lawn2023AdolAdultsTHC_pseControlDF,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
693,Schnell,Schnell,"Schnell, Thomas, Christina-Marie Grömm, and Nils Klöckner. ""Predictive impact of different acute cannabis intoxication effects with regard to abstinence motivation and cessation of use."" Scientific reports 13, no. 1 (2023): 709.",2023,2020-2021,Observational,Germany,24.24,18,NA,Can.PAR,psych_like,“taking steps” (indicator for the concrete efforts to remain abstinent),Efforts to remain abstinent,no,Other,Other,independent,extract_Schnell2023_takingSteps_paranoia,pEstimate_Schnell2023_takingSteps_paranoia,cohen,,Yes,Yes,
694,Schnell,Schnell,"Schnell, Thomas, Christina-Marie Grömm, and Nils Klöckner. ""Predictive impact of different acute cannabis intoxication effects with regard to abstinence motivation and cessation of use."" Scientific reports 13, no. 1 (2023): 709.",2023,2020-2021,Observational,Germany,24.24,18,NA,Can.PLE,psych_like,“recognition” (indicator for awareness of problem),Awareness of problem,no,Other,Other,independent,extract_Schnell2023_recognition_PLE,pEstimate_Schnell2023_recognition_PLE,cohen,,Yes,Yes,
695,Schnell,Schnell,"Schnell, Thomas, Christina-Marie Grömm, and Nils Klöckner. ""Predictive impact of different acute cannabis intoxication effects with regard to abstinence motivation and cessation of use."" Scientific reports 13, no. 1 (2023): 709.",2023,2020-2021,Observational,Germany,24.24,18,NA,Can.PAR,psych_like,“recognition” (indicator for awareness of problem),Awareness of problem,no,Other,Other,independent,extract_Schnell2023_recognition_paranoia,pEstimate_Schnell2023_recognition_paranoia,cohen,,Yes,Yes,
696,Schnell,Schnell,"Schnell, Thomas, Christina-Marie Grömm, and Nils Klöckner. ""Predictive impact of different acute cannabis intoxication effects with regard to abstinence motivation and cessation of use."" Scientific reports 13, no. 1 (2023): 709.",2023,2020-2021,Observational,Germany,24.24,18,NA,Can.PAR,psych_like,"“ambivalence” (indicator for the process of balancing two options—namely, to remain or become abstinent versus continued substance use)",Ambivalence about becoming abstinent,no,Other,Other,independent,extract_Schnell2023_ambivalence_paranoia,pEstimate_Schnell2023_ambivalence_paranoia,cohen,,Yes,Yes,
697,Schnell,Schnell,"Schnell, Thomas, Christina-Marie Grömm, and Nils Klöckner. ""Predictive impact of different acute cannabis intoxication effects with regard to abstinence motivation and cessation of use."" Scientific reports 13, no. 1 (2023): 709.",2023,2020-2021,Observational,Germany,24.24,18,NA,Can.PAR,psych_like,Intention to quit,Intention to quit,no,Other,Other,independent,extract_Schnell2023_quit_paranoia,pEstimate_Schnell2023_quit_paranoia,cohen,,Yes,Yes,
698,Schnell,Schnell,"Schnell, Thomas, Christina-Marie Grömm, and Nils Klöckner. ""Predictive impact of different acute cannabis intoxication effects with regard to abstinence motivation and cessation of use."" Scientific reports 13, no. 1 (2023): 709.",2023,2020-2021,Observational,Germany,24.24,18,NA,Can.PLE,psych_like,Intention to quit,Intention to quit,no,Other,Other,independent,extract_Schnell2023_quit_PLE,pEstimate_Schnell2023_quit_paranoia,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
699,Englund,McGuire2023,"Englund, Amir, Dominic Oliver, Edward Chesney, Lucy Chester, Jack Wilson, Simina Sovi, Andrea De Micheli et al. ""Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD: THC ratios."" Neuropsychopharmacology 48, no. 6 (2023): 869-876.",2023,2017-2019,Experiment,UK,26.6,21,50,THC.PLE,psych_like,CBD (30mg),CBD (30mg),no,CBD (administration),CannabisDynamics,dependent,extract_lEnglund2023CBD_PANSS,pEstimate_lEnglund2023CBD_PANSS,cohen,,Yes,Yes,
700,Englund,McGuire2023,"Englund, Amir, Dominic Oliver, Edward Chesney, Lucy Chester, Jack Wilson, Simina Sovi, Andrea De Micheli et al. ""Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD: THC ratios."" Neuropsychopharmacology 48, no. 6 (2023): 869-876.",2023,2017-2019,Experiment,UK,26.6,21,50,THC.PAR,psych_like,CBD (30mg),CBD (30mg),no,CBD (administration),CannabisDynamics,dependent,extract_lEnglund2023CBD_SSPS,pEstimate_lEnglund2023CBD_SSPS,cohen,,Yes,Yes,
701,Englund,McGuire2023,"Englund, Amir, Dominic Oliver, Edward Chesney, Lucy Chester, Jack Wilson, Simina Sovi, Andrea De Micheli et al. ""Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD: THC ratios."" Neuropsychopharmacology 48, no. 6 (2023): 869-876.",2023,2017-2019,Experiment,UK,26.6,21,50,THC.PLE,psych_like,CBD (30mg),CBD (30mg),no,CBD (administration),CannabisDynamics,dependent,extract_lEnglund2023CBD_CAPE,pEstimate_lEnglund2023CBD_CAPE,cohen,,Yes,Yes,
702,Englund,McGuire2023,"Englund, Amir, Dominic Oliver, Edward Chesney, Lucy Chester, Jack Wilson, Simina Sovi, Andrea De Micheli et al. ""Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD: THC ratios."" Neuropsychopharmacology 48, no. 6 (2023): 869-876.",2023,2017-2019,Experiment,UK,26.6,21,50,THC.PLE,psych_like,CBD (30mg),CBD (30mg),no,CBD (administration),CannabisDynamics,dependent,extract_lEnglund2023CBD_PSI,pEstimate_lEnglund2023CBD_PSI,cohen,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
703,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PLE,psych_like,Age at first cannabis use,Age at first cannabis use,no,Age onset,CannabisHistory,independent,extract_johnson2023AnyPLE_age_onset,pEstimate_johnson2023AnyPLE_age_onset,cohen,,Yes,Yes,
704,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.HAL,psych_like,Age at first cannabis use,Age at first cannabis use,no,Age onset,CannabisHistory,independent,extract_johnson2023Hallucinations_age_onset,pEstimate_johnson2023Hallucinations_age_onset,cohen,,Yes,Yes,
705,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PAR,psych_like,Age at first cannabis use,Age at first cannabis use,no,Age onset,CannabisHistory,independent,extract_johnson2023Paranoia_age_onset,pEstimate_johnson2023Paranoia_age_onset,cohen,,Yes,Yes,
706,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PLE,psych_like,Duration of daily cannabis use,Duration of use,no,CannabisDuration,CannabisHistory,independent,extract_johnson2023AnyPLE_duration_daily,pEstimate_johnson2023AnyPLE_duration_daily,cohen,,Yes,Yes,
707,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.HAL,psych_like,Duration of daily cannabis use,Duration of use,no,CannabisDuration,CannabisHistory,independent,extract_johnson2023Hallucinations_duration_daily,pEstimate_johnson2023Hallucinations_duration_daily,cohen,,Yes,Yes,
708,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PAR,psych_like,Duration of daily cannabis use,Duration of use,no,CannabisDuration,CannabisHistory,independent,extract_johnson2023Paranoia_duration_daily,pEstimate_johnson2023Paranoia_duration_daily,cohen,,Yes,Yes,
709,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PLE,psych_like,Cannabis use disorder (present versus absent),Cannabis use disorder (present versus absent),no,CannabisSeverity,CannabisHistory,independent,extract_johnson2023AnyPLE_CUD,pEstimate_johnson2023AnyPLE_CUD,cohen,,Yes,Yes,
710,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.HAL,psych_like,Cannabis use disorder (present versus absent),Cannabis use disorder (present versus absent),no,CannabisSeverity,CannabisHistory,independent,extract_johnson2023Hallucinations_CUD,pEstimate_johnson2023Hallucinations_CUD,cohen,,Yes,Yes,
711,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PAR,psych_like,Cannabis use disorder (present versus absent),Cannabis use disorder (present versus absent),no,CannabisSeverity,CannabisHistory,independent,extract_johnson2023Paranoia_CUD,pEstimate_johnson2023Paranoia_CUD,cohen,,Yes,Yes,
712,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PLE,psych_like,Schizophrenia polygenic score,Schizophrenia polygenic score,no,PsychosisLiability,MentalHealthPersonality,independent,extract_johnson2023AnyPLE_schzPRS,pEstimate_johnson2023AnyPLE_schzPRS,cohen,,Yes,Yes,
713,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.HAL,psych_like,Schizophrenia polygenic score,Schizophrenia polygenic score,no,PsychosisLiability,MentalHealthPersonality,independent,extract_johnson2023Hallucinations_schzPRS,pEstimate_johnson2023Hallucinations_schzPRS,cohen,,Yes,Yes,
714,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PAR,psych_like,Schizophrenia polygenic score,Schizophrenia polygenic score,no,PsychosisLiability,MentalHealthPersonality,independent,extract_johnson2023Paranoia_schzPRS,pEstimate_johnson2023Paranoia_schzPRS,cohen,,Yes,Yes,
715,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PLE,psych_like,rates,NA,no,rates,rates,NA,rates_johnson2023AnyPLE,NA,rates,,Yes,Yes,
716,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.HAL,psych_like,rates,NA,no,rates,rates,NA,rates_johnson2023Hallucinations,NA,rates,,Yes,Yes,
717,Johnson,COGA,"Johnson, Emma C., Sarah MC Colbert, Paul W. Jeffries, Rebecca Tillman, Tim B. Bigdeli, Nicole R. Karcher, Grace Chan et al. ""Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users."" Schizophrenia bulletin 49, no. 3 (2023): 778-787.",2023,NA,Observational,US,32.4,NA,NA,Can.PAR,psych_like,rates,NA,no,rates,rates,NA,rates_johnson2023Paranoia,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
718,Schubert,Wheate,"Schubert, Elise A., Johannes C. Alffenaar, Masego T. Johnstone, John W. Barlow, and Nial J. Wheate. ""Medicinal cannabis for patients with chronic non-cancer pain: analysis of safety and concomitant medications."" International Journal of Pharmacy Practice 31, no. 1 (2023): 70-79.",2023,2020,MedicalSample,Australia,54,NA,NA,Med.HAL,AE,rates,NA,no,rates,rates,NA,rates_SchubertMedCan2023THCproductHallucinations,NA,rates,,Yes,Yes,
719,Schubert,Wheate,"Schubert, Elise A., Johannes C. Alffenaar, Masego T. Johnstone, John W. Barlow, and Nial J. Wheate. ""Medicinal cannabis for patients with chronic non-cancer pain: analysis of safety and concomitant medications."" International Journal of Pharmacy Practice 31, no. 1 (2023): 70-79.",2023,2020,MedicalSample,Australia,54,NA,NA,Med.PAR,AE,rates,NA,no,rates,rates,NA,rates_SchubertMedCan2023THCproductParanoia,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
720,Horsted,Leutscher,"Horsted, Tina, Karoline Lichon Hesthaven, and Peter Derek Christian Leutscher. ""Safety and effectiveness of cannabinoids to Danish patients with treatment refractory chronic pain—a retrospective observational real‐world study."" European Journal of Pain 27, no. 2 (2023): 234-247.",2023,2018-2021,MedicalSample,Denmark,60,NA,NA,Med.HAL,AE,rates,NA,no,rates,rates,NA,rates_Horsted2023_THCgroupHallucination,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
721,Bouassa,Bouassa,"Mboumba Bouassa, R.S., Needham, J., Nohynek, D., Singer, J., Lee, T., Bobeuf, F., Samarani, S., Del Balso, L., Paisible, N., Vertzagias, C. and Sebastiani, G., 2022. Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028). Biomedicines, 10(12), p.3168.",2022,2021-2022,MedicalSample,Canada,57,NA,NA,Med.PAR,AE,rates,NA,no,rates,rates,NA,rates_BouassaTHC_2022_paranoia,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
722,Clarke,Clarke,"Clarke, Stephen, Belinda E. Butcher, Andrew J. McLachlan, Jeremy D. Henson, David Rutolo, Sean Hall, and Luis Vitetta. ""Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain."" Plos one 17, no. 10 (2022): e0270543.",2022,NA,MedicalSample,Australia,62,NA,NA,Med.HAL,AE,rates,NA,no,rates,rates,NA,rates_Clarke_cancer2022_hallucination,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
723,Kimless,Kimless,"Kimless, Debra, Matthew Caloura, Virginia Markos, Jennie Ryan, Sally Abbonizio, and Sharon Janicki. ""An Observational Cross-Sectional Survey Exploring the Indications for and Responses to Medical Marijuana Use in Certified Patients in Pennsylvania."" Journal of Primary Care & Community Health 13 (2022): 21501319221129734.",2022,2021,MedicalSample,US,36.7,NA,NA,Med.PAR,AE,rates,NA,no,rates,rates,NA,rates_KimlessMedCan2022_paranoia,NA,rates,,Yes,Yes,
,,,,,,,,,,,,,,,,,,,,,,,,,
724,Melges,Melges,"Melges, Frederick T., Jared R. Tinklenberg, C. Melvin Deardorff, Norma H. Davies, Richard E. Anderson, and Catherine A. Owen. ""Temporal disorganization and delusional-like ideation: Processes induced by hashish and alcohol."" Archives of general psychiatry 30, no. 6 (1974): 855-861.",1974,NA,Experiment,,24,21,30,THC.PAR,AE,rates,NA,no,rates,rates,NA,rates_melges1974_20mgTHC_fast_paranoia,NA,rates,,Yes,Yes,